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Abstract: 
The use of aptamers acting within novel biosensors as molecular recognition elements is 
well documented with a wide variety of techniques being adapted to take advantage of the 
benefits of oligonucleotide detection. A continuing barrier to the commercial use of ssDNA 
or RNA aptamers remains the lack of a high-throughput system that confers reliable 
selection and description of suitable species. Here we describe simple methodologies that 
utilise fusion proteins, modified affinity chromatography, HPLC, and, nanopore assays, along 
with other techniques to isolate novel aptamers to well-characterised proteins. These 
methods have yielded novel aptamers to the HsdR, and HsdS subunits of type I restriction-
modification system EcoR124I and to the human rhinovirus 3C protease, along with an 
enriched libraries for nitrotyrosine. In addition to the isolation of novel aptamer species, 
methods for the characterisation of the binding capabilities of candidate aptamers are 
presented. The techniques of SPR, EMSA, and dot blotting are evaluated and utilised in the 
appraisal of the novel aptamer sequences.  
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1 Introduction: 
1.1 Aptamers 
Aptamers coming from the Latin “apta” meaning to fit, and “mer” meaning many, are short 
oligonucleotides ranging from 20-90 base pairs in length. Usually derived using Systematic 
Evolution of Ligands by Exponential Enrichment (SELEX) methodologies, aptamers are seen 
to be a synthetic alternative to antibodies due to their high specificity and high affinity for 
their target (Stoltenburg et al., 2007). Aptamers have specific advantages over antibodies 
because of their reduced production costs, ease of synthesis, and the fact that they do not 
require an organism for their production.  
Considerable work has been undertaken within the two decades since aptamers and their 
potential were first identified. Aptamer technology can be separated into two groups, 
therapeutic and diagnostic, the aim of therapeutic aptamers can be seen as the use of 
aptamers as inhibitors, catalysts and mimics of enzymes and other molecules in a similar 
manner to many drugs. Currently the only aptamer to be approved (in the U.S.A) for use as 
a drug is Macugen® (Doggrell 2005), which is a treatment for wet age-related macular 
degeneration and this aptamer inhibits Vascular Endothelial Growth Factor (VEGF). The 
approval of this aptamer, and the success of treatment using this aptamer, is encouraging 
with regard to the potential use of aptamers in treatment of cancer and other diseases, as 
aptamers can now provide a new series of potential treatments. Diagnostic uses of 
aptamers primarily focus on the use of aptamers as molecular recognition elements within a 
larger biosensing system (Figure 1), using the aptamers as probes for target molecules in a 
similar way to antibody technologies (Jayasena, 1999).  
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Figure 1  Schematic diagram of a biosensor. Cartoon of a generic biosensing system showing 
information being passed from analyte through to signal. This highlights the role of the Molecular 
Recognition Element (e.g. an antibody) within the biosensor acting as a probe for the analyte before the 
signal is passed on to the transducer (e.g. a fluorescent molecule) for detection. 
Recent studies have investigated the use of aptamers as both the MRE and the reporter 
element by using chemical modifications of the oligonucleotides such as attachment of 
fluorophores, or the inclusion of modified nucleotides (Latham, Johnson et al. 1994; Li, Cao 
et al. 2008). The full breadth of possibilities of recognition for aptamers are still to be fully 
realised as aptamers are found to an increasing number of target molecules for example; 
small molecules, proteins, co-factors, even entire cells have aptamers evolved against them 
(Stoltenberg et al. 2007).  
1.1.1 Standard SELEX 
Systematic Evolution of Ligands using EXponential evolution (SELEX) was devised by (Tuerk 
& Gold, 1990) in 1990. A starting pool of oligonucleotides with random sequences, 
traditionally flanked by constant Polymerase Chain Reaction (PCR) primer regions, for the 
initiation of polymerisation, is introduced to a chosen, immobilised target molecule. 
Unbound sequences are washed away, whilst bound molecules are later eluted and 
amplified using PCR. The amplified library is then reintroduced to the target and the whole 
process is repeated. This repeated process replicates evolution in a rapid, microcosmic way.  
The random library consists of single stranded oligonucleotides, typically 30-100 bases in 
length with a central section of random sequence. The size of the random library is 
determined to be 4n (where n is the length of random sequence in bases) and tend to consist 
20 
 
of 1012 to 1014 different sequence (Stoltenburg et al., 2007). This library is then pre-screened 
against any part of the procedure that could produce a false positive, such as the media to 
which the target is bound, or part of the target which anchors the target, such as a chemical 
linker. Once the library has progressed through pre-screening it can be introduced to the 
objective for the SELEX process. Classically the target is bound to a matrix through a tag or 
linker (Stoltenburg et al., 2007) and the library of random sequences is screened for binding 
to the target by washing.. This process is repeated for 10-13 rounds of selection and 
amplification with the final library being isolated in a DNA cloning vector and sequenced 
with the goal of arriving at a consensus sequence. The consensus sequence is the final 
outcome of a successful SELEX selection procedure, detailed within the sequence would be 
any motifs or patterns that give the highest affinity and specificity for an aptamer to the 
target of interest. 
1.2 DNA vs. RNA aptamers 
Due to the definitive chemical difference between RNA and DNA, namely the 2’- hydroxyl 
group, which DNA lacks (Figure 2), DNA and RNA aptamers can form entirely different 
secondary structures to identical targets. The hydroxyl group found on RNA, provides a 
more reactive group when folding into secondary structures allowing the formation of 
hairpins, “kissing-loops” and pseudoknots. Multiple SELEX strategies for the RNA-based, ATP 
aptamer have been undertaken and the ς-loop (Sazani et al., 2004) structure shown in 
Figure 15 has repeatedly been identified from a number of studies (Huiaenga(1995), 
Huang(2003), Feigon et al.(1996)). If, however, an RNA aptamer is converted to an identical 
DNA aptamer (with thymine, substituted for uracil) a reduced level of binding is observed 
(Lato et al., 2002). The same can be said for the inverse situation, and this is the case for the 
majority of aptamers save only one reported instance for riboflavin (Lauhon & Szostak, 
1995). 
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Figure 2  Nucleotide differences between DNA and RNA. Comparison of guanine in RNA and DNA 
form, highlighting the difference between the 2’-hyrdoxyl group lacking in DNA (A) and present in RNA (B), 
this is due to the C-OH bond found on RNA being more chemically reactive than the C-H bond found in DNA. 
DNA can be considered a reasonably stable biomolecule, resistant to degradation over a 
range of different pH values and temperatures and it is because of this stability that DNA is 
so useful as a means for storing genetic material. Yet, it is RNA, which is repeatedly cited as 
the basis of all life - the idea of the “RNA world” was first discussed in the 1960s by Sol 
Speigelman (Spiegelman & Haruna, 1966), and the inherent ability of RNA to readily adopt 
secondary structures seems to have been the ideal catalyst for life and the cornerstone of 
genetic inheritance (Lam & Joyce, 2009). RNA is susceptible to degradation from 
environmental factors such as unfavourable pH and nucleases which can be attributed to 
the hydroxyl group found on RNA being more chemically promiscuous. The addition of the 
2’-OH also improves stability by increasing the melting temperature and locking an RNA 
duplex into a more compact A-form helix compared to DNA’s B-form helix. 
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Figure 3  Nucleotide modification used in SELEX. Possible modifications on an oligonucleotide strand 
to generate modified oligonucleotide libraries for the SELEX process. Modification at the 2’- position (Circle) 
of the sugar confers nuclease stability, whereas various modifications at the C-5 position (Star) of the 
pyrimidines could be used either to attract certain classes of targets or to generate covalent cross-links with 
targets. Modifications indicated by the arrows have represent some examples of the potential substitutions 
that could be used for the SELEX process.(Jayasena, 1999) 
1.3 Secondary Structures 
Aptamer binding relies on the bases of single stranded DNA, or RNA, forming conventional 
base pairs (Watson & Crick, 1953), Hoogsteen base pairing (Figure 4),  base stacking 
between the pi bonds of the aromatic groups of the bases and the formation of secondary 
structures (Hermann & Patel, 2000).  The three dimensional shape of the aptamer confers 
the specificity and affinity of binding to the target molecule. DNA secondary structures are 
less readily formed than the RNA counterparts because of weaker stacking energies (Chan et 
al. 1966), and the less reactive C-H bond found in the ribose of DNA compared to the C-OH 
counterpart of the 2’- carbon of RNA (Figure 2). The RNA pseudoknot (Figure 8) secondary 
structure is exclusive to RNA; whereas, the DNA G quadraduplex (Figure 7) tends to form 
within single, double and even multiple strands of DNA.  
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A) B)  
Figure 4  Diagram of Hoogsteen base pairing. A) Hoogsteen pairing is an alternative method for base 
pairing between adenosine and thymine residues with hydrogen bonding occurring between the N7 
nitrogen of the adenosine rather than the N1. B) The alternative binding method provides the platform for 
impromptu triplex DNA formation (Matthews C., 1990). 
 
1.3.1 Hairpins 
DNA and RNA hairpins are the simplest oligonucleotide secondary structure, the formation 
of which are thermodynamically favourable due to the low energies required for base pair 
formation. A hairpin is formed when a length of ssDNA, or RNA, has regions of 
complementarity that flank an unstructured region, the complementary regions form base 
pairs resulting in a hairpin motif (Figure 5). 
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Figure 5   Diagram of a DNA hairpin. A diagram of a DNA hairpin in a short oligonucleotide, drawn 
using mfold DNA folding software (Zuker, 2003) 
1.3.2 G-quadraduplex 
Of the documented ssDNA secondary structure motifs the G-quadraduplex can be 
considered one of the most common within DNA aptamers (Gatto et al. 2009). As with the 
RNA pseudoknots, the G-quadraduplex has been found to be a biologically and 
physiologically relevant structure with particular relevance to the G-rich sequences found in 
eukaryotic telomeres. G-quadruplexes are higher-order DNA and RNA structures formed 
from G-rich sequences that are built around tetrads of hydrogen-bonded Hoogsteen paired 
guanine bases and often around a centrally located monovalent cation such as K+ (Figure 6).  
 
Figure 6  Base formation of a G-quartet. Four guanine residues forming a G-quadraduplex, the 
guanines can be on a single strand, or, two, three or four separate strands of DNA. 
In addition to the proposed G-quadraduplex arrangement found in telomeres, non-
telomeric genomic DNA, such as in nuclease-hypersensitive promoter regions, are also 
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thought to contain naturally occurring G-quadraduplexes forming from the G tetrad (Halder 
et al.,2005). The natural role and biological validation of these structures is now being 
explored, and there is particular interest in them as targets for therapeutic intervention 
(Burge et al., 2006) The motif is now considered to be so important that there are drugs in 
development that target quadruplexes from particular genes (Ou. et al. 2008). 
 
Figure 7   Comparison of intra- and intermolecular G-quadraduplexes. G-quadraduplexes can be 
assembled from single stranded DNA in an intramolecular (backfolded) fashion or intramolecular G-
quadruplex topologies called ‘chair’ and ‘basket’ are shown Alternatively, up to four DNA strands can 
associate to form an intermolecular G-quadruplex. (Luedtke, 2009) 
The biological relevance of the G-quadraduplex has become apparent following the analysis 
of full eukaryotic and prokaryotic genomes that have shown them to occur throughout the 
gemone (Todd et al., 2005, Rawal et al., 2006, Simonsson et al., 1998).  
1.3.3 RNA pseudoknot 
The RNA pseudoknot is a secondary structure that forms when two stem loop structures 
occur and then interact with each other. Commonly found in nature, often within viral 
genomes (Pleij et al., 1985), the RNA pseudoknot has been accepted to have widely varying 
functions within biological processes (Brierley et al., 2007) ranging from the regulation of 
the initiation of protein synthesis by inducing ribosomal frame-shifting in many viruses 
(Shen & Tinoco, 1995, Barton et al., 1999), to template recognition by viral replicase (Klovins 
& van Duin, 1999), or forming the catalytic core of various ribozymes (Rastogi et al., 1996) 
(Ke et al., 2004), the self-splicing introns (Adams et al., 2004), and the core structural 
domain  of human telomerase (Theimer et al., 2005).  
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Figure 8  Formation of the RNA Pseudoknot. Cartoons detailing the formation of RNA pseudoknots 
through base to base interactions (Puglisi & Wyatt, 1995) 
1.4 Aptamers vs. Antibodies 
As mentioned above, aptamers are considered to be the nucleic acid equivalent of 
antibodies and also provide a reliable alternative to antibodies as molecular probes within a 
bio-sensor (Figure 1). Antibodies have been used extensively as molecular recognition 
elements since the 1970s, and their applications have become increasingly complex such as 
usage within Enzyme-Linked ImmunoSorbent Assays (ELISA) (Lequin, 2005), 
immunohistochemistry techniques(Buchwalow and Böcker, 2010), immunoprecipitation of 
biological molecules(Barrett et al. 1960), and cell differentiation in flow cytometry 
(Kamentsky, (1970), Dittrich & Göhde (1971) ). Monoclonal antibodies – antibodies that 
recognise and bind a single epitope on the antigen - represent the pinnacle of antibody 
technology (Riechmann et al. 1988). This is where a specific clone for a known antibody has 
been isolated and reproduced using cell culture allowing large quantities of the antibody to 
be produced and the easier optimisation of downstream experiments(Kohler & Milstein, 
1975, Schwaber & Cohen, 1973, Riechmann et al., 1988). Antibodies, however, are not 
without their limitations, for example, when raising an antibody to an antigen, the target 
molecule typically needs to be introduced to a host animal, this procedure raises questions 
of ethics and also requires the target to draw an immunoresponse from the organism. 
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Additionally, if the target molecule is toxic to the animal it can prevent a sufficient response 
from the immune system, which can restrict the amount of antibodies retrieved. In contrast 
to antibodies, aptamers are, once isolated, easy to synthesise and do not require the use of 
any organism.  
Due to the methods by which antibodies are derived and recovered there tends to be a 
large variation between each batch and this can be attributed to the varying levels in the 
organism’s immune response, this results in immunoassays needing to be optimised for 
each batch of antibodies (Jayasena, 1999). When you compare this to nucleic acid synthesis 
where the methods of fabrication are constant and reliable and, as a result, high levels of 
aptamers can be produced quickly and with confidence of the accuracy of the chemistry. 
Modifications to aptamers are easily achieved using conventional chemistry methods by 
attaching functional groups during synthesis or by including modified nucleotides during 
synthesis. By this method fluorescein or biotin can be included either within or on a specific 
end of an aptamer with confidence (Agrawal et al., 1986, Richardson & Gumport, 1983). 
These molecules confer a reporting ability onto aptamers that cannot be so easily achieved 
with antibodies without the use of a secondary antibody. As antibodies are organically 
derived probes they require close to physiological conditions for storage and use within 
other applications. This fragility also impacts on long term storage restricting the useful 
lifetime of the molecule, also once denatured the antibodies become irreversibly useless, in 
contrast aptamers can be stored, denatured and regenerated with relative ease. Aptamers 
will remain stable at room temperature and over a range of pH and salt concentrations, 
which, when compared to the more delicate antibody technologies, is a highly favourable 
situation, although alterations to the binding conditions can result in a loss of 
binding (Klussmann, 2006).  
Therefore, aptamers can be seen as a viable alternative to antibodies and within this study 
the aim was to show the ease of isolation of aptamers in order to supplement and improve 
on antibodies as molecular recognition experiments within specific biosensor systems. 
1.5 Aptamers as therapeutics 
As aptamers have been shown to exhibit a high binding affinity to the target and a 
selectivity that is usually associated with antibodies, there are a growing number of 
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instances of aptamers being used as treatments rather than just drug delivery tools. For 
example, the major goal for boranophosphate nucleotide aptamers would be their use as a 
suitable delivery method of boron for use within Boron Neutron Capture Therapy (BNCT, 
Figure 3,Lato et al., 2002) providing a low toxicity cancer treatment as an alternative to 
conventional chemotherapy. The boron-containing aptamers are selected towards tumour-
forming cancer cells using Cell-SELEX (Shangguan et al., 2007, Shangguan et al., 2006) and 
only the species with the highest affinity specificity are chosen. Due to their innate 
resistance to blood borne nucleases, the boranophosphate nucleotide containing aptamers 
have an increased half-life in vivo (Porter et al., 1997). The affected area is then irradiated 
with neutrons which are, in turn, accepted by the 10B converting it to 11B. The 11B then 
releases radiation in the form of 7Li and 1H nuclei and 4alpha radiation killing all tissue within 
a 5-9 µm radius of the boron isotope. The inclusion of boron-containing 5’-α-borano G and 
U within an aptamer using wild-type T7 RNA polymerase proved successful, with multiple 
anti-ATP aptamers having been identified that made use of the presence of 
boranophosphate linkages to bind the target (Lato et al., 2002). The use of a well–
characterised and understood aptamer, in this case the anti-ATP aptamer, to test a new 
aptamer technology can be reasoned because the binding of the aptamer to the target can 
be assumed to be consistent with the reported affinity. Additionally, comparisons can be 
drawn with regards to any difference in binding that can be elucidated from the study.  
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Figure 9  Schematic Diagram of BNCT. The firing of a neutron beam will convert 10Boron to 11Boron 
causing the Boron to divide into 7Lithium and the release of 4alpha particle radiation causing a local 
ionization over a region of 1 µm diameter. This causes localised cell death within an area of around a cell’s 
width of the Boron nucleus.   
1.6 Alternative SELEX techniques 
Due to the repetitive nature of the SELEX methodology and the length of time that standard 
SELEX can take to successfully amplify an aptamer, alternative methods to produce useful 
aptamers have been sought. SELEX, in essence, is the selection of prospective ligands based 
on the separation of target-bound and unbound species, so, there is large potential for 
novel methods of partition and augmentation of the procedure.  Detailed below are a 
number of alternative SELEX techniques that differ from standard SELEX and the benefits 
and detractors of each system. 
1.6.1 Capillary Electrophoresis SELEX 
Capillary Electrophoresis SELEX (CE-SELEX) or Non-equilibrium Capillary Electrophoresis of 
Equilibrium Mixtures (NECEEM)(Berezovski et al., 2003) is rapidly becoming the most 
reliable and efficient way to develop aptamers from the oligonucleotide pool, this method 
involves immobilising the target to the wall of a capillary tube of the Capillary 
Electrophoresis device using covalent chemistry, and passing the aptamer library over it. 
Some species within the library are retarded by interactions with the target and those with 
the lowest dissociation constant are held longest.  
30 
 
  
 
  
 
 
 
 
 
 
 
 
 
Figure 10  Schematic of CE-SELEX. A library of ssDNA molecules is incubated with target molecule. 
Capillary electrophoresis is used to isolate bound sequences. Binding oligonucleotides are PCR amplified and 
purified giving an enriched ssDNA pool, suitable for further rounds of selection. High affinity aptamers are 
typically obtained after two to four rounds of selection. Figure taken from (Mosing et al., 2005) 
Derived from a oligonucleotide purification technique (Cohen et al., 1988), CE-SELEX was 
first described in 2002 (Clark & Remcho, 2002) and relies on the refinement of an aptamer 
library following repeated rounds of SELEX using capillary electrophoresis to ensure the 
separation of bound and unbound species. Due to the advanced separation efficiency the 
number of rounds required to isolate aptamers with high binding efficiencies, can be 
reduced to 2–4, after this, generally no further improvement in binding efficiency is usually 
observed (Mendonsa & Bowser, 2004). CE-SELEX has been successfully employed to raise 
aptamers to three large proteins: Age (Mendonsa & Bowser, 2004), farnesyltransferase 
(Berezovski et al., 2005), and HIV-1 Reverse Transcriptase (Mosing et al., 2005) and also to 
two smaller molecules: Ricin toxin (Tang et al., 2006), Neuropeptide Y (Mendonsa & Bowser, 
2005) and most recently the anthrax toxin polypeptide (Cella et al.). 
An apparent limitation associated with the CE-SELEX methodology is a reduced starting 
library, this is a result of the low sample volume, which is often “touted” as one of the 
benefits of the technique (Mosing et al., 2005). The reduced volume of approximately 50 µL 
restricts the number of species from the starting ~1013 library that can be introduced to the 
target, therefore, omitting many potentially binding species from selection.   
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1.6.2 Modified Oligonucleotide-SELEX 
Mod-SELEX is SELEX technique that is undertaken with modified nucleotides; these include 
morpholinos as well as 2’- fluoro nucleotides (Keefe & Cload, 2008). The limiting factor 
involved in this form of SELEX is deemed to be the polymerase involved in the PCR 
amplification steps. The problem is whether the chosen polymerase will incorporate the 
modified nucleotides. There have been several studies to optimise the incorporation of 
modified nucleotides (Sousa & Padilla, 1995, Huang et al., 1997, Fa et al., 2004) by the 
existing widely used polymerases, such as taq polymerase or T7 RNA polymerase or, 
whether novel polymerases need to be identified that will integrate the alternative 
nucleotides (Chelliserrykattil & Ellington, 2004). 
Aptamers constructed with modified nucleotides have one major advantage, complete, or 
partial, resilience to degradation by nucleases (Strehlitz et al. 2008). This in turn can 
increase the potential use of aptamers as therapeutics in vivo. If modifications to an 
aptamer which has been selected to target a protein present in blood can increase the half 
life of the aptamer, but the total residency time in vivo remains limited, then the use of an 
aptamer as a therapeutic reagent can be considered viable. In 2000, the first aptamer 
therapeutic was approved by the FDA in the USA. Macugen® is now commercially available 
as a drug therapy for macular degeneration. The aptamer in question targets a protein 
Vascular Endothelial Growth Factor VEGF-1 known to be instrumental in the progression of 
the degenerative disease (Mousa & Mousa). 
Mod-SELEX pathways can be further categorised by the modified nucleotide that is 
incorporated into the oligonucleotide: 
1.6.2.1 2’-Amino pyrimidines 
The first successful attempt to substitute modified nucleotides, achieved by Lin et al (Li et 
al., 2008), was an attempt to investigate the potential of aptamers as therapeutics, in this 
case a resistance to blood-borne nucleases. 2’-amino pyrimidines and 2’-hydroxyl purines 
were included in the starting library and throughout every subsequent amplification step 
giving rise to an aptamer that binds and inhibits fibroblast growth factor (bFGF) with high 
affinity (350pM) and is 1000 times more stable than RNA in human serum and urine. The 
use of 2’-amino pyrimidines however, is limited due to difficulties arising during the 
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chemical synthesis of the 2’-amino pyrimidines which restricts the amount of the nucleoside 
that can be produced per synthesis (Jellinek et al., 1995) 
1.6.2.2 2’-fluoro pyrimidines 
The most successful attempt to incorporate modified nucleotides in order to prolong the in 
vivo half-life of an aptamer, and create the first therapeutic aptamer, involved the 
incorporation of 2’-fluoro pyrimidines into a well-described aptamer. Although not 
technically derived from mod-SELEX as the modified nucleotides were substituted for the 
wild-type hydroxyl pyrimidines as a post-SELEX optimisation, the target was Vascular 
Endothelial Growth Factor a protein involved in age-related macular degeneration. Another 
2’-fluoro pyrimidine based aptamer that is currently undergoing clinical trials, is the anti-
Factor IX aptamer RB006 (Keefe & Cload, 2008). This aptamer is intended to act as an anti-
coagulant by interfering with the blood clotting cascade by means of binding and inhibiting 
the enzyme involved in coagulation of blood.  
Higher yields of amplification products during Mod-SELEX, using the traditional SELEX 
method, can be achieved using 2’-fluoro pyrimidines and the Y639 mutant of T7 RNA 
polymerase for the PCR amplification stage suggesting that mod-SELEX can be undertaken 
with the same efficiency as conventional SELEX (Kopylov & Spiridonova, 2000). The Y639 
mutant of T7 RNA polymerase (Kostyuk et al., 1995) can incorporate both 2’-deoxy-
nucleotide and non-deoxy nucleotides when synthesising oligonucleotides with no loss of 
specificity for the substrate as the reduced fidelity of the mutated enzyme allows the 
efficient incorporation of non native nucleotides.  
1.6.2.3 2’-O-methyl pyrimidines 
2’-O-methyl nucleotides are a naturally occurring modified nucleotide, which also help to 
confer nuclease resistance to aptamers during post-SELEX modifications whilst providing 
chemical stability. The 2’-O-methyl can occur as a post-transcriptional modification to RNA 
with an occurrence of around 100 per ribosome (Burmeister et al., 2005) and studies using 
the modification have been successful by incorporating the nucleotide using the mutant 
Y639F/H784 T7 polymerase for PCR. In a study by Burmeister aptamers were successfully 
raised to VEGF including the 2’-O-methyl nucleotide post SELEX modification have found to 
have a dissociation constant of 2 nM (Burmeister et al., 2006). 
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1.6.2.4 4’-Thio pyrimidines 
In another approach for confering nuclease resistance to an aptamer, the 4’-oxygen atom of 
the nucleotide ribose ring was targeted as a possible site of modification. By substituting 4’-
thio UTP and CTP into the SELEX library during selection for a modified thrombin binding 
aptamer, Kato et al reported a 50-fold resistance to RNase A-mediated degradation when 
compared to unmodified RNA, whilst retaining a dissociation constant of 5 nM for the 
aptamer-target (Kato et al., 2005).  
 
 
Figure 11 Diagram of modified nucleotide bases available. Grid detailing some of the modified 
nucleotides and nucleosides available for nucleic acid variation. 
1.6.3 Toggle SELEX 
Occasionally a situation arises where it is beneficial for an aptamer to have specificity 
towards two similar, but distinctly different targets, two isoforms of a protein for example. 
In these cases toggle-SELEX (White et al., 2001) can be utilised. It consists of conventional 
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SELEX rounds of screening and amplification, but, instead of screening against one target 
consistently the library is introduced to the variants in alternating rounds of screening step 
(Figure 6).   
The major benefit of toggle-SELEX is that the resulting aptamers will tend to bind the closely 
related regions that will exist in both two related targets. In the first reported example of 
“toggle” SELEX  (White et al., 2001) the aptamer library was screened against human and 
porcine thrombin and produced RNA “toggle” aptamers that bound human thrombin with 
dissociation constants from 1 to 4 nM and porcine thrombin with a dissociation constants for 
the screened library all  less than 1 nM whilst maintaining their ability to inhibit the clotting 
activity of both human and pig blood clotting Factor IIa.  
 
Figure 12 Schematic diagram of “toggle” SELEX methodology. Schematic diagram of the toggle SELEX 
process. Libraries are exposed to two related targets in alternative rounds of selection, enriching a library 
towards the two antigens (White, Rusconi et al. 2001). 
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1.6.4 Photo SELEX 
Aptamer binding relies solely on the shape which the potential aptamer adopts when folded 
in predefined conditions, these conditions however, are likely to be optimised so that the 
target protein remains in its native state. Although maintaining these conditions may 
preserve the structure of the target molecule, it may not be conducive to the best possible 
binding by the aptamer because the pH or solvent concentrations may prevent a potential 
aptamer from forming a suitable secondary structure required for the tightest binding. An 
interesting mechanism to overcome this problem is to photochemically crosslink the 
potential aptamer(s) to the protein of interest and as a result any aptamers that have weak 
interactions can be covalently linked to the protein of interest (Golden et al., 2000), which 
allows isolation of these aptamers. The process of cross-linking requires the incorporation of 
a modified nucleotide into the potential aptamers during the amplification steps that will 
absorb light and are excited sufficiently to form a bond with the aromatic and sulphur 
bearing amino acid residues found in the target protein. Golden et al. (2000) described the 
use of 5-bromo-2’-deoxyuridine (BrdU) to replace thymidine as BrdU absorbs light in the 
310 nm range where the native chromophores of nucleic acids and proteins do not absorb, 
or absorb only weakly. This absorption of light at 308 nm results in cross linking by photo-
coupling of BrdU nucleotides that are located in a reasonable proximity to the aptamer 
(Dietz & Koch, 1987, Dietz & Koch, 1989). 
Using this method aptamers have been produced that show an unprecedented affinity for 
the target human fibroblast growth factor 155 (bFGF155). The two aptamers 06.50 and 
06.15, derived in this study, were found to have dissociation constants of ≈16 pM and ≈560 
pM respectively (Golden et al., 2000), which compare very favourably to conventionally 
made aptamers for the same targets that show interaction dissociation constants of for the 
aptamers 06.15 and 06.50 that range in the tens of nM. 
1.6.5 Cassette Expression SELEX 
The use of aptamers as therapeutic agents still has a significant barrier with regard to the 
delivery of aptamers in vivo to the site of action; the majority of organisms have methods 
for ensuring that foreign DNA and RNA are quickly broken down and destroyed. Cassette 
Expression SELEX avoids the need to deliver the foreign aptamer into the cell by deceiving 
the organism into fabricating the nucleic acid sequence itself in vivo.  
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Figure 13 Construction of the expression cassette vector. An oligonucleotide containing the 
pseudoknot sequence was cloned downstream of the tRNA gene and upstream of the polymerase III 
termination signal generating the DCT5T-pseudoknot vector. (B) Secondary structure prediction of the 
pseudoknot motif within the chimeric tRNA-pseudoknot RNA transcript. The pseudoknot part is shown in 
bold letters. The additional base at the 3’-end of the transcript arises from the termination signal (Chaloin et 
al., 2002). 
 
 The process involves the use of a retroviral vector (Chaloin et al., 2002) created from a  
chimera that was produced by transiently expressing the molecule in eukaryotic cells as a 
polymerase III-driven chimeric gene that consisted of the human initiator tRNAMet (tRNAMeti) 
sequence and the 33 nt pseudoknot sequence. This method inserts the aptamer sequence 
into the flanking regions of the viral genome to produce the chimeric tRNAMet/RNA aptamer 
that binds and inhibits the HIV type I reverse transcriptase. This technique provided a 75% 
inhibition of HIV particle release when co-transfected with HIV-1 DNA in human 293T cells. 
Another report of the use of this technique (Martell et al., 2002) inserted an aptamer that 
inhibits a family of transcription factors. These transcription factors provide a crucial role in 
the process of cell proliferation. The aptamer, called the E2F aptamer, was placed into a 
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tRNA expression cassette and applied to the virus in vitro. This study demonstrated high 
levels of chimeric tRNA that bound its target protein E2F1 with high affinity and in addition 
provided inhibition of functional transactivation by up to 80%.  
1.6.6 Primer-free SELEX 
An essential part of SELEX and, by extension, aptamer isolation is amplification of DNA or 
RNA, between rounds of screening, and due to the nature of amplification using PCR the use 
of fixed primer regions is fundamental (Yang et al., 2007). The problems arising from this is 
that after selection these regions need to be removed as the constant regions can interfere 
with the elucidation of the best binding sequences by providing false positives and 
preventing the random sequence from forming the secondary structures required for 
efficient binding (Pan et al., 2008). By including an additional cleavage step to remove the 
priming sections of the library before the screening part of the SELEX process the 
interference by constant regions is minimised.  
1.6.7 Cell-SELEX 
Cell-SELEX or complex target SELEX (Morris et al., 1998) focuses on whole cell targets for 
selection and tends to identify aptamers to surface bound membrane proteins, but it does 
not require the potential aptamers to exclusively bind to the outer membrane of the cell. In 
fact, the first theory advanced suggested that the random DNA library was absorbed into 
the cell and the aptamers bound to cell-specific targets within the cell (Daniels et al., 2003). 
In one particular case (Daniels et al., 2003),the selection was performed by creating a 
monolayer of U251 glioblastoma cells, a series of washing steps, then harvesting of the cells 
before a recovery of the DNA using phenol:chloroform extraction and ethanol precipitation. 
After 21 rounds of repeated screening and washing the library was cloned and 163 clones of 
possible aptamers were obtained. After computer based analysis (method not reported) of 
the motifs and the recurring clonal dominance of some species, one aptamer sequence was 
decided upon as the consensus sequence, (CCCAGAGGGAAGACTTTAGGTTCGGTTCACGTCC) 
(Daniels et al., 2003). 
The ability to selectively bind cell surfaces has a huge potential for the future application of 
aptamers, both therapeutic and analytical. An aptamer that selectively binds a certain type 
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of tumour cell could be used both as a potential guide for drug targeting, or, in line with 
modern techniques, as a probe for affinity-based sorting and tagging (Daniels et al., 2003).   
In order for the application of Cell-SELEX to be successful in this area, attention needs to be 
focussed on whether the target cells can be differentiated following up-regulation of 
specific proteins expressed on the cell surface. It is the displayed and accessible membrane 
proteins of the cell surface that enable the technique of Cell-SELEX (Fang 2009) although, 
the proteins of interest may only be elucidated after further investigation using the resulting 
aptamer as probes in an affinity purification procedure.  
Studies to discover aptamers selected via this method tend toward cancerous and healthy 
cell differentiation with aptamers being selected to several cell types such as small cell 
(Chen et al., 2008) and non-small cell lung cancer (Tang et al., 2007b), liver cancer 
(Shangguan et al., 2008b) and lymphocytic and myeloid leukaemia (Shangguan et al., 2006). 
1.6.8 Surface binding 
The generic biosensor largely requires the interaction of a ligand with a known binding 
partner that has been immobilised on a surface in order for detection to occur. 
Electrochemical aptasensors (Xu 2009) work in this way for example, along with Surface 
Plasmon resonance (Jost et al. 1991) and the quartz crystal microbalance (QCM) (Hianik 
2005). As a result some attention must be paid to the methods available for tethering a 
biologically active molecule to a surface.  
Streptavidin is a 60,000 Da tetrameric biotin-binding protein that was originally isolated 
from Streptomyces avidini (Chaiet & Wolf, 1964, , 1998). It consists of four subunits which 
are capable of binding four D-biotin molecules. D-biotin has a molecular weight of 244 Da 
and binds tightly to streptavidin with a dissociation constant of Kd=10
-15 mol dm-3 (Green, 
1975). The strong interaction between D-biotin and streptavidin has been utilised in a wide 
range of technologies ranging from affinity chromatography to biochemical assays (Wilchek 
& Bayer, 1990) 
An alternative to the use of a biological methodology to immobilise a biomolecule to a 
surface is the use of amine coupling (Fischer 2010). This method works by the activation of a 
surface that will result in ester bonds forming primarily with the lysines and the α-amino 
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groups of proteins (Aslam and Dent 1999). A common biological method for the surface 
attachment of proteins when orientation is not crucial is the use of N-hydroxy-succinimide 
(NHS) esters, these chemical bonds have been found to be moderately reactive toward 
amines, with high selectivity toward aliphatic amines(Smyth et al. 1964). The use of NHS 
esters is desirable for biological methodologies because the reaction rate with aromatic 
amines, alcohols, phenols, and histidine is relatively low(Smith 1993), this allows the 
selection of molecules that adsorb to the surface under known conditions.  
1.7 Peptide Aptamers 
Given the success of RNA and DNA aptamers as tools for molecular recognition and the 
detection of a wide range of biomolecules, other polymeric biological molecules, that have 
an ability to form distinct three dimensional structures, have been investigated with the aim 
of providing alternative technologies to the established and well characterised use of 
nucleic acids (Gold et al. 2010). The leading alternative to nucleic acid aptamers are peptide 
aptamers (Crawford et al. 2003). Although derived by the more laborious technique of using 
a microarray of potential sequences, peptide aptamers are distinct from traditional peptide 
binding sequences as only through the formation of the 3D secondary structure is binding of 
the peptide to the target facilitated (Colas 2008). Peptide aptamers were designed using the 
IgG antibody as a model, the aptamer consists of a “scaffold” and a variable region inserted 
onto it and although the synthetic peptide aptamer is not as ordered (Figure 14) as the IgG 
molecule, the similarity between the two remains (Baines & Colas, 2006).  However, the 
major benefits of a peptide aptamer over IgG is there is no requirement for disulphide 
bonds required to enable binding (Colas 2008) and the relative compactness of the peptide 
aptamer (Colas, 2008). Additionally the scaffold can be used to confer a possible reporting 
or probing ability onto the peptide aptamer, historically the most common scaffold protein 
was thioredoxin, (LaVallie et al., 1993), a fusion protein that allowed swift and reliable 
purification of the proteins. Other scaffolds for the delivery of the peptide aptamers have 
also been used, green fluorescent protein (GFP)(Abedi et al., 1998), which confers an 
inherent fluorescent reporting ability to the molecule, Staphylococcal nuclease (Norman et 
al., 1999) and Stefin A, a protease inhibitor (Woodman et al., 2005)  both of which provide 
biologically inert scaffolds that remain stable in physiological conditions in order to maintain 
the conformation of the peptide aptamer. 
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Figure 14  Peptide based recognition molecules. Three major classes of constrained recognition 
protein molecules are depicted: immunoglobulin G (IgG), T cell receptor (TCR) and peptide aptamer. Black 
lines represent constant framework or scaffold residues. Blue lines represent variable peptidic regions. Red 
dotted lines represent disulfide bonds. Major distinguishing features of peptide aptamers include the much 
smaller size and the absence of requirement of disulfide bonds to ensure structural constraint of the 
variable region, as opposed to IgG and T-Cell Receptor(TCR) molecules (Baines & Colas, 2006). 
The method for peptide aptamer derivation relies on a microarray system, which can 
contain from 10 to 109 individual peptide probes in the microarray a number that is 2-4 
orders of magnitude smaller than oligonucleotide random libraries (Colas et al. 1996). This 
inferred lack of complexity within the peptide starting library can be seen as a problem for 
the validity of the technique, but can be used to create structured libraries that focus on 
predicted motifs. Using the information that has been gathered from collections of reagents 
with peptide aptamers that have already been selected for and characterised and that are 
known to specifically bind proteins and their mutant isoforms, the structured libraries can 
lead to enhanced rates of peptide aptamer identification, greater specificity and greater 
affinity between the aptamer and target (Colas, 2008).  
1.8 Previously described aptamers 
In order to evaluate the usefulness of nucleic acid aptamers and compare the technology to 
an established and widely used system, there is a requirement to isolate aptamers to 
diverse targets. This process requires specific time and dedication due to the nature of 
SELEX and more specifically there remains no reliable high-throughput method for the 
production of novel aptamers. When the need for an aptamer to a target has been 
identified there must an intensive search of the literature in order to establish whether a 
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previous study has identified a consensus sequence or even a pool of sequences known to 
bind the target with a high specificity and affinity.  
Due to the rapid growth of the field of aptamer research, it is difficult to estimate the 
number of targets to which aptamers have been described. A recent study provides an 
encouraging report of the reproducibility across different SELEX techniques, in this account 
three separate projects result in the production of consensus sequences to the 60 kDa 
protein streptavidin (Bing et al.). A comparison of the resultant consensus sequences 
displays a common motif of a hairpin loop structure with a characteristic bulge along the 
leading (5’) strand of the formation.  
The following section aims to identify and highlight previous investigations that have proven 
successful in the identification of novel aptamer sequences whilst providing a rationale as to 
why each target has been identified as such.  
 
1.8.1 ATP-binding DNA and RNA aptamers 
An early development in the establishment of aptamers as viable alternatives, if indeed 
superior, to antibodies was the discovery that aptamers also bound small molecules (less 
than 88 Da). Of the small molecules which aptamers have been shown to bind the most 
thoroughly researched is the adenosine-5’-triphosphate (ATP) binding aptamer. The first 
aptamer to be isolated that target ATP was an RNA aptamer, which was first isolated in 1993 
(Sassanfar & Szostak, 1993) with the solution structure following in 1996 (Dieckmann et al., 
1996). A DNA-based ATP aptamer was first described in 1995 (Huizenga & Szostak, 1995). 
Although ATP was one of the first targets to have aptamers produced using both DNA and 
RNA, it was quickly found that each nucleic acid made use of a distinct consensus sequence 
that produced radically different secondary structures in order to bind the target. It was 
proposed by Huizenga and Szostak (Huizenga & Szostak, 1995) that the DNA aptamer 
formed a G-quadraduplex; whilst projected secondary structure models for the RNA-based 
ATP binding aptamer indicated an 11 nucleotide loop that encircled the ATP molecule. The 
11 nucleotide loop has repeatedly been reported and is considered one of the most 
conserved and stable motifs found in aptamers isolated using SELEX (Figure 15) (Huizenga & 
Szostak, 1995). 
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An interesting ability of the RNA-based ATP aptamer is the ability to bind to several 
analogues of ATP, with the apparent target for the aptamer being more specifically the 
adenosine base of the molecule rather than the molecule as a whole.  These aptamers show 
the ability to bind 3’-5’ cAMP, ADP, dATP, 2’-O-MeA, 5’AMP, ITP and NAD, but a deficiency 
for binding other ATP analogs that lack the adenosine (Lato et al., 2002).  
 
Figure 15 RNA anti-AMP aptamer. Proposed structure for the ATP/AMP binding RNA-based aptamer. 
The sequence was first reported in Sassanfar and Szostak (1993) and the circled nucleotides represent bases 
that were conserved in all of the sequences that were isolated. Diagram reproduced from (Dieckmann et al., 
1996). 
Further studies of the RNA-based ATP binding aptamer provided evidence that the highly 
conserved aptamer consensus sequence occurred naturally within a viral RNA genome (Shu 
& Guo, 2003). In this study, Shu & Guo found a similar sequence to the consensus sequence 
that had been frequently arrived at from previous ATP aptamer binding studies, was found 
to occur in Phi29-encoded 120 base pRNA (packaging RNA). pRNA is a non-structural RNA 
molecule, which naturally helps form the DNA filled capsid of the virus [REFS]. The pRNA 
forms a secondary structure that holds the ATP within in it until it is required by the DNA 
packaging motor (Parris et al., 1988). The close proximity of the ATP allows the packaging of 
the viral DNA into the capsid to occur at an accelerated rate (Morita et al., 1993).  
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1.8.2 Thrombin 
Thrombin is a 36,000 Da serine protease that is found in mammalian blood and is the final 
active product of the blood clotting cascade (Wolberg, 2007). Thrombin is derived from 
prothrombin, a 72,000 Da protein, from which the active protein is cleaved by Factor Xa to 
produce two thrombin molecules for every single prothrombin. Thrombin then cleaves 
fibrinogen into fibrin which is then hydrolysed into a mesh of fibres in conjunction with 
platelets to provide a scaffold for the formation of blood clots  (Lenting et al.1998).  
The subject of one of the first examples of in vitro selection of aptamers was to human 
thrombin (Bock et al., 1992). Following the initial isolation, the thrombin binding aptamer 
has been thoroughly characterised by several studies adding to the understanding of 
aptamer to target interactions and binding (Wang et al., 1993, Macaya et al., 1993, Paborsky 
et al., 1993), this has been put to good use in the form of starting points and reference 
interactions for the development of further aptamer based technologies utilising aptamer to 
target interactions (Rye & Nustad, 2001, Hu et al., 2009, Xie et al., 2009). The outcome of 
this wealth of knowledge is that any potential biosensor, or biosensing technique, tends to 
be tested using ssDNA thrombin aptamer binding its target.  
The thrombin aptamer consensus sequence GGTTGGTGTGGTTGG (Figure 16) folds into a 
intramolecular quadraduplex with the guanine duplex forming around a metal ion, such as 
K+ which serves to stabilise the secondary structure (Kumar & Maiti, 2004, Wilcox et al., 
2008)).  
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Figure 16  3D image of a complex of Human Alpha-thrombin with the thrombin binding aptamer 
GGTTGGTGTGGTTGG based on X-ray diffraction data. A predicated computer model of complex between 
thrombin and the thrombin binding aptamer produced from data from a crystallographic and NMR solution 
structure (Padmanabhan et al., 1993 and Padmanabhan et al. 1996)with the thrombin depicted as an amino 
acid rainbow and TBA rendered in beige.  
1.8.3 Whole Cell  
One of the most successful example of whole cell-SELEX is the study carried out by 
Shangguan et al. (Shangguan et al., 2008a) targeting protein biomarkers with the aim of 
identifying disease specific protein expression. The DNA aptamers were selected against a 
cell line known to carry the disease T-cell acute lymphoblastic leukaemia (T-ALL), and from 
the resulting library one aptamer in particular (scg8) was found to have a high affinity for 
most of the T-ALL cells along with some specificity for acute myeloid leukaemia (AML) and 
B-cell acute lymphoblastic leukaemia (BALL) cells. 
1.9 Biosensor design  
The biosensor concept as mentioned above relies on a high affinity, highly specific molecular 
recognition element. Aptamers may provide a useful solution in the quest to determine the 
best possible resolution to this problem. Once the potential of aptamers as the MRE in a 
biosensor can be realised their place in combination, substitution, or, eventually as 
dominant alternative can be attained due to the ease of aptamer isolation demonstrated 
herein.  
45 
 
1.9.1 Modified ELISA system 
An existing method that utilises antibodies as a molecular recognition element within a 
biosensor is ELISA. This technique requires the use of an antibody as a recognition molecule 
that will specifically bind an antigen, the detection of the binding event is then probed using 
a secondary antibody that has been raised to the primary (recognition) antibody. Attached 
to the secondary antibody is a reporter molecule, typically a fluorophore that can be 
detected at very low concentrations (nM to pM) allowing detection of an antigen at 
concentrations much below those required for bulk analysis such as absorbance 
spectroscopy (GoldFarb, 1951)  
With the aim of displaying the benefits of aptamer technology as a possible alternative to 
antibodies, the use of aptamers within a modified ELISA sandwich has not yet been fully 
investigated. Although some published work (Tennico et al., 2010) does detail the use of 
aptamers as either the primary or the secondary portion of the ELISA sandwich (Ferreira et 
al. 2008), there is, as yet, no report of a complete ELONA (Enzyme-Linked Oligonucleotide 
Assay) sandwich functioning.  
1.9.2 The Generic Biosensor Concept 
The proposed use of aptamers within a generic biosensor is as follows; the concept is based 
on the ligand-enabled release of a motor protein and the subsequent detection of the 
motor activity. Figure 17 is a schematic diagram of the concept, which utilises polyclonal 
antibodies as the MRE and a series of enzymes to initiate, amplify and enable a signal.  The 
antibody  ELISA sandwich will form an around any analyte to which antibodies can be raised, 
e.g. bacteria, spores, viruses,  and proteins. 
46 
 
 
Figure 17  The Generic Biosenor concept. A. Ab1 and Ab2 form an ELISA sandwich around a target 
molecule. B. Ab 2 carries a streptavidin conjugation, to which a biotinylated protease B can be attached. 
Protease B can then be released by protease A. C. This protease will subsequently release a motor protein 
that has been bound to a surface by a peptide linker. D. This motor can then bind, then translocate a DNA 
strand that has been attached to a paramagnetic whose movement is then tracked.  
The biosensor uses the release of the molecular motor from EcoR124I bound to create 
signal by translocation of a DNA strand that is attached to a magnetic bead whose 
movement can be tracked by either a magnetic tweezers system or by a Hall effect sensor. 
Immobilisation of this on a GST column has demonstrated the detection of glutathione 
through motor release (the fusion protein will translocate DNA). Unpublished results have 
shown motor release through thrombin cleavage on the column can give an amplification of 
greater than 1000 motors released by each thrombin molecule through cleavage. 
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Figure 18  The proposed aptamer:antibody modified ELISA. A. Ligand1 and Ligand2 form an ELISA 
sandwich around a target molecule. B. Ligand 2 can carry a streptavidin conjugation, to which a biotinylated 
protease B can be attached. Protease B can then be released by protease A. C. This protease will 
subsequently release a motor protein that has been bound to a surface by a peptide linker. D. This motor 
can then bind then translocates a DNA strand that has been attached to a paramagnetic whose movement is 
then tracked as in the antibody ELISA version. 
From the original model of a generic biosensor (Figure 17) Ligand 1 can be replaced by a 
ssDNA or RNA aptamer. As could Ligand 2, although Ligand 2 is not an absolute requirement 
for the system to work as the aptamer can carry the reporting ability (Figure 18). One 
possible use is to develop aptamers to toxin-receptors. DNA translocation will pull the 
magnetic bead past a sensor. The sensor could switch a silicon-based device. This allows an 
interface between the ‘biological’ world and the ‘silicon’ world, and it is the purpose of this 
thesis to demonstrate the ease that aptamers can be isolated and that aptamers be 
substituted for antibodies and can be the gold standard MRE of any biosensor. 
48 
 
2 Materials and Methods 
2.1 Standard solutions 
2.1.1  5-bromo-4-chloro-3-indolyl-galactopyranoside (X-Gal) 
20 mg X–Gal was dissolved in 1 mL dimethylformamide and stored at 4oC until use.  
2.1.2  Adenosine Trio Phosphate (ATP) Stock 
0.05 g ATP, was dissolved in 1 mL 100 mM Tris.HCl pH 9 and stored at -80oC until use. 
2.1.3  Ampicillin stock 
Ampicillin, sodium salt, dissolved in AnalR water to a concentration of 100 mg mL-1, and 
filtered with a 0.2 µm filter. This stock was aliquoted, stored at -20oC and used at a final 
concentration of 100 µg mL-1 when required. 
2.1.4  Ammonium acetate 7.5M 
57.81 g Ammonium acetate was dissolved in 100 mL and stored at room temperature. 
2.1.5 Chloramphenicol 
A stock solution of 20 mg/mL chloramphenicol was made by dissolving 20 mg of 
chloramphanicol in 1 ml of ethanol and later diluted to a working concentration of 50 µg/µL 
prior to use.  
2.1.6 Coomassie Blue stain 1L 
250 mg of Brilliant Blue R250 was dissolved in 500 mL Methanol, 100 mL Acetic Acid and 
400 mL H2O and stored at room temperature. 
2.1.7 Destain 1L 
100 mL of 100% Methanol was combined with 100 mL of Glacial Acetic Acid and 800 mL of 
H2O and stored at room temperature.   
2.1.8 500 mM EDTA  
186.12 g di-potassium salt dehydrate (Sigma) was dissolved in 800 mL of AnalR water and 
then adjusted to pH 8. The solution was made up to 1 L with AnalR water and then 
autoclaved.  
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2.1.9 100mM HEPES 
2.38 g of 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES), was dissolved in 
100 mL of AnalR dH20 and the pH adjusted to pH 7.5  
2.1.10 HRV143C Cleavage buffer 
2.42 g of Tris, 8.76 g of NaCl 0.154 g of DTT, and, 0.124 g of EDTA were dissolved in 1 L of 
AnalR dH20 and the pH adjusted to pH 7.0. 
2.1.11 1 M Isopropyl-β-D-thio-galactopyranoside (IPTG) Stock 
1M IPTG stock solution was made by dissolving 2.38 g of IPTG in 10 mL of AnalaR water, 
followed by sterile filtering with a 0.2 µm filter. This stock was aliquoted into 1 mL and 
stored at -20oC 
2.1.12 10× Phosphate Buffered Saline (PBS) 
80 g NaCl, 2 g of KCl, 11.5 g of Na2HPO4, and 2 g of KH2PO4 were dissolved into 100 mL of 
AnalR water and then autoclaved. 
2.1.13 10 M Sodium Hydroxide 
40 g sodium hydroxide (NaOH) (Sigma) was dissolved in 80 mL of AnalaR water. The solution 
was then made up to the final volume of 100 mL with AnalR water. 
2.1.14 3× SDS Loading Buffer 
30 % w/v Glycerol, 15 % w/v β-Mercaptol Ethanol (Sigma-Aldirch UK), and 9% w/v Sodium 
Dodecyl Sulphate, were dissolved in 1 mL 180 mM Tris pH 6.8 and stored at room 
temperature.   
2.1.15 10× SDS–PAGE Running buffer 
75.75 g of Tris(hydroxymethyl)aminomethane (Tris), 360.0 g of Glycine, and, 25 g of Sodium 
Dodecyl Sulphate (SDS) were dissolved in 2.5 L of dH20. 
2.1.16 Sodium Tris EDTA (STE) 
5.84 g NaCl, 1.21 g Tris Base and 0.29 g EDTA  were dissolved into 800 mL AnalR water, then 
pH adjusted to 8.0 before being made up to 1 L. The solution was then filter sterilised using 
a 0.2 µm filter, autoclaved and stored at room temperature.  
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2.1.17 50× Tris Acetate EDTA (TAE) 
242 g of Tris base, 57.1 mL of glacial acetic acid and 18.6 g of EDTA were dissolved together 
and made up to 1 L with AnalR water. The solution was then filter sterilised using a 0.2 µm 
filter and stored at room temperature. 
2.1.18 Thrombin Storage Buffer 
0.11 g Sodium Chloride, 0.1 g Sodium Citrate were dissolved in 5 mL of AnalR dH2O and 
adjusted to pH 6.5, to this Glycerol was added to 50% v/v and filter sterilised before storage 
at room temperature. 
2.1.19 1 M Tris.HCl 
1M Tris.HCl solution was made by dissolving 121.14 g Tris (hydroxymethyl)-
aminomethane.HCl (Sigma) in 800 mL AnalaR water, then the pH was adjusted using 
concentrated Hydrochloric acid. The solution was then made up to 1 L with dH2O water and 
sterilised with a 0.2 µm filter and then autoclaved. 
2.2 Poly Acrylamide Gel Electrophoresis (PAGE)  
2.2.1 10% Sodium Dodecyl Sulphate (SDS) Poly-Acrylamide Gel Electrophoresis 
2.2.2 Preparation of Agarose gels 
0.74 g agarose was added to 1.8 mL 50x TAE and made up to 90 mL with AnalaR water. The 
mixture was then boiled using a microwave and allowed to cool to 65°C in an appropriate 
water bath. Ethidium bromide was added to a final concentration of 0.5 µg mL-1 before 
pouring into the plate of a gel electrophoresis tank, with comb(s) inserted, and allowing the 
gel to set at room temperature. A running buffer of 1x TAE and 0.5 µg mL-1 ethidium 
bromide was poured into the gel tank ensuring the gel and wells were covered.  
2.2.3 Agarose gel Electrophoresis 
Gel electrophoresis was used to separate DNA fragments by running the samples at 50 V for 
15 minutes then increasing to 100 V until full separation was observed. For fragment size 
comparison Bioline Hyperladder I was run alongside the loaded test samples. 
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Figure 19 Diagram of the two DNA molecular weight markers Hyperladders I and V (Bioline) 
 
 
Table 1 Solutions required for the construction of 10% SDS PAGE gels 
Solution A   Solution B   Solution C   
Acrylamide 30.4 g S.D.S 0.4 g S.D.S. 2 g 
Bisacrylamide 0.8 g Tris.HCl pH 8.8 18.2 g Tris.HCl pH 6.8 30 g 
dH2O 100 mL dH2O 100 mL dH2O 100 mL 
 
Table 2 Concentrations of solutions required for the construction of 10% SDS PAGE gels 
Resolving Gel Volume Stacking Gel Volume 
Solution A  2.7 ml Solution A 375 µL 
Solution B 2.0 mL Solution C 625 µL 
H2O   3.25 mL H2O   1.5 mL 
Ammonium 
Persulphate 
75 µL Ammonium Persulphate 20 µL 
TEMED 10 µL TEMED 5 µL 
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The components listed in Table 1 and Table 2 were added together in the order listed and 
gels poured immediately. An interval of 30 minutes was allowed before electrophoresis In 
order to ensure that the gels had fully polymerised. 
2.2.4 5% Native Gel 
Chemical Volume 
Accugel (40%) 2.5 mL 
50x TAE 400 µL 
1M DTT 60 µL 
 H20 17.04 mL 
Ammonium 
Persulphate 
100 µL 
TEMED 30 µL 
 
Constituents 1-4 were combined together before the sequential addition of ammonium 
persulphate and TEMED.The gel was poured immediately and left to set for 1 hour. The gel 
was then pre-run at 100 V for 1 hour at 4oC before electrophoresis of samples. 
2.3 Bacterial Strains 
Strain: Genotype: Origin: 
E. coli JM109 F’, traD36, proA+B+,  
laclqΔ(lacZ)M15/ Δ(lac-proAB), 
glnV44, e14-, gyrA96, recA1, 
relA1, endA1, thi, hsdR17 
(Yanisch-Perron et al., 1985) 
E. coli JM109 (DE3) endA1, recA,  gyrA96, thi-1, 
hsdR17(rk-, mk+), relA1, supE44, 
Δ(lac-proAB), *F’, traD36, 
proAB, laclqZΔM15+, λ(DE3) 
(Yanisch-Perron et al., 1985) 
E. coli BL21 F-, ompT, hsdSB(rB-, mB-), gal
 
(Weiner & Costa, 1994) 
E. coli BL21 (DE3) F-, ompT, hsdSB(rB-, mB-),dcm,  (Studier & Moffatt, 1986) 
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gal,  λ(DE3) (Weiner et al., 1994) 
E. coli BL21 (DE3) pLysS F-, ompT, hsdSB(rB-, mB-),dcm,  
gal,  λ(DE3), pLysS (Cmr) 
(Derman et al., 1993) 
E. coli DH5α Φ80lacZΔM15, recA1, endA1, 
gyrAB, thi-1, hsdR17(rk-, mk+), 
supE44, relA1, deoR, Δ(lacZYA-
argF) U169, phoA 
(Woodcock et al., 1989) 
 
2.4 Plasmids 
Plasmid: Function: Reference: 
pGEX-2T Ampr, GST-tag, thrombin cleavage site (Smith & Johnson, 1988) 
pGEX-6P Ampr, GST-tag, PreScission Protease cleavage site (Smith & Johnson, 1988) 
pCFD30 Ampr, based on pUC19, contains a single EcoR124I site (van Noort et al., 2004) 
pJS4M3 pJS4M based plasmid containing two tandemly 
arranged T7 gene 10 promoters 
(Zinkevich et al., 1997) 
pGEM-T-Easy Ampr, pGEM based plasmid containing T7 and SP6 
RNA polymerase promoters. Linearisedwith 3’ T 
overhangs.   
(Kobs. 1997) 
pGEX-2T-R Ampr, GST-tag, thrombin cleavage site, containing 
HsdR gene. 
Unpublished Plasmid 
pGEX-6P-R Ampr, GST-tag, PreScission Protease cleavage site, 
containing HsdR gene. 
Unpublished Plasmid 
pGEX-2T-PP Ampr, GST-tag, thrombin cleavage site, containing 
gene for Human Rhinovirus 14 3C. 
Unpublished Plasmid 
 
2.5 Culture media 
2.5.1 Luria Broth (LB) Media 
Bactotryptone (10 g), Bactoyeast extract (5 g) and sodium chloride (5 g) dissolved in AnalaR 
water; adjust pH to 7.2 and made up to 1 L in AnalR water and autoclaved immediately. 
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2.5.2 LB Agar 
Bactotryptone (10 g), Bactoyeast extract (5 g), sodium chloride (5 g) and bactoagar (15 g) 
were dissolved in AnalaR water; pH adjusted to 7.2 and made up to 1 L in AnalR water and 
autoclaved immediately. 
2.5.3 2× TY Broth 
Bactotryptone (16 g), Bactoyeast extract (5 g) and sodium chloride (5 g) dissolved in AnalR 
water; pH adjusted to 7.2 and made up to 1 L in AnalaR water and autoclaved immediately. 
2.6 Microbial techniques 
2.6.1 Liquid bacterial cultures 
Liquid cultures of E. coli were grown in Luria Broth with the required antibiotic after 
inoculation with a single colony using an inoculating loop or sterile alternative. Cultures 
were grown at 37oC with agitation at 180 rpm until the desired O.D.600 was achieved. 
2.6.2 Preparation of competent bacterial cells for transformation 
Cells of the required strain of E. coli were grown in an overnight culture in LB media at 37°C 
without antibiotic. 1 ml of the overnight culture was added to 100 ml pre-warmed LB 
medium in a 250 ml flask, and agitated at 180 rpm at 37°C until an O.D. of ~0.5 at a 
wavelength of 600 nm was reached. The culture was cooled on ice for 5 min, and 
transferred to a sterile, round-bottom centrifuge tube. The cells were harvested by 
centrifugation at 4000 x g for 5 minutes at 4°C. Cells were resuspended in cold 100 mM 
RbCl, 50 mM MnCl2, 30 mM potassium acetate, 10 mM CaCl2, 15% glycerol, pH 5.8, buffer 
the suspension was kept on ice for an additional 90 minutes. The cells were collected by 
centrifugation at 4000 x g for 5 minutes at 4°C. The supernatant was discarded. the cells 
were resuspended carefully in 4 ml of ice-cold 10 mM MOPS, 10 mM RbCl, 75 mM CaCl2, 
15% glycerol, pH 6.8  buffer. Aliquots of 100 μL were prepared in sterile microcentrifuge 
tubes and frozen in liquid nitrogen, or in a dry-ice-ethanol mixture.  Competent cells were 
stored at –70°C and defrosted for use when required. 
2.6.3 Transformation of Competent cells 
10 ng of Plasmid DNA of the required concentration was added to an aliquot of 100 μL of 
competent cells and incubated at 0°C for 20 minutes. The cells were then “heat shocked” for 
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90 seconds at 42°C and 500 μL of LB broth was added and the cells were transferred directly 
to an incubator at 37°C for 1 hour with agitation at 180 rpm.  The cells were then 
centrifuged for 15 seconds at 10,000 x g and resuspended in 200 μL of LB broth before 
spreading on an LB agar plate containing the required antibiotic. The plate was then 
incubated overnight at 37°C. 
2.7 DNA Techniquess 
2.7.1 Cloning and expression of aptamer sequences 
The Taq. polymerase amplified the library but Taq. leaves a 3’ adenosine overhang which 
faciliatated the ligation of the sequences into the pGEM-T-Easy plasmid which has a 5’ 
thymine overhang. The ligation was performed overnight at a temperature of 4oC to ensure 
complete ligation of the products. Following ligation the products were transformed into 
E.Coli [JM109] and analysed using the blue-white test (Maniatis et al., 1982). The blue-white 
test operates by the insertion of a gene into the multiple cloning site of a vector that has 
been cleaved by restriction enzymes within the LacZ gene. This disruption prevents the 
production of functional β-galactosidase. By incubation in the presence of 5-bromo-4-
chloro-3-indolyl-galactopyranoside (X-gal), the cells lacking the β-galactosidase cannot 
metabolise the X-gal to form 5-bromo-4-chloro-indoxyl. When metabolised the X-Gal is 
oxidized 5,5'-dibromo-4,4'-dichloro-indigo, which gives the colonies a blue pigment. A blue 
colony indicates the hydrolysed oxidized 5,5'-dibromo-4,4'-dichloro-indigo and therefore 
the gene and the vector is intact. White colonies indicate insertion of foreign DNA and loss 
of the cells' ability to hydrolyse the marker. White colonies displaying the insertiong were 
then placed in a nutrient broth and incubated at 37oC overnight before the plasmid DNA 
was isolated using QIAgen miniprep plasmid isolation kit. The recovered DNA was then sent 
for sequencing. 
2.8 Silver staining 
2.8.1 Staining procedure 
The gel is fixed by incubation with gentle agitation in 100 mL of fixing solution, 50 % 
methanol, 10 % glacial acetic acid, for 1 hour. The the fixing solution is refreshed with a 
further 100 mL change of the fixing solution (gel may be left in the second change fixing 
solution overnight).  After removal of the solution the gel was rinsed for 30 minutes in 
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100 mL of 5 % methanol, 7 % acetic acid with agitation. The solution is removed and is 
followed by an agitated wash for 30 minutes in 100 mL of 10 mM gluteraldehyde solution. 
The gel is washed thoroughly by 4 instances of a 15 minute incubation in AnalR dH20 then 
followed by a 30 minute agitated incubation in 100 mL of 77 µM DTT solution. After washing 
the gel is stained by incubation in 100 mL of 1 mM Silver nitrate (AgNO3) for 45 minutes 
then washed a further 3 times with freshly prepared developing solution (37 mM 
Formaldehyde, 3 mM sodium carbonate) for 1 minute. The gel was then agitated in fresh 
100 mL of 100% developing solution for 4 to 15 minutes or until the bands reach desired 
intensity.  
The developing reaction is stopped by the addition of 5 mL of 2.3 M citric acid to neutralise 
the developing solution and incubation for 15 minutes. The gel is washed again by 4 
instances of 15 minute incubation in AnalR dH20 then incubated with a 0.03% sodium 
carbonate solution for 15 minutes to prevent bleaching. The stained gel can then be stored 
at this stage in 20% methanol 5% glycerol 0.03% sodium carbonate in sealed plastic bag, or 
dried.  
2.9 Selective Evolution of Ligands using EXponential Enrichment (SELEX) 
100 µM Aptamer library of ssDNA was created by the dilution of 100 nmoles in 750 µL of 
nuclease free water and stored at -20OC. The library sequence consisted of two known 
primer regions flanking an unknown 30 base pair random region:  
GGC GGC GTA TTA TAN NNN NNN NNN NNN NNN NNN NNN NNN NNN GCG CTA TAT 
SELEX Forward Primer: CCG CCG CAT AAT AT 
SELEX Reverse Primer:  ATA TAG CGC 
2.9.1 Glutathione Sepharose Spin Column Preparation 
In a G-25 spin column (GE Healthcare®) a premixed suspension of 300 µL Glutathione 
Sepharose (GE Healthcare®) beads re-suspended added to the column and spun in a micro 
centrifuge at 1000 x g for 1 minute. 300 µL AnalR water was applied to the column and 
subsequently spun at 1000 x g for 1 minute and repeated three times to completely wash 
the column. The column is equilibrated by three sequential washes of 300 µL of the storage 
buffer required by the GST-fusion protein target each followed by a 1 minute spin at 
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1000 x g.  50 µL to 100 µL of the target protein is bound to the column media by incubation 
with together at ~21 oC for 10 minutes, any of the unbound remaining protein is removed by 
a spin in a micro centrifuge at 1000 x g for 1 minute. The column is washed with 300 µL of 
the specified buffer which is centrifuged at 1000 x g for 1 minute to removed excess buffer 
and repeated three times to ensure complete removal of unbound protein.  
2.9.2 Screening 
Following preparation of the column, 50 µL of aptamer library was introduced to the column 
and allowed to bind by incubation at ~21 oC for 10 minutes. Following incubation 300 µL of 
the required protein buffer are applied to the column with the removal of any unbound 
species removed with by centrifugation at 1000 x g for 1 minute. The washing step was then 
repeated three times to ensure a complete wash of the column. Elution of the bound 
species was achieved by the introduction of 100 µL 2 M NaCl2 elution buffer, which was 
incubate for 10 minutes at ~21 oC. Following incubation the eluent is collected by 
centrifugation at 1000 x g for 2 minutes and desalted using GE healthcare G-25 desalting 
spin column.  
2.9.3 Amplification 
The Resulting DNA is amplified using 25 µL 2 x GoTaq Polymerase master mix, 1 µL SELEX 
Forward primer, 1 µL Reverse primers and incubated using the following protocol; 
Denaturation step of incubation at 94oC for 3 minutes, then 94oC for 1 minute, 60oC for 30 
seconds, and, 68oC for 20 Seconds which is repeated 36 times. Then, a final extension of 
68oC for 1 minute 30 seconds followed by a 6oC soak.  
The screening and amplification cycles are repeated for 10-13 rounds, with each round 
analysed on a 15% native acrylamide gel, or non-denaturing HPLC using the Dionex 3000LC 
system. 
2.10 Dot Blot analysis 
Decreasing concentrations of protein to be probed were spotted onto nitrocellulose 
membrane in 1 µL dots and left to dry in air. The blots were then left to incubate overnight 
at 4oC in 200 mL 1x TBST (5% BSA). After 16 hours the blots are then separated into strips 
according to the potential aptamer being tested and incubated for 2 hours in 10 µM of 3’ 
biotinylated aptamer solution. The blots are then washed three times for 15 minutes in 
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200 mL 1x TBST (5% BSA), then in a 5 ml solution of the streptavidin-HRP conjugate, with the 
conjugate diluted 1:5000 in 1x TBST (5% BSA), for 2 hours at room temperature with 
agitation. The blots were then washed three times for 15 minutes in 200 mL 1x TBST (5% 
BSA) and then three times in 1x TBST for 5 minutes, following which a there was a final wash 
of 1 x PBS in which the blot was left until development. 
The blots were then developed by combinination with a mixture of two solutions; Solution 1 
: 100 l Luminol, 44 l pCoumeric Acid, 1 ml Tris HCl pH 8, 8.9 ml dH2O, and Solution 2 : 6 l 
H2O2, 1 ml Tris HCl pH 8, 9 ml dH2O. After 1 minute the dot blots were then visualised using 
Fuji FLA3000 with a 0.85 mm aperture and an exposure time of 1 minute or longer if 
needed. 
2.11 Surface Plasmon Resonance (SPR) 
Standard Surface Plasmon Resonance experiments were carried out on the Biacore T100 (GE 
Healthcare) with buffers selected according the experiment undertaken. All buffers were 
made to 1 L and filtered and degassed before use.  
Biotinylated aptamers were immobilised on a streptavidin coated Biacore SA chip in 
aptamer binding buffer (20 mM Tris pH 8, 10 mM MgCl2) at 10 µL/minute flow following 
three 10 µL injections of 1M NaCl2, 50mM NaOH to clean and prepare the surface. 
Sequential injections of 5 µM aptamer of increasing volume in binding buffer, from 1 µL to 
15 µL aiming for an immobilisation level of 1000 arbitrary response units.  
Kinetics of binding of the analyte was assayed by flowing samples of increasing 
concentration over the surface bound aptamers.  
2.12 Purification of GST-PP-HsdR and GST-PP  
10 ng of the plasmid pGEX-6P-R was transformed into competent E. Coli [BL21(DE3)] and 
incubated overnight at 37oC. From this transformation single colonies were picked and 
grown in overnight cultures of 10 mL Luria Broth with 10 µg/mL ampicillin. After incubation 
500 mL cultures of 2x TY with 10 µg/mL ampicillin were inoculated and incubated at 37oC 
with 180 rpm agitation until a 600 nm optical density of 0.6-1.0 was reached. Once the 
optical density was reached the cells were induced with 1 mM IPTG and incubated overnight 
at 24oC with 180rpm shaking. The following morning the cells were harvested by 
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centrifugation at 7000 x g for 12 minutes. The cell pellet was then resuspended in sonication 
buffer (1x PBS, 1mM DTT, 1mM Benzamidine, 0.1mM PMSF, 2 non-EDTA protease tablets.) 
and sonicated at a 40% amplitude for 3.3 seconds then 9.9 seconds recovery for a total of 15 
minutes. The sonicate was then centrifuged at 27,000 x g for a total of 30 minutes, then the 
supernatant transferred  to ultra-centrifuge tubes and centrifuged at 200,000 x g for 2 
hours. The supernatant was loaded onto Glutathione Sepharose™ Fast Flow column (GE 
Healthcare) that was pre-equilibrated with PBS, 1 mM DTT and then buffer exchanged into 
buffer A (10 mM Tris.HCL pH8, 0.2 M NaCl, 0.1 mM EDTA, 1 mM DTT) and purified GST-
tagged protein eluted with Tris buffer B (10 mM Tris.HCL pH8, 0.2 M NaCl, 0.1 mM EDTA, 
1 mM DTT, 10 mM Glutathione) into 4 ml fractions. Any peaks were investigated using SDS-
PAGE and any fractions found to contain protein of the correct size were pooled. Free 
Glutathione was removed by using 100,000 MW cut off spin columns (Centricon©). 
Depending on the application, the purified protein was used straight away or made to 50% 
glycerol for long term storage at 20oC. 
2.13 Ecor124I HsdM Subunit Isolation 
10 ng of the plasmid pJS4M3 (Patel & Firman, 1992) was transformed into competent E. Coli 
[JM109 (DE3)] and left to incubate overnight at 37°C, from this 20 colonies were selected at 
random and incubated in 3 mL Luria broth at 37°C with agitation at 180 rpm over 8 hours. 
After incubation 1 mL samples were taken, these samples were then spun at 13000 x g for 1 
minute to pellet the cells after which the cells were resuspended in 30 µL SDS loading buffer 
and boiled at 100 °C for 5 minutes. All 20 samples were then run on a 10% SDS PAGE gel and 
expression of the wild type HsdM subunit was estimated using a semi-quantitative ocular 
assay.  The colony exhibiting the greatest expression level was selected for further growth in 
large scale culture. The cells were then grown for 16 hours at 37°C with shaking at 180 rpm, 
and then harvested by centrifugation at 3,500 x g for 30 minutes. The cell pellet was 
resuspended in sonication buffer (50 mM Tris.HCl pH 8.0, 20% glucose, 3 mM DTT, 5 mM 
EDTA, 0.1 mM PMSF, and 1 mM benzamidine) and sonicated with 3.3 s bursts of 40% 
amplitude and a recovery time of 9.9 s for a total time of 10 minutes. The cell lysate was 
then centrifuged at 27,000 x g for 30 minutes to clear the sonicate and followed by a 2 hour 
centrifugation step at 200,000 x g to clear the majority of cell debris from the lysate. The 
supernatant was then adjusted to 500 mM NaCl, 10 mg/mL protamine sulphate, and rocked 
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gently at 4°C for 30 minutes from which any DNA was pelleted by centrifugation at 
27,000 x g for 30 minutes. The supernatant was then subjected to a 70% ammonium 
sulphate fractionation and centrifugation step of 27,000 x g for 30 minutes. The pellet was 
then resuspended in buffer A (50 mM Tris.HCl pH 8.0, 50 mM NaCl, and 1mM EDTA) and 
desalted using a pre-equilibrated HiTrap™ desalting column (GE Healthcare) in tandem 
(10 mL total volume) and eluted of a 100 mL gradient of 50 mM to 500 mM NaCl using 
buffer B (50 mM Tris.HCl pH 8.0, 1 M NaCl, and 1mM EDTA). Fractions found to contain the 
wild type HsdM subunit were then pooled and desalted into buffer C (50 mM Tris.HCl pH 
8.0, 100 mM NaCl, and 1mM EDTA) using the previously described method above. After 
desalting the pooled fractions were loaded onto a HiTrap™ Heparin column (GE Healthcare) 
and the protein eluted using a 100 mL gradient from 100 mM to 1 M NaCl using buffer B. 
The fractions found to contain the HsdM subunit were pooled and made to a 50% glycerol 
solution and stored at -20°C until required 
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3 Analysis and/or characterisation of a known aptamer 
3.1 Thrombin 
The aim of this chapter is to demonstrate the binding of a known aptamer through widely 
available molecular laboratory techniques. Presented here is the application of two 
techniques; Fluoresence Resonance Energy Transfer (FRET), and Surface Plasmon Resonance 
(SPR), in the analysis of binding of a known aptamer (TBA), to its target (thrombin). 
The thrombin binding aptamer, (TBA) first described by Bock et al.,(Bock et al., 1992) is a 
well defined DNA aptamer and as further studies have been published the mechanism of 
folding and binding of the aptamer to thrombin has been thoroughly understood. The 
aptamer occupies the heparin binding site of thrombin mimicking the molecule’s footprint 
on the active site and preventing binding of thrombin to fibrinogen with similar efficiency to 
the chemical(Bock et al., 1992). Using this stable aptamer to target binding partnership, 
further aptamer binding validation methods can be developed with reference to the 
published characteristics and binding affinities.  
3.2 Fluorescence resonance energy transfer (FRET) 
Fluorescence resonance energy transfer (FRET) is a distance-dependent interaction between 
the electronic excited states of two molecules in which excitation is transferred (Runnels & 
Scarlata 1995) from a donor molecule to an acceptor molecule without the emission of a 
photon (Figure 20). FRET can be an important technique for investigating a variety of 
biological processes which result in changes in the molecular proximity of two known 
components, for example the cleavage of a peptide with a fluorescent molecule and a 
quenching molecule in close proximity would result in an increase in fluorescence (Figure 
21). FRET can be used as a contrast mechanism, that is, to probe the co-localization of 
proteins and other molecules. This facilitates a method of imaging and an insight into spatial 
resolution, which is far beyond the limits of conventional optical microscopy (Hell, 2009).  
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Figure 20 Diagram of electron transfer overlap in FRET. Schematic representation of the FRET 
spectral overlap, where J is the emission wavelength required for the absorption that results in the 
excitation of the acceptor between a quencher and emission FRET pair. 
Http://probes.invitrogen.com/handbook/boxes/0422.html 
 
The ability to report whether two molecules are in close proximity can be used to detect the 
presence or absence of a cleavage enzyme, be it nucleic acid or peptide. The detection of 
cleavage can also be extended to an inhibitory agent preventing cleavage. In a method 
similar to the molecular beacon concept (Tyagi & Kramer, 1996) the cleavage assay will 
report the cleavage of a peptide via the change in signal achieved when cleavage occurs.  
Such an event can occur when thrombin cleaves its substrate peptide in imitation of the 
protease’s role within the blood clotting cascade (Esmon, 1995). If a cleavage event does 
happen, the quencher and donor molecules are a sufficient distance apart for the quenching 
effect to cease and fluorescence will occur (Figure 21). Assuming efficient cleavage of the 
peptide by the protease an inhibitory effect can be observed and possibly calculated by a 
reduction in signal. Inefficient cleavage can be caused by inappropriate conditions such as 
incorrect buffer constitution, pH or temperature, or an inhibitory agent. In the case of the 
serine protease thrombin, its proteolytic activity is inhibited by a number of chemical 
compounds, heparin and warfarin notwithstanding; there are approximately 50 
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commercially available drugs available that reportedly inhibit thrombin’s coagulant ability 
(Levy et al., 2007). The common feature of the thrombin inhibitors is the occupation of the 
catalytic cleft that acts as the active site for the digestion of soluble fibrinogen to its 
constituent individual fibrils. The occupation can be achieved by a steric mimicry of the 
substrate fibrinogen and a greater affinity for the inhibitor preventing substitution. The Bock 
thrombin inhibitor aptamer uses this method to occupy the heparin binding site with a 
dissociation constant of ~ 60 nM and subsequently reduces coagulation accordingly (Bock et 
al., 1992). 
 
Figure 21 Cleavage Assay diagram, Diagram depicting the mechanism through which peptide 
cleavage can be converted to a FRET response. http://www.mimotopes.com/Uploads/Images/peptides-
and-antibodies/Advanced-FRET-Principal-3a.jpg 
 
With reference to the FRET detection system, the peptide carried a fluorescence reporting 
mechanism along with a peptide sequence containing the recognition and cleavage site for 
α-thrombin (GLVPRGSG)(Chang, 1985). Assuming the efficient cleavage of the substrate an 
increase of FRET can be measured by increasing fluorescent signal in a concentration 
dependent manner. Conversely a decrease in signal not attributable to inefficient cleavage 
can be assumed to be due to an inhibitory effect such as the presence of an aptamer 
inhibitor. It is this effect that may give an insight into the inhibitory effects of the Bock 
thrombin binding aptamer. 
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3.3  Surface Plasmon Resonance (SPR) 
The technique of SPR relies upon a physical anomaly that occurs at the interface of light and 
particular metals e.g.  Gold, silver or copper it creates an evanescent wave due to the 
creation of polaritons or “plasmons” resulting in a phenomenon called the plasmon effect. 
This field has a unique characteristic that it will deflect light by a discrete angle that is reliant 
on the nature of the surface it is emitted from. The deflection of a laser beam can be 
measured with a high level of accuracy giving rise to the ability of being able to detect mass 
applied to the reverse of the gold surface. The detection of mass can be so sensitive it is 
possible to determine and measure quantities that are within the nano- and picogram scale. 
Modern approaches also allow the tracking of molecular interactions making it possible to 
interpret and quantify results with the aim of deriving binding affinities and dissociation 
constants for the interaction being studied (BIACORE, 1998).  
Surface Plasmon Resonance has a number of advantages that set the technique apart from 
other systems. A major benefit of the method is the ability to provide and to collect real-
time kinetics data for association and dissociation reactions. As only one of the binding 
partners need be immobilised to the surface labelling of the other molecule/s is not 
necessary, labels and tags are known to interfere with binding, by both inhibiting and 
assisting binding (Liedberg et al., 1995).  So, the benefit of using at least one or two 
unlabelled factors will serve to remove some doubt as to the stringency of the recovered 
data concerning affinity.  
SPR relies on the shape of molecules interacting with the surface. It can give an idea of mass 
because of the size of molecule or compound interfering with the plasmon effect but not 
discrete numbers regarding an accurate molecular weight or density. Alternatives to SPR 
that can provide reliable information regarding mass and density are Dual Polarisation 
Interfereometry (DPI) and using a Quartz Crystal Microbalance (QCM). A major disadvantage 
of the technique also lies in one of its strengths. As the technique requires the 
immobilisation of one of the analytes, the surface is required to have some properties that 
enable molecules to interact and to bind to it. As the gold surface and dextran matrix carry 
an electrostatic charge in low (3-4) pH’s some molecules can interact and bind to the surface 
in a non-specific manner depending on the pH of the solution they are dissolved in. As a 
result the surface can interfere with binding reaction through this method and also through 
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steric hindrance. Steric hindrance can occur when the binding site of the immobilised 
component is too close to the surface preventing the other binding partners from access by 
sheer physical size.  
It is through this method that growing number of aptamer:antigen interactions have been 
studied (Wang et al., 2007),  the thrombin binding aptamer for example has been studied in 
this method twice giving an estimated dissociation constant of Kd = 0.5 nM (Tang et al., 
2007a, Balamurugan et al., 2006). Although this method for characterisation of aptamers is 
not novel, it is prudent to develop and understand a suite of techniques that endow the 
project with the capabilities to assay any potential aptamers that may need to be defined. 
By immobilising a potential aptamer on a gold surface through a biotin:streptavidin linkage 
and passing over a known concentration of the aptamers target molecule it is possible to 
arrive at putative parameters of interaction.   
This chapter demonstrates the ability to assay aptamer to target binding within a regular 
molecular laboratory with standard equipment. It demonstrates the characterisation and 
evaluation of aptamers in an efficient and reliable manner. The efficiency of aptamer 
binding is assayed using surface plasmon resonance (SPR), Fluorescence Resonance Energy 
Transfer (FRET), and Electrophoretic Mobility Shift Assay (EMSA). Each method presented 
here is analysed and evaluated as an exhibition of useful methods for the analysis of 
aptamer:antigen interactions.  
3.4 FRET based Cleavage assay 
3.4.1 Custom Peptide Cleavage Assay 
The first step in the creation of a biosensor is the ability to confidently assay the 
components of a reaction that are pertinent to the user. In order to determine the 
usefulness of a technique a known and well characterised system is preferred. As 
mentioned above, the inhibitory effects of the thrombin binding aptamer are well reported 
(Bock et al., 1992), and the aim of these assay was to take advantage of this foundation of 
evidence and demonstrate aptamer binding through the inhibition of cleavage. After the 
construction of a calibration curve to determine the kinetics and reliability of a thrombin 
catalysed cleavage of the custom peptide, a titration of TBA can indicate the inhibitory 
effect of an aptamer on thrombin cleavage and be used to demonstrate binding.  
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In order to assay thrombin activity a FRET based assay was developed based on the cleavage 
of the peptide through the creation of a calibration curve using custom peptide received 
from mimotopes (H-(161)GLVPRGSG(160)-NH2) and thrombin  protease. Concentration 
required for each assay determined with reference to the literature a concentration of 4 μM 
per reaction (Esmon, 1995).  
Each 100 μl (total volume) reaction took place in one well of a 96-well plate with 
fluorescence measured on Biotek FL 600 Fluorescence and Absorbance Reader.Each 
reaction was carried out in 1 x PBS and concentration of the peptide required for each assay 
determined with reference to the literature a concentration of 4 μM per reaction. The 
samples were then incubated at 22C for 2 hours and a fluorescence reading taken every 15 
minutes. 
A series of thrombin dilutions from 100 U/mL to 0.001 U/ mL (Table 4) were used and their 
activity monitored by measuring the final fluorescence output at 570 nm as presented in 
Table 3 and Figure 22.   
Table 3 Thrombin Cleavage Calibration Curve construction. Table showing the results of the cleavage of the 
FRET substrate. Each well contained a 100 µL reaction consisting of: custom peptide 4 µM, 1x PBS, and α-
thrombin at varying concentrations 
   Thrombin concentration (U/ml)  
Time (minutes) 0.001 0.01 0.1 1 10 100 
0 0 0 0 0 0 0 
15 0 0 12 95 455 421 
30 3 0 0 153 449 415 
45 0 0 0 229 443 391 
60 6 0 3 272 433 397 
120 0 0 18 388 409 369 
 
The data shown in Table 3 and graphically represented in Figure 22 highlight the shallower 
nature of the initial rate curve at 1 U/mL when viewed in contrast to the higher and lower 
concentrations of thrombin an inhibition of the initial rate may be observable. It is with this 
in mind that the concentration to take forward as a suitable assay for inhibition would be 
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1 U/mL any inhibitory effects by an aptamer would be detectable via a deviation from this 
known curve.  
 
 
Figure 22 Thrombin Cleavage Calibration Curve of fluorescence against time. A graphical 
representation of the results of the cleavage of the FRET substrate (Table 3). Each well contained a 100 µL 
reaction consisting of: custom peptide 4 µM, 1x PBS, and α-thrombin at varying concentrations.  
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Figure 23 Thrombin Cleavage Calibration Curve concentration against RU. A graphical representation 
of the results of the cleavage of the FRET substrate. The data here shows the reaction rate is concentration 
dependant and that the limiting factor for the reaction can either be time or concentration. Each well 
contained a 100 µL reaction consisting of: custom peptide 4 µM, 1x PBS, and α-thrombin at varying 
concentrations. 
 
From the graph of the results of the calibration curve construction (Figure 22) it is apparent 
that using 1 NIH unit/mL is best suited to the equipment and allows a comparable figure for 
the determination of initial rate to be arrived at after a 15 minutes incubation period. From 
a rearrangement of the data (Figure 23) a conclusion about the concentration dependent 
nature of the reaction can be drawn. The dissociation constant of the thrombin peptide 
interaction can be determined from this graph to be ~1 U/mL which is the equivalent to 
2.73 µM. This is the same order of magnitude for the affinity constant of thrombin to its 
natural substrate fibrinogen which is 1.3 ± 0.3 µM (Mathur et al., 1993) this corroborates 
the finding that this method can be assumed to provide reliable data relating to initial rate 
calculations.  
3.4.2 Inhibition Assay 
Following the successful creation of a calibration curve and a determination of desirable 
considerations for the assay of thrombin cleavage of the peptide, an inhibition assay was 
sought that would display aptamer binding through the inhibition of thrombin cleavage by 
three known aptamers (Bock et al., 1992). Using the pre-defined conditions, which remain 
constant throughout, titration of different concentrations of aptamers and the degree to 
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which they inhibit, can be solved because of deviations in the amount of fluorescence 
observed. This does assume that pipetting errors and concentrations are minimal and are as 
stated and suitable.  
Table 4 Table detailing the construction of the cleavage assay 
 
 
 
 
 
 
 
 
 
Thrombin 
Concentration 
(U/mL) 
 
 
0 
 
 
0.1 
 
 
0.5 
 
 
1 
 
 
5 
 
 
10 
 
 
50 
 
 
100 
Aptamer (5 
µM) 
        
15 minutes         
v1 5 9 15 92 85 49 137 107 
v3 64 0 6 0 134 9 119 61 
R70E 70 55 31 52 92 95 85 177 
2 Hours         
v1 113 10 143 363 171 153 449 372 
v3 296 76 92 0 620 10 436 345 
R70E 302 162 244 330 394 381 430 507 
Repeat         
Thrombin 
Concentration 
(U/mL) 
 
 
0 
 
 
0.1 
 
 
0.5 
 
 
1 
 
 
5 
 
 
10 
 
 
50 
 
 
100 
Aptamer (5 
µM) 
        
15 minutes         
v1 6 40 3 15 64 89 156 134 
v3 37 61 18 89 95 76 122 55 
R70E 49 55 67 89 58 61 49 34 
2 Hours         
v1 27 165 76 110 269 314 388 372 
v3 208 269 95 336 614 339 394 287 
R70E 259 311 293 436 296 339 269 208 
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Figure 24 Inhibition of Thrombin-mediated Custom peptide cleavage Assay using anti-thrombin 
aptamer v1. Thrombin inhibition assay using anti-thrombin aptamer v1 as the antigen. Each reaction was 
assayed at 15 and 120 minutes. Fluorescent response observed at λ570 nm with 5 µM peptide, 5 µM 
aptamer, and increasing concentrations of thrombin in 1 x PBS at ~21oC. 
The lack of reproducibility involved with the cleavage of thrombin is a worrying factor, 
although a slight downward trend can be observed this is against the literature. As the 
concentration of the aptamer increases so does the signal. Unfortunately this trend is 
replicated across the entire data set and can be found for the R70E hybrid aptamer also. The 
v3 aptamer (Figure 25) gives no noticeable trend in either direction except an anomalous 
result which should be instantly discredited as error.  
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Figure 25 Inhibition of thrombin dependant custom peptide cleavage assay using anti-thrombin 
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aptamer v3. Thrombin inhibition assay using anti-thrombin aptamer v3 as the antigen. Each reaction was 
assayed at 15 and 120 minutes. Fluorescent response observed at λ570 nm with 5 µM peptide, 5 µM 
aptamer, and increasing concentrations of thrombin in 1 x PBS at ~21oC. 
As discussed before, the trend across all three aptamer inhibition assays continues, this 
serves as further evidence of a sensitivity issue for this method. Inhibition is not 
demonstrable via this method as any deviation in the rate of cleavage of the custom peptide 
is evidentially outside the range of detection due to the sensitivity of the instrument 
employed for this task. It should also be noted that the peptide decays rapidly preventing 
the reproduction of results from one experiment to the next. 
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Figure 26 Inhibition of thrombin dependent custom peptide cleavage assay using anti-thrombin 
aptamer R70E. Fluorescent Response units observed after 15 and 120 minutes following the cleavage of the 
fluorescent peptide by thrombin according to reaction conditions detailed above. Thrombin Binding 
Aptamer R70E was present throughout at a concentration of 5 µM.  
 
The results do not show any noticeable trends which could be the result of a number of 
possible issues. The most obvious of these is experimental error; if the same amount of 
peptide is not being added each time it would make it extremely difficult to be able to draw 
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any useful comparisons. If, as is seen here, the experimental error exceeds the all other 
variation it is impossible to draw any conclusions from the results.  
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Figure 27  Inhibition of thrombin cleavage after 15 minutes. Fluorescent response observed after 
fifteen minutes at λ570 nm with 5 µM peptide, 5 µM aptamer, and increasing concentrations of thrombin in 
1 x PBS at ~21oC. 
After 15 minutes all three of the thrombin aptamers display some inhibition of the target 
with R70E producing the greatest amount of inhibition across all the concentrations (Figure 
27). However, after 120 minutes the inhibition is less profound. This reduction in inhibition 
could be due to binding of the aptamer and target in equilibrium not being permanent and 
because of this the thrombin only need cleave the substrate once for a signal change. 
Alternatively, it may also be attributable to the degradation of the fluorescent peptide 
substrate as later work indicates some thermal instability which renders the peptide void 
(data not shown).  
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Figure 28  Inhibition of thrombin cleavage after 120 minutes. Fluorescent response observed after 
fifteen minutes at λ570 nm with 5 µM peptide, 5 µM aptamer, and increasing concentrations of thrombin in 
1 x PBS at ~21oC. 
This instability furthers the suggestion that peptide cleavage assay is unsuitable as a useful 
aptamer binding study. This instability will limit the conditions under which the assay is 
performed and negate one of the benefits of using aptamers, the point that aptamers will 
bind in a variety of conditions. This, coupled with the fact that the inhibition assay as 
presented here relies on the inhibition of proteolytic cleavage, would restrict the potential 
aptamer targets for derivation to proteases and other enzymatic targets that produce a 
known molecular event.  
3.5 Surface Plasmon Resonance (SPR) 
Three aptamers were selected from the literature  (Bock et al., 1992)  to bind thrombin at a 
range of affinities, thrombin binding aptamer v1, v3 and aptamer hybrid R70E were chosen 
to have relatively strong, medium and weaker affinity to thrombin respectively (Figure 29). 
Through the comparison of the interactions the results may give an insight into the nature 
of the interactions as it is possible to determine dissociation constants, binding affinities, 
and gain thermodynamic insight amongst others using this method. 
The thrombin binding aptamer v1, being one of the first aptamers studied, is well defined in 
its adapted secondary three dimensional structure and the interactions of aptamer and 
antigen almost fully understood. The aptamer is understood to occupy the heparin binding 
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site of thrombin mimicking the drug’s footprint on the active site (ref), preventing 
proteolysis with a comparable affinity to that of heparin. In order to further characterise the 
interaction of the thrombin binding aptamer to thrombin, Surface Plasmon Resonance (SPR) 
studies were performed. These studies aim to corroborate the data and conclusions drawn 
in the scientific paper from Tang et al. (Tang et al., 2007a) and determine our ability to 
detect and quantify thrombin within an unknown solution. If successful, the use of SPR as 
would provide a high-throughput and reliable method for the examination of candidate 
oligonucleotides that arise as the result of SELEX.  
 
 
 
 
 
 
Figure 29 Consensus sequences used for Aptamer. Three aptamers were designed using the 
consensus sequence drawn from Bock (Bock et al., 1992). The affinity of the target to each individual ligand 
being relatively strong, medium, and weak. 
 
3.5.1 Immobilisation of Aptamer candidates 
Figure 30 depicts the successful surface attachment of aptamer v1 via a biotin streptavidin 
interaction. The reverse of the gold surface is supplied with streptavidin covalently bound to 
the dextran matrix via an amine linkage to functionalised carboxyl groups.  The streptavidin 
coated SPR sensor chip and the 5’ biotinylated aptamer v1 are incubated together with a 
low flow rate across the chip until the response units reach the required level. Injections of 
the aptamer solution fall at time points 410 s, 520 s, 570 s, 610 s with the desired level of 
response achieved after 675 s. After surface immobilisation the oligonucleotide can be 
assumed to be bound to the matrix with confidence, as the high affinity between 
streptavidin and biotin providing an almost irreversible and stable interaction that is in the 
order of Kd=10
-15 mol dm-3 (Green, 1975).  
Aptamer sequences: 
Thrombin Aptamer v1: GGTAGGTGTGGTTGGTGCAAC 
Thrombin Aptamer v3: GGTAGGTTTGGTTGGTGCAACGC 
Thrombin Aptamer R70EssP5: GGTAGGTAGGTATGGTGCAACGC 
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Figure 30 SPR sensorgram of biotinylated thrombin binding aptamer v1 immobilised to the 
streptavidin coated SPR chip. This figure shows the initial binding of the biotinylated aptamer to the 
streptavidin coated SPR chip (Biacore). 5 pulses of 1mM aptamer solution and wash steps of 50 mM NaOH 
to the required net change in response units of 1000 RU. After the fifth pulse and wash step the required 
response unit change was achieved indicating complete binding of the aptamer to the surface. 
 
3.5.2 Probing the thrombin binding aptamer:thrombin interaction 
Figure 31 is a sensorgram illustrating increasing concentrations of thrombin being passed 
over an SPR chip with TBA v1 aptamer bound. Thrombin concentration increases from 0 nM, 
5 nM, 10 nM, 50 nM, 100 nM, 200 nM, 400 nM, 600 nM, 800 nM, 1000 nM. The sensorgram 
is the response units of a channel containing the surface bound thrombin binding aptamer 
against a reference channel. Ruling out the possibility of non-specific binding interfering 
with the observed level of aptamer: thrombin interaction. Using only one channel for 
detection, thrombin is flowed over the chip-aptamer conjugate; with injection of increasing 
concentrations of thrombin starting at time point 0 s and halting after 20 s. Following the 
injection the dissociation rate can be deduced to be slow due indicating thrombin:aptamer 
interactions. When analysed, the apparent dissociation constant for the TBA v1 is 
approximately Kd=8.57 
-7 m which, is comparable with the initial findings for the thrombin 
binding aptamer of Kd= 0.25-2 
-7 m (Bock et al., 1992). Using the same method and 
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concentrations it was possible to define dissociation constants for TBA v3 and R70E which 
can be reported to be 1.5 µM and 0.2M respectively. These results corroborate the 
hypothesis that the candidate aptamers would be a strong, medium and weaker binding 
species. 
 
Figure 31 Increasing concentrations of thrombin passed over the SPR chip with the thrombin binding 
aptamer v1 bound. Increasing concentrations of thrombin passed over the SPR chip with the aptamer 
bound. Thrombin concentration increases from 0 nM, 5 nM, 10 nM, 50 nM, 100 nM, 200 nM, 400 nM, 
600 nM, 800 nM, 1000 nM. From injection the off-rates can be seen to be slow, highlighting 
thrombin:aptamer binding. The sensorgram is the response units of a channel containing the thrombin 
binding aptamer against a reference channel. Ruling out the possibility of non-specific binding interferring 
with the observed level of aptamer:thrombin interaction. 
 
Using results extrapolated from the affinity plot of TBA v1 and v3 a distinct curve can be 
seen, following a classic michelis menten binding pattern, albeit on a reduced rate, a one to 
one binding for the interaction can be predicted. Although, this would be expected due to 
the competitive nature of the progressive iterations of SELEX that the aptamers were intially 
isolated using. An aptamer that required another oligonucleotide may not be selected as the 
amplification step would require both species to be amplified in equal measure, if both were 
to be amplified at all. The nature of PCR means that from the initial pool it is chance that 
dictates which sequences are amplified, a prevelence of one exact species rarely occurs and 
indeed, the are no reports of an aptamer requiring a binding partner to selectively bind it’s 
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substrate. Also, when consensus sequences are drawn from a sequenced aptamer pool, two 
similar sequence could be grouped into a sub-group and following further investigation 
discarded due to an apparent lack of binding through no fault of the investigator.  
 
Figure 32 Affinity plot of increasing concentrations of thrombin binding to v1. Affinity plot of 
increasing concentrations of thrombin passed over surface bound aptamer v1. Graph created using 
BIAevalutaion software. Kd can be extrapolated due to estimated on/off rates gathered from the data. 
3.5.3 Metal Ions 
It has been reported in the literature that the G-quadraduplex that forms the three 
dimension motif requires a monovalent cation in order to form (Howard et al., 1977, Clay & 
Gould, 2005). It has been proposed that for the thrombin binding aptamer this motif is held 
in place by a centrally localised K+ ion with the presence of the potassium seen to be crucial 
for the formation of the structure (Dingley et al., 2005). Using this prior knowledge of 
quadruplexes the fidelity of the technique can be assayed. The reliability up on the 
monovalent cation can be been attributed to the strong negative electrostatic potential that 
is created by the guanine’s O6 oxygen atoms, which can be seen to form a central “channel” 
of the G-tetrad stack (Figure 33), with the cations located centrally within this “channel”.  
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Figure 33 G-quadraduplex arranged around a bivalent metal ion. Schematic diagram of the formation 
of G-quadraduplex located around a centralised divalent metal ion (Burge et al., 2006) 
 
As the cations are considered to be crucial for the formation and stability of TBAs secondary 
structure it is worth taking into account the role of other cations that may have a similar 
effect to the potassium. Na+ for example can provide an alternative cation with 
monovalency as it is more commonly found in natural G-tetrads, but investigations have 
shown that the G-tetrad, when formed around different cations adopts a different topology 
depending on the element involved (Olsen et al., 2009, Olsen et al., 2006). This series of 
experiments was designed to investigate the role of the monovalent cation in thrombin 
binding aptamer affinity to thrombin, and to provide an insight into the nature of aptamer 
secondary structure using SPR. 
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Figure 34  Sensorgram of thrombin binding aptamer to thrombin using the Lithium cation. Increasing 
concentrations of thrombin passed over the SPR chip with the aptamer bound. Thrombin concentration 
increases from 0 nM, 5 nM, 10 nM, 50 nM, 100 nM, 200 nM, 400 nM, 600 nM, 800 nM, 1000 nM. The buffer 
varied from the regular running buffer by containing 50 mM Li. 
 
 
Figure 35 Sensorgram of thrombin binding aptamer to thrombin using the Lithium cation with a 
calculated fit. Reproduction of Figure 20Figure 34with fit calculated by BIAevaluation software according to 
a 1:1 binding stoichiometry 
 
Table 5 is a summary of the data compiled from the thrombin binding aptamer to thrombin 
interaction as studied on the Biacore T100 Surface Plasmon Resonance machine (GE 
Healthcare®, Amersham, UK) with different monovalent cations present in the running 
buffer.  
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Table 5  Table depicting the apparent affinity constants derived from SPR data comparing different 
monovalent cations.  
Thrombin Binding 
Aptamer variant 
Monovalent Cation 
Apparent KD(M) 
Li+
 
 
 
Mn+
 
 
 
K+
 
v1 3.55x10-5 3.62x10-6 8.5x10-7 
v3 8.79x10-6 2.9x10-6 1.5x10-6 
R70E 2.52x10-6 1.5x10-5 2.6x10-4 
 
The data displayed in Table 5 provides a useful insight into the nature of binding of the 
thrombin binding aptamers when incubated in the presence of different monovalent 
cations. This would agree with the literature as discussed before as the aptamers and 
variants display a distinct increase in affinity for K+ cations when compared to the estimated 
dissociation constants for the Li+ and Mn+ cations. This is in agreement with the literature 
(Kankia & Marky, 2001) which states the thrombin binding aptamer forms a more stable,  
and therefore, higher melting temperature complex with K+ when compared with Li+ and 
Mn+. The proposed reason for this is that an ionic radius of 1.3-1.5 Å is required for the 
more stable G-quadruplex formation which the Li+ and Mn+ cations cannot bridge for 
because of their smaller ionic radii. In the same study it is suggested that Sr+ can be a very 
useful replacement for K+, but K+ is a much more abundant cation, both biologically and 
scientifically.  
3.5.4 Lysozyme control 
 In order to rule out non-specific binding of thrombin to the SPR chips or the aptamers, an 
identical control experiment using a similar protease, in this case lysozyme was used. 
Although lysozyme, a 14 kDa enzyme, is much smaller than thrombin it is a useful control 
because lysozyme can provide a removed null control that would demonstrate non-specific 
binding.  As can be seen from the figure (Figure 36) the dissociation rates of the lysozyme 
are almost instantaneous but some non-specific binding can be observed. This is most likely 
due to the lysozyme interacting with the dextran matrix of the SPR chip as mentioned 
before and as a result the specificity of the aptamer can be determined with confidence. 
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Figure 36 SPR sensorgram of the thrombin binding aptamer v1 when probed with increasing 
concentrations of lysozyme. Control experiment using lysozyme rather than thrombin highlighting the 
extent of specificity of aptamer to apitope. Identical conditions of aptamer, buffer, concentrations, contact 
times and flow rate but retention time minimal. Some non-specific binding can be observed, this is however, 
more likely to be interaction with the dextran matrix of the sensor chip not the aptamers. 
 
3.5.5 Prothrombin 
Thrombin forms the penultimate part of the blood clotting cascade, prothrombin is the 
precursor to the α-thrombin that has been the subject of the majority of this study to this 
point. Prothrombin is cleaved by Factor Xa to from the active serine protease thrombin, and 
it is through this action that the body can control the progression of blood clotting. In order 
to further investigate the thrombin binding aptamer and its interaction with α-thrombin it is 
useful to investigate whether binding is affected completely by the presence or absence of 
the part of the prothrombin (Bajaj et al., 1981) precursor that is removed prior to the 
activation of thrombin. The experiment is the identical to the procedure that has been 
determined to provide reliable data and will probe the similarity between thrombin and 
prothrombin in relation to the thrombin binding aptamer, and give an insight into the 
specificity of the aptameric probes under investigation.   
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Figure 37 Affinity Graph of increasing concentrations of prothrombin binding to the thrombin 
binding aptamer v1. Affinity Graph of increasing concentrations of prothrombin binding to the thrombin 
binding aptamer, sensorgram produce on the Biacore T100 SPR machine using identical parameters to the 
standard experiment derived earlier. 
 
The apparent dissociation constant of the Prothrombin interaction with TBA v1 is according 
to the information recovered from SPR data and converted to an approximate value. Using 
the projected concentration graph it can be seen that the dissociation constant where Ka=Kd 
would be at around 1.34 x 10-6. This apparent dissociation constant must be treated with 
some trepidation however, as the response units for the interaction are low (when 
compared to the average response units for the same interaction using thrombin which 
ranges from 150-200 RU for the higher concentrations). As the response units are so low it 
can be assumed that the results for this interaction can largely be ignored, as although there 
is some binding, it is of little to no consequence and can be attributed to non-specific 
binding. The sensorgram from which this data is drawn can be seen to serve the argument 
that the binding is restricted to non-specific events although it is not included here.  
3.5.6 Assembly and disassembly 
A good biosensor can be said to be able to reliably and sensitively detect specific biological 
with a high signal to noise ratio. A challenge to the creation of a biosensor is the ability to 
interchange the target molecule without the need to completely rebuild an entire system.  
Aptamer technology may provide a useful method of change the analyte of interest because 
of the relative ease with which DNA can be constructed, deconstructed and clean within a 
laboratory environment. It is proposed that an anchor region of a complex can be 
immobilised on a surface by biotin:streptavidin interaction, covalent cross-linking of the 
phosphate backbone, or thiolation of an activated group attached during synthesis. To this 
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single stranded anchor portion of DNA an aptamer can then simply be annealed through 
interaction of the Watson and Crick base pairing of a complementary segment that is 2-6 
base pairs in length. Using the previously designed and characterised thrombin binding 
aptamer:thrombin binding partner’s experiment using Surface Plasmon Resonance, the 
possibility of using a system derived from this can be explored.  
 
Figure 38 Schematic diagram of the thrombin binding aptamer TBA v1 attached to anchor region 
immobilised to an SPR chip via biotin streptavidin interaction. A cartoon representation of the construction 
of the surface bound aptamer assembly. The surface is a streptavidin coated dextran matrix to which the 5’ 
biotinylated DNA anchor region is bound with high (15 fM) affinity. The blue represents the complementary 
binding region of varying length, with the TBA v1 portion represented in red.  
 
To localise the anchor region to the streptavidin coated dextran matrix of the SPR chip the 5’ 
terminal nucleotide of the anchor sequence has a biotin attached during synthesis. The 
anchor region sequence is as follows: 5’biotin-GGCCTATATAGCGC 3’. The previously defined 
Thrombin Binding Aptamer Sequence: GGTTGGTGTGGTTGG (Bock et al., 1992) was 
synthesised with increasing regions of complementarity as detailed in (Table 6) . As the 
number of complementary base pairs increases the energy required to remove the 
hydrogen bonds formed between the bases will increase. The increase of dissociation 
energy will serve to stabilise the two DNA strands, in theory, as the length of the 
overlapping section increases the higher the ionic strength of the buffer required to 
dissociate the TBA v1 from the immobilised anchor.   
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Table 6  Table detailing the construction of Thrombin binding aptamer to anchor conjugates 
Complementary 
Region  
Length 
Anchor Region Thrombin Binding aptamer with 
overlapping region 
Overlapping 
Region Tm 
(kcal/mole) 
1 base pair 5’biotin-
GGCCTATATAGCGC 3’ 
3’  GTAGGTTGGTGTGGTTGG 5’         -1.5 
2 base pairs 5’biotin-
GGCCTATATAGCGC 3’ 
3’  CGTAGGTTGGTGTGGTTGG 5’   -3.07 
3bp base pairs 5’biotin-
GGCCTATATAGCGC 3’ 
3’  GCGTAGGTTGGTGTGGTTGG 5’   -6.75  
4bp base pairs 5’biotin-
GGCCTATATAGCGC 3’ 
3’  CGCGTAGGTTGGTGTGGTTGG 5’   -9.89 
5bp base pairs 5’biotin-
GGCCTATATAGCGC 3’ 
3’  TCGCGTAGGTTGGTGTGGTTGG 5’   -11.49 
6bp base pairs 5’biotin-
GGCCTATATAGCGC 3’ 
3’  ATCGCGTAGGTTGGTGTGGTTGG 5’   -12.45  
 
For ease of study three overlapping regions were selected of 2, 4, and, 6 base pair overlaps 
for comparison. The 2 base pair overlap would be the least stable of the three with the 6 
base pair overlap comparatively stable and the 4 base pair overlap exactly halfway when 
considering stability. Conversely, the least stable binding partners should be the easier to 
reassemble following denaturation, due to the lower amount of energy required to form the 
hydrogen bonds between the pairings.  
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Figure 39 Overlapping Region OLR 2 immobilised to the SA chip.  Overlapping Region OLR 2 
immobilised to the SA chip. Sequential pulses of biotinylated aptamer anchor conjugate Overlapping Region 
OLR 2 immobilised to the Streptavidin coated SPR chip 
 
Following the successful immobilisation of the aptamer:anchor conjugate to the SPR chip 
the validity of the thrombin binding portion of the aptamer was tested for comparison to 
the unmodified thrombin binding aptamer v1 tested previously. Identical conditions were 
used for determining the viability of the annealed aptamer to those used to determine the 
binding conditions and kinetics of the thrombin binding aptamer v1. The resulting 
sensorgram (Figure 40) of this assay will give an insight into whether this method can be 
considered for the construction of an interchangeable molecular recognition element of a 
biosensor.  
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Figure 40 Increasing concentrations of thrombin passed over TBA v1 annealed to the anchor region. 
Sensorgram of increasing concentrations of thrombin interacting with TBA v1 attached by annealing to 
anchor region v1. Sensorgram created by Biacore T100 Surface Plasmon Resonance machine.  
 
Following the successful immobilisation of the aptamer:anchor conjugate to the SPR chip 
the validity of the thrombin binding portion of the aptamer was tested for comparison to 
the unmodified thrombin binding aptamer v1 tested previously. Identical conditions were 
used for determining the viability of the annealed aptamer to those used to determine the 
binding conditions and kinetics of the thrombin binding aptamer v1. The resulting 
sensorgram (Figure 40) of this assay will give an insight into whether this method can be 
considered for the construction of an interchangeable molecular recognition element of a 
biosensor.  
As can be seen by the sensorgram (Figure 40) the thrombin does interact in a concentration 
dependent manner, indicating that the aptamer is constructed and located on the chip after 
successful attachment and creation of the complex. A challenge remains as to whether the 
formation, can then be deconstructed, and then re-assembled within the environment 
required for accurate generation of results. Figure 41 is an adjusted version of the 
sensorgram Figure 40 with a calculated fit assumed for the projection of binding kinetics as 
determined by the program BIAevaluation (GE Healthcare, Amersham, UK).  
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Figure 41 Sensorgram depicting thrombin interacting with OLR aptamer with calculated fit. 
Sensorgram depicting thrombin interacting with OLR aptamer with calculated fit. Sensorgram details 
increasing concentrations of thrombin interacting with TBA v1 attached by annealing to anchor region v1. 
Sensorgram created by Biacore T100 Surface Plasmon Resonance machine. 
Following the successful immobilisation of the aptamer:anchor conjugate to the SPR chip 
the validity of the thrombin binding portion of the aptamer was tested for comparison to 
the unmodified thrombin binding aptamer v1 tested previously. Identical conditions were 
used for determining the viability of the annealed aptamer to those used to determine the 
binding conditions and kinetics of the thrombin binding aptamer v1. The resulting 
sensorgram (Figure 40) of this assay will give an insight into whether this method can be 
considered for the construction of an interchangeable molecular recognition element of a 
biosensor.  
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Figure 42 Sensorgram displaying increasing concentrations of NaCl affecting RU for the OLR Aptamer. 
Sensorgram displaying increasing concentrations of NaCl affecting RU for the OLR Aptamer. This sensorgram 
depicts a reduction in SPR response units following the application of the NaCl washes 
 
As can be seen from the sensorgram (Figure 42) the first sample of running buffer (in red) 
has the expected result of no discernable response unit change, but, from 0.2 M NaCl 
through to 2 M NaCl the response units drop following each round. This change can be 
attributed to the OLR of the aptamer that is attached to the anchor being dissociated 
through a higher ionic strength buffer overcoming the energy needed to keep the DNA base 
pairs together. The immobilised anchor regions were then subjected to the pre-defined 
thrombin binding kinetic program and found to not bind the thrombin above a level 
associated with non-specific binding. From these results it can be assumed that the 
thrombin binding aptamer portion of the conjugate has been displaced, but, the initial goal 
of the experiment was to displace and then re-assemble the complex when immobilised to 
the chip. This proved extremely difficult due to the limitations of the machine on which the 
assays were to be completed which prevented the incubation as the flow rate can only be 
slowed, and not halted. 
3.6 Conclusions 
The concept for the cleavage assay remains solid, but, further investigation or alternative 
equipment specifications may show that the ratio of signal to noise could be pushed to a 
more favourable conclusion. A further complication is the apparent half-life of the peptide 
substrate. This was found to be far below an acceptable level; given the relative cost of 
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synthesising the substrate such a poor return renders the consideration of this method as a 
viable, long-term and repeatable assay questionable. The data acquired from the assay 
however, can be seen to support that which has previously been published on the nature of 
the Thrombin Binding Aptamer and its affinity to the substrate.  
Some sound conclusions can be drawn from the Surface Plasmon Resonance experiments 
however; the technique gave consistent, comparable, and reproducible data regarding the 
determination of a dissociation constant for the TBA species and their target protein 
thrombin. The findings also served to strengthen data supporting the published conclusions 
of specificity regarding the aptamers and thrombin. By using the precursor Prothrombin and 
the unrelated protein lysozyme as controls for non-specific binding it can be said that TBA 
v1 and v3 will bind specifically thrombin and that the binding site is interfered with by the 
peptide “shield” of the fibrinogen binding active site. This secondary conclusion supports 
the initial findings in the original paper of Bock et al ((Bock et al., 1992) in which the 
aptamer pool was selected against coagulation rates of blood. Drawing meaningful and 
convincing conclusion from the Surface Plasmon Resonance data remains complicated. This 
is due to the fact that directly comparing the binding affinities of interactions between 
molecules continues to provide a number of difficulties because of the nature of the 
technique only showing shape changes when associated with the chip surface. As referred 
to earlier, one drawback of Surface Plasmon Resonance is the determination of mass of the 
molecule interacting with the surface when the technique is limited to detecting the shape 
of interfering molecules.   
As the concept driving this chapter is the determination of a suitable method for a rapid, 
reliable, and reproducible method for the assay of aptamer to target interactions, there 
must be some consideration as to the length of time needed to create such a method using 
SPR. The process of repeated and expensive iterations with the intention of arriving at an 
assay can be a time-consuming one. Once a concept for the reaction conditions required to 
begin such a labourious task has been determined, the systematic process of repeating the 
protocol with slight alterations can cause deterioration of the expensive specialised chips 
after time.  
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The model for the building and deconstruction of an aptamer scaffold is an attractive one as 
it provides the means to alter the “meta” biosensor in a cheap and rapid way. Attaching an 
aptamer to a scaffold creates a modular approach to aptamer characterisation allowing the 
interchanging of aptamers without the need to redesign. The method has been shown to 
work as far as the assembly of the anchor-aptamer scaffold to the removal of the active 
aptamer portion. Replacing one aptamer for another without the need to set up an entire 
experiment increases the throughput of an assay greatly, as aptamer generation methods 
can produce large amounts of possible aptamer sequences which need to be validated. If 
the method can be automated then the prospect of an interchangeable aptamer recognition 
element remains a seductive one, however, this investigation into the viability of the 
reusable portion of a biosensor stalled at the regeneration of the conjugate. Due to low 
dissociation constant of the streptavidin to biotin binding interaction, this rules out 
regeneration of the surface with an entirely new aptamer:anchor conjugate or novel 
aptamer species, the only method that was forthcoming was the removal and replacement 
of the active aptamer. Whether the removal is through an high ionic strength buffer, such as 
2-3 M NaCl, or the use of a restriction enzyme that would cleave the DNA at a predefined 
point within the sequence of the anchor using the Biacore T100 SPR is restrictive in the 
available conditions for the annealing of any single stranded DNA to the immobilised anchor 
region. As the over-lapping region of the two strands varied from 2 to 6 base pairs, it could 
be assumed that the temperature required for the formation of the hydrogen bonds 
necessary to create the base could be achieved. Each base pair requires an increase of 
temperature of approximately 6oC, so it can be assumed that the 2 base pair over-lapping 
region would require around 12 oC to form, 24 oC for the 4 base pair overlap and 36 oC for 
the 6 base pair overlapping region. Although, the machine was capable of achieving the 
temperatures required to ensure annealing of the complementary regions, the program 
prevents the user from pausing the flow of sample on the chip. This is potentially what 
prevented the two binding partners to form the scaffold, as no discernable response units  
increase was observable. The repetition of the thrombin binding protocol helped to confirm 
the summation that the scaffold had not re-assembled because there was a distinct lack of 
interaction between thrombin and the oligonucleotide immobilised on the surface above 
that of non-specific binding.   
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4 Production of novel aptamers – Immobilisation methods 
4.1 The HsdR subunit of the Type II Restriction Modification system 
EcoR124I 
In this chapter the method of affinity SELEX is undertaken, with the aim of producing novel 
aptamers to two distinct protein targets, GST-HsdR and GST-HRV143C(GE Healthcare). Both 
protein targets have a glutathione-S-Transferase fusion protein affinity tag and the SELEX 
iterations carried out using glutathione sepharose as the affinity media. The entire screening 
process is carried out using a bench top microcentrifuge, highlighting the ease with which 
SELEX can be achieved. The intention of the characterisation of the method is to provide a 
quick, reliable and simple method to isolate aptamer species that could be undertaken by 
any user. Once the aptamer pools have been defined the next step is to characterise those 
species of interest, and methods need to be identified with which the potential aptamers 
can be characterised and some work is done towards determining the most useful of the 
potential aptamers. Using the methods already described earlier such as Surface Plasmon 
Resonance assays, there is an attempt to characterise the binding of the aptamers to the 
target with the aim of determining a dissociation constant that can be associated with each 
species. Any aptamers arising from the selection will be good candidates for use within the 
generic biosensor as a molecular recognition element. 
HsdR is the largest individual subunit of the type I R-M enzymes at 120 kDa and associates 
with the MTase to produce the restriction nuclease (Yuan, 1981).The HsdR subunit of the 
type I restriction modification enzymes is required for DNA cleavage and translocation when 
complexed with the MTase complex forming the endonuclease. HsdR has not been shown 
to have any independent activity through DNA binding experiments (Zinkevich et al., 1997) 
however it is responsible for ATPase activity of the endonuclease which has been shown 
only in the presence of the HsdR protein. This ATPase activity has been linked to a motor 
activity, which allows the translocation of DNA through the DNA-bound enzyme (Davies et 
al., 1999b, Davies et al., 1999a), unidirectionally and independently for each HsdR subunit, 
along polymer tracks (Kliche et al., 2001). The translocation activity is similar to helicase 
activity and identified to contain super family two helicase motifs through sequence 
alignment of the DEAD/H box motifs (Gorbalenya & Koonin, 1991) 
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The main activity of the HsdR subunit is the restriction activity. HsdR binds with the MTase 
complex and switches to a restriction enzyme on the detection of un-methylated DNA at the 
restriction site (Yuan & Meselson, 1970). The restriction-modification enzyme has been 
shown to remain attached to its recognition site resulting in DNA being looped beneath the 
molecule. DNA cleavage takes place when translocation is impeded either by collision with 
another translocating complex or by the topology of the DNA substrate. Combined, these 
factors make HsdR a good candidate as a target for aptamer selection, being a well 
characterised protein helps to optimise the selection and later aptamer validation towards 
methods known to work with the native protein. 
4.2 HsdR SELEX 
The HsdR subunit of EcoR124I has a definitive role in the cleavage of double stranded DNA, 
providing a primitive type of immune system for E. coli when complexed with the co-
expression partner subunits, HsdS (the specificity subunit) and HsdM (the methylation 
subunit). Complexed together the subunits form a restriction enzyme that identifies hemi-
methylated foreign DNA which it translocates and cleaves at two un-specified points. It is 
the HsdR subunit which is responsible for the translocation of the DNA (Weiserová & 
Firman, 1998) and it has been shown to be an ATP dependent (Davies et al., 1999a) process. 
It is because of the ability of the HsdR subunit to translocate DNA that the subunit can be 
said to be a molecular motor “pulling” DNA through it, as opposed to moving along in a 
ratchet type manner.  
Due to the interest in the HsdR subunit as a crucial part of a generic biosensing system, it 
was an obvious choice for the first target to which aptamers were to be isolated. Crucially, 
the HsdR gene has previously been cloned into a plasmid vector that, when expressed as a 
protein, gave rise to a fusion protein. The fusion protein consists of a 26000 Da fusion 
protein Glutathione-S-Transferase (GST) then a peptide linking region containing a cleavage 
site (for Human Rhinovirus 14 3C or (HRV143C ) which is then followed by HsdR subunit. The 
addition of the GST provides a means with which to bind the protein to a column through 
the use of Glutathione Sepharose media (GE Healthcare®, Amersham, UK). The interaction 
of the GST with the glutathione sepharose can be said to be relatively strong with a 
dissociation constant in the region of Kd = 6.9 x 10
–9 mol/L (Waterboer et al., 2005), the 
binding of the two partners has been utilised within affinity chromatography to purify 
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proteins. It is proposed that through the immobilisation of the target via the 
GST:Glutathione sepharose interaction to the column it will be possible to isolate a pool of 
aptamers to the HsdR subunit of EcoR124I using SELEX.  
If the protein can be said to be reversibly attached to the column media, the aptamer library 
can be introduced to the bound protein and following thorough washing any bound species 
can be collected by elution with a high ionic strength buffer. Some attention must be paid to 
the removal of potential aptamers species that will bind to either the glutathione sepharose 
media or to the GST portion of the fusion protein. These un-wanted sequences are removed 
by a pre-screening step that involved the introduction of the library to the cleaved and 
washed GST and remaining linking region bound to the column. Any species that do not bind 
to the media or any unwanted portion of the apparatus are removed using this step. Once 
regenerated following a series of washes using a glutathione containing buffer the complete 
fusion protein of GST-HsdR is bound to the column and the first round of SELEX screening is 
undertaken. Following 13 rounds of sequential screening and amplification the pool of 
potential aptamers is cloned into a sequencing vector and sequenced using Sanger 
sequencing. Following sequencing, the library of putative aptamer sequences can then be 
probed to determine whether an aptamer with high specificity and affinity has been isolated 
or a consensus sequence for the reliable binding of the aptamer to the protein has been 
arrived at. 
Although GST-HsdR has Glutathione-S-Transferase attached to the target, there are other 
methods to reversibly immobilise a protein target to affinity media. There are a number of 
commercially available affinity tags such as HIS, CBP, CYD (peptide tag), Strep II, FLAG, HPC 
(heavy chain of protein C) peptide tags, MBP a second protein fusion tag (Lichty et al., 
2005). Each method provides a compromise between high affinity resin and low binding 
capacity, when purifying proteins. If, as in the case of SELEX the process requires previously 
purified protein samples with the affinity tag in place, the binding capacity is not relevant 
but, the affinity of the resin is. This is due to the fact the lower the concentration of the 
target which the library of random oligonucleotides is applied to the more stringent the 
SELEX round will be. As there is less physical material for the different species of potential 
aptamers to bind to, the species with the higher affinity will out-compete those lower 
affinity aptamers making it more likely that the surviving species will be selected.  
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4.3 HsdR SELEX  
The progressive rounds of SELEX can be seen in Figure 43, this native PAGE gel can be used 
to follow the refinement of an aptamer selection library. A distinctive band can be seen at 
75 base pairs in length. Although the library should be 54 base pairs in length this change in 
migration difference can be attributed to the secondary structure formation of the aptamer 
species causing retardation through the acrylamide gel matrix. Each sample is taken after 
the amplification step of each round and can be assumed to not be PCR primers because of 
comparison with the first lane of just the 1 µM forward and reverse primers used in the 
amplification of the SELEX library.  
 
Figure 43  Progressive rounds of SELEX to HsdR showing the development of aptamer pools. 16% 
Native acrylamide gel. Lane 1 Hyperladder V (Bioline), lane 2 unused primers, lanes 3,4,5,6,7,are rounds 
9,10,11,12,13 of SELEX respectively. Stained with Silver stain (FLUKA). 
Figure 44 depicts a detailed insight into the final aptamer pool before insertion into a 
cloning vector. This shows the aptamer library at closer to its true length of 50 base pairs in 
length and also highlights some impurities from possible mis-priming occurring in the 
amplification process.  
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Figure 44   Native Gel showing the final pool before cloning into pGEM-T-Easy. 16% native 
acrylamide gel. Lane 1 Hyperladder V (Bioline), lane 2 unused primers, lane 3 is result of round 13 PCR 
amplification. Stained with Silver stain (FLUKA). 
After the full length of 13 rounds of SELEX screening and amplification the final screened 
library is cloned into a vector that utilises the fact that during polymerisation Taq DNA 
polymerase will leave an adenosine at the terminus of polymerisation. The pGEM-T-Easy™ 
(Promega) vector is linearised with a final thymidine overhang which eases the ligation of 
two DNA segments. As the only requirement for the insert is the automatic A-overhang left 
by polymerisation with a common polymerase, the preparation of the aptamer library for 
cloning is simple and rapid, as once the plasmid is cloned into a host bacterium the 
amplification of the potential cloned library is rapid and effective as it is carried out through 
the life cycle of the bacteria. After selection for a single colony, each potentially successful 
clone is extracted from the cells and prepared for sequencing that is carried out by 
Cogenics®. One potential area of error in cloning using this method is the orientation, and 
number of potential inserts within the vector. As the clones can orientate in any direction, 
some care needs to be taken when studying the resultant sequences and the direction of 
the primers needs to be established to determine whether the putative aptamer is viable.  
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Table 7  List of potential HsdR binding aptamers 
Aptamer 
name 
Aptamer Sequence %C %G %A %T 
HBA 1 CCAAGCGGGCGCGAGAACAACGTACGGT 28.5% 35.7% 28.6% 7.1% 
HBA3    CCGAGCAGAAGGTGCGATGCTTTATGGT 14.3% 35.7% 21.4% 25.0% 
HBA8    CCGAGCAGAAGGTGCGATGCTTTATGGT 10.7% 35.7% 21.4% 25.0% 
HBA14 CCCGGGCGGACAGACGGGTGTTCGTTGC 28.6% 42.8% 10.7% 17.9% 
HBA15  CCCGGGCGGACAGCAGGCTGTTCGTTGC 32.1% 39.3% 10.7% 17.9% 
HBA16  CCCGTAGCGTACAGTCCCAGCTTGGGAT 32.1% 28.6% 17.9% 21.4% 
HBA20  CCACAACGAGCCGGGATTGCGGATTGCA 28.6% 32.1% 25.0% 14.3% 
 
Table 1 shows the results of the putative aptamers recovered from sequencing of the 
putative aptamer clones. The sequencing results gave 7 potential sequences for further 
characterisation in order to determine affinity and specificity for each individual species. An 
interesting note is the propensity for a majority of guanine residues, this hints at the 
formation of the g-quadraduplex motif.  
4.3.1 Non-denaturing High Performance Liquid Chromatography of Progressive 
rounds of HsdR SELEX 
As the iterative process of aptamer pool refinement progresses it is difficult to ascertain the 
development of definitive groups of binding motifs or the clonal dominance of some 
sequences when compared to the co-isolated library without time consuming and 
potentially distracting investigations into the nature of the library at each round throughout 
the refinement. Using HPLC provides an insight into the development of the enriched 
library. 
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Figure 45  Non-denaturing HPLC analysis of the refinement of HsdR aptamer library. Chromatograms 
of Progressive rounds of HsdR SELEX analysed using the Dionex 3000 HPLC system and DNAPac column. The 
peaks symbolize the absorption of UV light at λ260 nm and represent the refinement of the DNA aptamer 
library through rounds 1,6,10, and, 13 of HsdR SELEX. 
Using non-denaturing High Performance Liquid Chromatography methods is possible to see 
the refinement of the aptamer library into three distinct groups. As the method does not 
denature the secondary structures the putative aptamers form the different groups will 
migrate through the resin at different rates, due to simple occlusion of the motifs. As each 
round of SELEX progresses there are three well defined peaks, each indicating a different 
motif with two smaller peaks that may be the species that are not selected against.  
4.3.2 HsdR binding 
Once the potential aptamers were recovered from the received sequencing data an initial 
experiment to determine the viability of the aptamers was undertaken.  This simple and 
cost-effective method relies on the protein adhering to a nitrocellulose membrane which is 
then blocked with Bovine Serum Albumin (BSA), to prevent non-specific binding of the 
biotinylated aptamer probes. The aptamer to antigen interaction can then be probed using 
a Horse Radish Peroxidase:streptavidin conjugate (HRP) as a reporter molecule, as this will 
bind to the biotin of the aptamers. An insight into the viability of the aptamers species can 
be gained by application of a constant concentration of aptamer to decreasing immobilised 
target concentrations. Using this method it is also possible to determine putative 
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dissociation constants for aptamers quickly and in a multiplex fashion. It is also 
advantageous to probe specificity in the assay by including a control protein, such as 
lysozyme.  
4.3.3 Electrophoretic Mobility Shift Assay of HsdR and potential aptamer 
candidates 
A well established and common practise for the first investigations for probing a suspected 
binding interaction is the Electrophoretic Mobility Shift Assay (EMSA). The components of 
the binding assay are incubated together and subjected to an electric field inducing them to 
move through a gel matrix which will separate molecules according to size. When in 
complex with each other the larger ligand:target will migrate through the matrix at a slower 
rate than the constituents parts. The technique can be sensitive enough to provide data “in 
bulk” that can be extrapolated into dissociation constants in addition to other binding 
information such as whether a protein dimerises in solution, or perhaps, the candidates 
require trimerisation for example. The nature of the technique renders it a cost effective 
and rapid method for high-throughput screening of multiple candidates simultaneously.  
 
 
A B   
Figure 46 Electrophoretic Mobility Shift Assay of increasing concentrations of HsdR incubated with 
10 µM HBA15. EMSA depicting the binding of HsdR with the aptamer ligand HBA 15 in a 6% Native 
acrylamide gel. HsdR concentrations going from left to right 0, 10nM, 50 nM, 100 nM, 500 nM, 1 µM, 2.5 
µM, 5 µM, and 7 µM. The gel is first stained with SYBR gold nucleic acid stain (A) then with Coomassie 
Brilliant blue protein stains (B). 
Figure 46 binding can be observed for HBA15 from approximately 500 nM through to 7 µM, 
and although this does give a positive result as to whether the aptamer in question does 
bind or not, the data recovered is not sensitive enough to carry forward for further 
manipulation. The bands forming can be attributed to HBA 15 binding to HsdR as retro 
Coomassie blue denaturing staining of the gel indicates the location of the HsdR band’s 
99 
 
migration into the gel, corroborating the findings that the aptamer is binding to the target in 
a bulk solution. Another method for the validation of aptamer binding was sought for 
greater certainty and clarity for the characterisation of the HBA to HsdR binding partners. 
4.3.4 Dot blots 
Dot blots are a quick and useful technique for the analysis of two binding partners. In this 
method increasing “dots” of protein are bound to nitrocellulose membrane and allowed to 
dry. A solution of the second binding partner is washed over and binding is assayed through 
a reporter attached to the second binding partner (Materials and Methods 2.10) 
The initial prospective dot blots used a micro molar range of concentrations to determine 
the viability of using the assay and whether any of the aptamer species bound the target 
below the level associated with non-specific binding. Figure 47 depicts the first of these dot 
blots with a micro molar range from 20 µM HsdR immobilised to the surface through to 
1 µM, as can be seen from the figure, all aptamer species were found to bind the target 
protein sufficiently well as to carry on reducing the concentration down to a nanomolar 
range.  
 
Figure 47  Dot blot HsdR binding aptamer against HsdR of decreasing concentrations. Dot blot of HBA 
1, 3, 15, 16, and 20 blot from left to right against decreasing concentrations of HsdR (20 µM, 10 µM, 5 µM, 
1 µM) progressing downwards, probed using streptavidin:HRP conjugate (0.125 ng/mL) and visualised using 
Fujifilm™ Las3500 Intelligent Dark Box.  
 
Figure 48 is a direct repeat of the initial dot blot but, with the lower concentration range 
moving from 500 nM through to a no protein control. From this it can be seen that below 
500 nM the amount of binding is quickly reduced to a very low level. This indicates that the 
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dissociation constant, where half the concentration of ligand is bound and half is free in 
solution lies between 1 µM and 500 nM for all the putative aptamer species. It should also 
be noted that the column furthest to the right contains a no-DNA control and shows a very 
low level response, this indicates that the streptavidin:HRP conjugate is binding specifically 
to the biotinylated aptamer species and can be considered a viable and high-throughput 
method of aptamer characterisation. 
 
Figure 48 Repeat of HBA dot blot with lower concentrations. Repeat of HBA dot blot with lower 
concentrations  Dot blot of HBA 1, 3, 15, 16, 20, and a no DNA control blot from left to right against 
decreasing concentrations of HsdR progressing downwards (500 nM, 400 nM, 300 nM, 200 nM, 100 nM, 
50 nM, 10 nM, 0 nM) 
4.3.5 SPR 
As described before the technique of Surface Plasmon Resonance (SPR) lends itself to the 
verification of aptamer species that have been found to bind to a target protein. Using a 5’ 
biotinylated aptamer that is bound to the streptavidin-dextran matrix of a pre-prepared SPR 
chip (Biacore®, GE Healthcare) it is possible to begin to probe the binding kinetics of the 
aptamer to target interactions using increasing concentrations of the antigen (in this case 
HsdR). The resulting data can then be used in conjunction with that of other assays to create 
an overall picture of the protein to ligand interaction, including dissociation constants, and 
aptamer to target specificity.  
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Figure 49 Surface Plasmon resonance sensorgram of the Immobilisation of HBA1. SPR sensorgram of 
immobilisation of 5 µM 5’ biotinylated HBA applied to the pre-prepared streptavidin coated SPR chip.  
 
Initially HsdR Binding Aptamer 1 (HBA1) was chosen for further experimentation, and once 
100 RU of ligand were bound to the chip (Figure 49) representing a favourable ratio of 
target to analyte for signal characterisation, as recommended by the literature (BIACORE, 
1998). As HsdR has a larger mass than the surface bound aptamer, 145000 Da for the HsdR-
GST fusion protein compared to ~16399 Da for the 54 base pair oligonucleotide, the amount 
of immobilised material needed for a large shift in response units upon binding is relatively 
small using this instrument.  
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Figure 50 Sensorgram of control channel indicating increasing concentrations of HsdR attached to 
surface. Control sensorgram showing the binding of HsdR to the control channel, increasing concentrations 
of HsdR 0 nM, 10 nM, 50 nM, 100 nM, 200 nM, 400 nM, 600 nM, 800 nM, 1000 nM. 
 
As can be seen from the sensorgram (Figure 50) of HsdR binding to the control channel 
progressive and increasing concentrations of the target HsdR cause an increase of response 
units associated with persistent non-specific binding of the target. The increase of response 
units that builds up is not removed following the high ionic strength (2 M NaCl) regeneration 
events and consequently invalidates any data that can be derived from the procedure. The 
same can be said for the active channel that contains the immobilised HsdR binding aptamer 
(Figure 51) with identical levels of non-specific binding observed. An identical procedure of 
immobilising the candidate aptamer to the surface was carried for all the potential HsdR 
binding aptamers (HBA3, HBA15, HBA16, and HBA20) with the same result (data not 
shown). 
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Figure 51 Sensorgram of sample channel HBA1 indicating increasing concentrations of HsdR attached 
to surface.  Sensorgram showing the binding of HsdR to HBA1 immobilised to Biacore SA Chip, increasing 
concentrations of HsdR 0 nM, 10 nM, 50 nM, 100 nM, 200 nM, 400 nM, 600 nM, 800 nM, 1000 nM. 
 
4.3.6 Binding of HsdR to CM5 chip 
An alternative method to the immobilisation of the candidate HsdR binding aptamers to the 
streptavidin coated surface of the Biacore SPR chip was sought. In order to capitalise on the 
affinity HsdR displays to the gold surface of the SPR sensor chip (Figure 50, Figure 51) it is 
possible to attach the target protein to the surface using chemistry through the primary 
amines found on the side chains of the polypeptide backbone of the protein. By 
functionalising the surface and relying on the electrostatic attraction of the HsdR to the gold 
sensor chip, surface immobilisation of the target can be achieved.  
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Figure 52 Immobilisation of HsdR to Biacore CM5 chip through primary amine attachment. 
Immobilisation of HsdR to Biacore CM5 chip through primary amine attachment. A – Concentration analysis 
of HsdR sample. B – Surface functionalisation using EDC/NHS. C – Successive 1 µL, 3 µL, 4 µL, 2 µL, and 4 µL 
pulses of 1 µM HsdR. D – 70 µL Ethanolamine wash. Increased baseline of 2075 response units bound to the 
surface. 
 
Following the successful immobilisation of HsdR to the sensor chip surface (Figure 52) the 
candidate aptamers can be introduced to the target with any binding observable through a 
change in Response units. Any such change can be said to be the binding of aptamers to the 
target. A consequence of the reversal of the immobilisation of the target rather than the 
aptamer is the relative change in response units associated with a binding event. HsdR can 
be said to be a large protein (~145 kDa native molecular weight) which is a much larger 
mass than that associated with the aptamers (8582.6 Da for a 28 base pair aptamer). Due to 
the large relative mass ratio (1:16 HsdR aptamer) the detection of aptamers upon binding is 
difficult using SPR methodologies, it is not however, impossible.  
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Figure 53 SPR analysis of HsdR binding aptamers binding to immobilised HsdR. SPR analysis of HsdR 
binding aptamers binding to immobilised HsdR.  Surface bound HsdR (Figure 52) introduced to candidate 
aptamers according to legend. 5 µM HBA1 , 5 µM HBA3, 5 µM HBA15, 5 µM HBA16, 5 µM HBA20, and 5 µM 
control DNA TBA R70E.  
 
As can be seen from the sensorgram Figure 53, there is no significant change in response 
unit observed for any of the candidate aptamers, this lack of binding can be attributed to 
the protein being in a non-native state that is the result of the immobilisation method, it 
may also be attributed to the candidate aptamers not forming the secondary structure 
motifs required for binding in the analysis buffer.  
Unfortunately the issue of non-specific binding could not be solved, it being neither the GST 
tag, nor the buffer in which the HsdR was in. After the series of higher ionic strength buffers 
and increasing and varied use of detergents to discourage HsdR interaction with the control 
channel as well as the active channel the reliable use of HsdR with this method of SPR 
proved redundant. The persistent non-specific binding of the protein to the unprepared 
control channel could be due to electrostatic attraction of HsdR to the gold surface, 
although this is not investigated here. Also, due to the comparatively expensive nature of 
reversing the experiment around, with HsdR bound to the chip and the aptamer species 
flowed over, and with the difficulty of immobilising native and folded HsdR to a surface 
through primary amine coupling an alternative method of assaying the potential aptamer 
species was sought.  
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Table 8  Table of potential aptamers and estimated dissociation constants 
 
Aptamer name Apparent dissociation constant (Kd) 
HBA1 200 nM 
HBA3 450 nM 
HBA15 450 nM 
HBA16 450 nM 
HBA20 650 nM 
 
4.3.7 Activity assay 
A previously reported method for assaying the restriction activity of the HsdR subunit could 
be used to further characterise the HsdR binding aptamers. By establishing whether the 
aptamer, upon binding, interferes with the known level of cleavage activity associated with 
the HsdR subunit a  direct comparison that can give insight into whether an aptamer is 
directly binding one of the active epitopes of the protein.  
 
Figure 54 Initial EcoR124I digestion of pCFD30. Restriction Inhibition Assay. Lane 1 HsdM:HsdR ratio 
0, Lane 2 HsdM:HsdR ratio 1:1, Lane  3 HsdM:HsdR ratio 1:2, Lane 4 HsdM:HsdR ratio 1:5, Lane 5 HsdM:HsdR 
ratio 1:10, Lane 6 No Enzyme Control, Lane 7 EcoR1 restriction control. A. No Aptamer control B. Restriction 
Assay with 10 uM anti-ATP aptamer.   
 
107 
 
 
Figure 55 Control Restriction Assay band analysis. Control Restriction Assay band analysis of 
EcoR124I digestion of pCFD30. Image analysed with ImageJ software and band intensity quantified and 
expressed as a percentage of total response. 
 
 
Figure 56 Anti-ATP Aptamer Restriction Assay band analysis. Anti-ATP Aptamer Restriction Assay 
band analysis A repeat of experiment Figure 55 with 10 µM DNA anti-ATP aptamer added to the reaction. 
Image analysed with ImageJ software and band intensity quantified and expressed as a percentage of total 
response. 
Analysis of the relative intensities of the digested bands (Figure 55) indicates that the level 
of restriction of the pCFD30 substrate from supercoiled linear is inhibited by the presence of 
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the DNA ATP aptamer. Using the data generated it can be seen that at the 1:2 ratio of 
HsdM:HsdR approximately 48-50% of the substrate is digested after 2 hours, and from the 
analysis of the inhibition assay with the added DNA ATP aptamer (Figure 56) the restriction 
is inhibited to 4% of the total DNA present. The level of restriction inhibition observed can 
be used as proof of concept for the validation of the restriction assay as a method for 
probing possible aptamer binding sites.  
4.4 SELEX to isolate Human Rhinovirus 14 3C binding aptamers 
After the success of isolating a series of aptamers to the fusion protein HsdR, a distinct but 
relatively similar protein target was sought to validate the technique of affinity SELEX as 
realised in this investigation. The protease Human Rhinovirus 14 3C (HRV143C) is 
commercially available as a fusion protease known as HRV143C(GE Healthcare®). Like GST-
HsdR, HRV143C is purified using a glutathione-S-Transferase fusion protein partner the 
bindings reversibly with glutathione that is bound to an affinity matrix. In an identical 
method to that described for HsdR SELEX, HRV143C SELEX relies on the affinity of the GST 
fusion tag to immobilise the target to the affinity column. With progressive iterations of the 
SELEX screening and amplification process, a final aptamer pool was cloned into the vector 
pGEM-T-Easy™ (Promega) after 13 rounds. 20 candidate clones were sequenced with a total 
of 94 potential aptamer sequences recovered (Table 3). 
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Figure 57 6% Native acrylamide gel of rounds of SELEX against protein target HRV143C. 15 % Native 
acrylamide gel showing the immobilisation of PBA aptamer library. Lane 1: Hyperladder V, Lane 2: SELEX 
Forward Primer, Lane 3: SELEX reverse Primer, Lanes 4 – 10: HRV143C  SELEX rounds 4 – 10 respectively. 
Stained with SYBR™ (Promega) 
Table 9 Multiple sequence alignment of Recovered Sequences for HRV143C binding aptamers 
Aptamer sequence  
1               -------CCCACACACTACTCTGCCGATTTGGT----- 19              -----CCCATCGACAGTCTG-CTTCAGATCGGT----- 
14              -------CCCACACACTACTCTGCCGATTTGGT----- 39              -----CCCATCGACAGTCTG-CTTCAGATCGGT----- 
17              -------CCCACACACTACTCTGCCGATTTGGT----- 37                   ----CCTCATCAGTAGTCAT-CATCGT----------- 
25              -------CCCACACACTACTCTGCCGATTTGGT----- 6               ----CCCAAT-GAACATGCCACAGTTGGTCGT------ 
70              -------CCCACACACTACTCTGCCGATTTGGT----- 13              ----CCCAAT-GAACATGCCACAGTTGGTCGT------ 
75              -------CCCACACACTACTCTGCCGATTTGGT----- 22              ----CCCAAT-GAACATGCCACAGTTGGTCGT------ 
58              -------CCCACACACTACTCTGCCGATTTGGT----- 48              ----CCCAAT-GAACATGCCACAGTTGGTCGT------ 
68              -------CCCACACACTACTCTGCCGATTTGGT----- 7               ----CCCAAT-GAACATGCCACANTTGGTCGT------ 
56              -------CCCACACACTACTCTGCCGATTTGGT----- 42              ----CCCAAT-GAACATGCCANANTTGGTCNT------ 
57              -------CCCACACACTACTCTGCCGATTTGGT----- 31              ----CCCAAT-GAANATGCCANANTTGGTCNT------ 
38              -------CCCACACACTACTCTGCCGATTTGGT----- 32              ----CCNANCAAAAGGTGCNATGCTTTACN-------- 
50              -------CCCACACACTACTCTGCCGATTTGGT----- 43              ----CCNANCANAANGTGCNATGCTTTACNGN-----
- 
16              ---CCAAGCGGGATAC-ACACTACTGGGACGC------ 23              ----CCGAGCAGAAGGTGCGATGCTTTACGGT------ 
24              ---CCAAGCGGGATAC-ACACTACTGGGACGC------ 53              --------CCAAGCGGGCGCGAGAACAACGTACGGT-
- 
63              ---CCAAGCGNNATAC-ACACTACTGANANNC------ 66              --------CCAANCGGGCGCNAGAACAACGTACGGT-
- 
18              -----CCTCGGGACGGTGCTTCACCCTGCTGGT----- 5               ----------AGGCGGGGGGACTGACAATGTG------ 
26              -----CCTCGGGACGGTGCTTCACCCTGCTGGT----- 62              --CCGGGGCACACTGACGGGACTAACAGCGCGC--
-- 
2                   ---CCTCGGGACGGTGCTTCACCCTGCTGGT----- 67              --CCGGGGCACACTGACGGGACTAACAGC--------- 
20              -----CCCACAGACATTAGGACGCTACATGGGGT---- 60              -CCCGGGAATAACCGTACGAGTTCGGGGT--------- 
21              -----CCCACAGACATTAGGACGCTACATGGGGT---- 11              ---CCCGGGCGGACAGCAGGCTGTTCGTTGC------- 
55              -----CCCACAGACATTAGGACGCTACATGGGGT---- 12              ---CCCGGGCGGACAGCAGGCTGTTCGTTGC------- 
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59              -----CCCACAGACATTAGGACGCTACATGGGGT---- 27              ---CCCGGGCGGACAGCAGGCTGTTCGTTGC------- 
28              -----CCCACAGACATTAGGACGCTACATGGGGT---- 49              ---CCCGGGCGGACAGCAGGCTGTTCGTTGC------- 
3               -----CCCACAGACATTAGGACGCTACATGGGGT---- 51              ---CCCGGGCGGACAGCAGGCTGTTCGTTGC------- 
76              -----CCCACAGACATTAGGACGCTACATGGGGT---- 74              ---CCCGGGCGGACAGCAGGCTGTTCGTTGC------- 
45              -----CCCACAGACATTAGGACGCTACATGGGGT---- 15              ---CCCGGGCGGACAGCAGGCTGTTCGTTG-------- 
10              -----CCCACAGACATTAGGACGCTACATGGGGT---- 47              -----CCGGCGGGCGGGAGGCATCTGAGGGAGT---
-- 
52              -----CCCACAGACATTAGGACGCTACATGGGGT---- 33              ---------CCAACCGGAATCCAGTCGAGGT------- 
36              -----CCCACAGACATTAGGACGCTACATGGGGT---- 4               --------CCACATTGTCCTTCCTTGTGTGT------- 
46              -----CCCACAGACATTAGGACGCTACATGGGGT---- 8               --------CCACATTGTCCTTCCTTGTGTGT------- 
40              -----CCCACAGACATTAGGACGCTACATGGGGT---- 44              ------TCGTGCGTAACGTGTGCTTGGTGGT------- 
69              -----CCCACAGACATTAGGACGCTACATGGGGT---- 65              ---CCATCGT-CGTNAATTGTCTTCNGTGGT------- 
72              -----CCCACAGACATTAGGACGCTACATGGGGT---- 54              CCCATGACCTGCGTTCATCG-TGTTCGGT--------- 
73              -----CCCACAGACATTAGGACGCTACATGGGGT---- 61              --CCGGCTGTGCTTTTACTGGTGTTGGGT--------- 
30              -----CCCACAGACATTANGACGCTACATGGGGT---- 29              --CGTTTTCTTGATGTTTTTGCATTGGT---------- 
41              -----CCCACANACATTANGACGCTACATGGGGT---- 9               -------CATGGCAGGG--TGCANTTGTGGT------- 
71              -----CCCACAGACATTAGGACGCTGCATGGGGT---- 35              ----CTCTATGGCAAGCGTTGTGTTTGTGGT------- 
64              -----
CCCACATACATTAGGACNCTACATGGGGTGCGC 
 
 
A multiple sequence alignment highlighted the fact that recurring sequences of 
CCCACACACTACTCTGCCGATTTGGT and CCCACAGACATTAGGACGCTACATGGGGT were 
common. The ten most common recurring sequences were chosen for further investigation 
using the methods refined from the HsdR binding aptamers.   
Table 4. Table of PBA candidates, along with sequence and predicted dissociation constants determined by 
dot blot 
Aptamer name Aptamer Sequence Predicted dissociation 
constant (Kd) 
PBA 1 CCCACACACTACTCTGCCGATTTGGT ~900 nM 
PBA 2 CCAAGCGGGATACACACTACTGGGACGC ~7.5 µM 
PBA 3  CCCACAGACATTAGGACGCTACATGGGGT ~950 nM 
PBA 4 CCCATCGACAGTCTGCTTCAGATCGGT ~1.25 µM 
PBA 5 CCCAATGAACATGCCACAGTTGGTCGT Nil 
PBA 6 CCGGGGCACACTGACGGGACTAACAGC Nil 
PBA 7 CCCGGGCGGACAGCAGGCTGTTCGTTGC ~950 nM 
PBA 8 CCGGCTGTGCTTTTACTGGTGTTGGGT ~7.5 µM 
PBA 9 CGTTTTCTTGATGTTTTTGCATTGGT ~5 µM 
PBA 10 CTCTATGGCAAGCGTTGTGTTTGTGGT ~5 µM 
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4.4.1 Non-denaturing HPLC of HRV143C  SELEX rounds 1-9 
HPLC analysis of the progressive rounds (Figure 58) that resulted in the enhanced HRV143C 
aptamer pool proved largely inconclusive. A slight refinement of the reduced peak with a 
retention time of 3 minutes is observable, although greatly reduced from the first round (in 
blue) the peak can be seen to diverge from one large peak to two combined peaks in rounds 
3 to 9 of HRV143C SELEX. Although the SELEX process can be deemed to be successful 
(Figure 57), in the case of the HRV143C SELEX process, the distinction between the aptamer 
libraries cannot be said to be sufficiently different as the HsdR binding aptamer according to 
the HPLC analysis (Figure 44). This may be due to the structural variation of the enriched 
HRV143C SELEX libraries not being as distinct as those of HBA SELEX.  
 
 
Figure 58 Non-denaturing HPLC of HRV143C SELEX rounds 1-9. Chromatograms of Progressive rounds 
of HRV143C SELEX analysed using the Dionex 3000 HPLC system and DNAPac column. The peaks symbolize 
the absorption of UV light at λ260 nm and represent the refinement of the DNA aptamer library through 
rounds 1,3,4,5,8 and 9 of HRV143C SELEX.  
4.4.2 Dot Blot 
Following the established methodology for the rapid assay and validation of a potential 
aptamer pool described above for the HsdR binding aptamer the candidate sequences of 
the HRV143C binding aptamer (PBA). Each sequence carries a 5’ biotin attachment for 
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detection using the streptavidin HRP conjugate, and was incubated with a series of 
concentrations of HRV143Cthat had been dried onto a nitrocellulose membrane and 
blocked with 3% Bovine Serum Albumin. As a result it is possible to detect the concentration 
at which the amount of binding falls from 100%, an extrapolation from this is that 50% of 
Kmax is Ka/Kd or Kd which can give an estimate of the dissociation constant of each particular 
species of aptamer in the specified conditions. [A]Total 
    
        
 
This insight can be used to contribute to the decision as to which of the PBAs to take 
forward for further, more concentrated, investigation methods, such as SPR or ultimately 
structural modelling methodologies (protein crystallography, and Nuclear Magnetic 
Resonance studies).  
A  B  
Figure 59 Dot blot assay of HRV143C Binding Aptamer (PBA) species 1-10 against decreasing 
concentrations of HRV143C. Dot blot of 5 µM PBA 1 through to 20 at a concentration of from top to bottom 
against decreasing concentrations of HRV143C (10 µM, 5 µM, 1 µM, 900 nM, 800 nM, 700 nM, 600 nM, 
500 nM) progressing from left to right, probed using streptavidin:HRP conjugate (0.125 ng/mL) and 
visualised using Fujifilm™ Las3500 Intelligent Dark Box. Row 11 is the no DNA control. A – Native dot blot, B- 
Inverted Pixel repeat  
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Figure 60 Summary of PBA dot blots Chemiluminescent responses. Summary of PBA dot . Graphic 
representation of results of the dot blots (Figure 59). Data generated by intensity of response divided by 
area in ImageJ . 
 
From the dot blot assays (Figure 59) and the subsequent values resulting from the analysis 
(Figure 60) the aptamer sequences that have been seen to have a response that indicates 
aptamer binding can also have a dissociation constant predicted, although this prediction 
has a series of caveats for the reliability of the data produced from this method as 
mentioned above, the predictions are detailed in the table below (Table 10)  
Table 10 Table of PBA candidates, along with sequence and predicted dissociation constants determined by 
dot blot 
Aptamer name Aptamer Sequence Predicted dissociation 
constant (Kd) 
PBA 1 CCCACACACTACTCTGCCGATTTGGT ~900 nM 
PBA 2 CCAAGCGGGATACACACTACTGGGACGC ~7.5 µM 
PBA 3  CCCACAGACATTAGGACGCTACATGGGGT ~950 nM 
PBA 4 CCCATCGACAGTCTGCTTCAGATCGGT ~1.25 µM 
PBA 5 CCCAATGAACATGCCACAGTTGGTCGT nil 
PBA 6 CCGGGGCACACTGACGGGACTAACAGC nil 
PBA 7 CCCGGGCGGACAGCAGGCTGTTCGTTGC ~950 nM 
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PBA 8 CCGGCTGTGCTTTTACTGGTGTTGGGT ~7.5 µM 
PBA 9 CGTTTTCTTGATGTTTTTGCATTGGT ~5 µM 
PBA 10 CTCTATGGCAAGCGTTGTGTTTGTGGT ~5 µM 
  
 
4.4.3 Activity Assay 
The simplistic method in which candidate aptamer pools are screened and amplified and 
ultimately arrived at, largely leaves a gap in the knowledge of the location or epitope to 
which each individual aptamer is preferentially binding to. In an effort to decipher the 
location of the primary binding epitope of each individual candidate PBA, an assay was 
required that utilises the primary function of HRV 14 3C protease. The fusion protein clone 
of EcorR124I HsdR subunit used for the expression of GST-HRV143C-HsdR contains a linker 
region that holds the peptide recognition sequence and subsequential cleavage site for HRV 
14 3C . By creating the conditions in which HRV 14 3C will cleave its peptide substrate, in 
this case the glutathione-S-Transferase subunit of the larger fusion protein, it is possible to 
gain an insight into whether any of the proposed aptamer sequences occupy the active site 
of HRV 14 3C. Through comparison to the known cleavage event, any reduction in overall 
cleavage can indicate inhibition through competition. The resultant gel, Figure 61, gives a 
clear result in that a total lack of inhibition can be observed. Through comparison to the 
control in lane 12, it is possible to see that the cleaved GST tag will migrates at ~24000 Da in 
a denaturing SDS page gel. HRV 14 3C migrates at ~56000 Da with the completely cleaved 
HsdR subunit migrating through the gel at ~121000 Da, which is to be expected as the native 
fusion protein is known to be 145000 Da from previous work.   
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Figure 61  HRV143C Cleavage of HsdR . 10% SDS PAGE gel of 100 ng HsdR incubated with 2 NIH units 
of HRV143C (2 mg/ml) and 10 µM PBA, for 4 hours at 24oC. Lane 1 Benchmark Prestained protein ladder 
(Promega), Lanes 2-11 PBA 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, Lane 12 No aptamer control. 
Using assays such as the inhibition of cleavage assay and the dot blot, Figure 61, and Figure 
59  respectively, a larger picture for where an aptamer is binding can be drawn. Although 
the techniques are limited, without the use of other, further studies, primarily focused on 
the structural properties of the protein and their aptameric ligands, it is difficult to construct 
the exact nature of the interaction. This is not the purpose of this investigation, although 
there continues to be an interest in the further examination of the PBA:HRV143C such as a 
cure for the common cold (as HRV143C is the virus responsible for this) and much further 
work can be undertaken in order to further characterise the interaction.  
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5 Production of novel aptamers- Separation methods 
5.1 The Methylase subunit of EcoR124I 
The methods presented in this chapter are designed to further highlight the ease with which 
SELEX can be achieved, and the variation of proteins and targets to which aptamers can be 
isolated. Through the use of gel electrophoresis, HPLC, and nanopore molecule sorting, 
aptamer library refinement can be achieved, highlighting the ease of which aptamers can be 
raised to targets. This chapter will also demonstrate the enrichment of random DNA 
libraries towards a small molecule target. This will in effect complete the desired suite of 
aptamer derivation techniques in a typical laboratory environment.  
The methylase, (MTase) subunit of EcoR124I is a 58kDa (Taylor et al., 1994) protein that 
associates with one HsdS specification subunits, to form the modification portion of the 
enzyme, and with two HsdR subunits and to form the active restriction modification system 
(Janscák et al., 1996). The subunit is of interest because of an extensive characterisation 
that has progressed over a period of 30 years and in conjunction with the HsdR subunit 
combine to form the restriction modification system EcoR124I in the configuration R2M2S1 
(Janscák et al., 1998). 
Given the ability of the MTase subunit to specifically bind double stranded DNA at the 
known recognition sequence it is an interesting point to note whether the ssDNA aptamers 
derived through the SELEX process will bear any resemblance to the published DNA 
recognition sequence of EcoR124I (Yuan et al., 1980) (Studier & Bandyopadhyay, 1988, 
Dryden et al., 1997, Szczelkun et al., 1997). Aptamers have been isolated to DNA binding 
proteins previously, Bai et al. (Bai et al., 2005) islotated ssDNA aptamers to the DNA binding 
protein Rv3676 with the resulting sequence bearing a large resemblance to the known 
recognition sequence. The outcome of this could point to some enticing conclusions. For 
example, if the sequence does resemble the dsDNA binding site, are the aptamers forming a 
novel secondary structure, or merely mimicking the sequence found in nature? The 
outcomes of this may alter the understanding of the methodology of SELEX, and the 
perceived ability of the technique to isolate novel binding sequences. Conversely, it may 
also point to the diversity of ssDNA structural motifs and an ability of ssDNA to form the 
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structure(s) required to arrange the required bases in correct configuration for recognition 
through base stacking, stem loops, and guanine quadraplexes ,for example. 
5.2 Nitrotyrosine 
Nitrotyrosine (NT) is a modified amino acid that can act as a biomarker for a number of 
medical conditions, such as diabetes (Ceriello et al. 2002), and in disease affected tissues 
(Bruijn et al., 1997). Nitrotyrosine is commonoly used as a marker molecule as it absorbs 
light at λ=450 nm (Walker, 1996), and it is because of this property that the molecule has 
been selected to be the target of this small molecule selection.   
 
Figure 62 Chemical Structure of 3-Nitrotyrosine. Cartoon Depiction of the chemical structure of 
Nitrotyrosine. 
5.3 Gel Electrophoresis SELEX (GELEX) 
This novel method lends itself to the derivation of aptamers to previously characterised 
proteins, unknown proteins, or even complex mixtures of multiple proteins providing there 
is sufficient difference in charge and shape of the constituents. This method is similar to the 
published methods CE-SELEX, (Mosing and Bowser 2009) and NECEEM (Berezovski & Krylov 
2002), but varies in the bulk nature of the method. The Capillary Electrophoresis methods, 
both work in minute quantities, and this will save much on sample preparation. But, if the 
amount of protein is not an issue, or it is more amenable to produce large amounts of 
protein rather than purchase an expensive piece of equipment, GELEX may provide an 
alternative.  
118 
 
 
Figure 63 Schematic of GELEX process. Schematic of GELEX process, A. Aptamer + target mixture B. 
Current applied and bound and unbound species separate C. Distinct fractions collected with bound species 
going on for further amplificiation and the next round of selection.D. Unbound species removed 
Using this method releases the target from the necessity of immobilisation, this in turn will 
give rise to aptamers that have been raised to native protein in the pH and ionic conditions 
determined to be the most beneficial for activity of the protein or for downstream 
applications of the required aptamer such as within a biosensor. The persistent drawback of 
the technique remains the length of time required to separate the bound and unbound 
libraries from each other.   
5.3.1 Isolation of Mtase binding aptamers using GELEX 
The GELEX process begun was incubation of the purified MTase subunit of the EcoR124I 
restriction endonuclease with an aptamer library of ~1013 species. The mixture was 
separated using a 20mm 6% Native acylamide gel and subjected to a 100v current for 4 
hours at 4oC and 64 1 mL fractions collected. All fractions found to be containing protein 
(Figure 69) were pooled and amplified, the process is repeated for 3 rounds, as 
recommended by Bowser (REF) with the final library cloned using the pGem-T-Easy vector 
system (Promega), and finally sent away to be sequenced (Cogenics UK).  
The BioRad Miniprep Cell (BioRad Ltd, US) is a device that has been designed to be used for 
the separation of proteins in native and denaturing environments. The method presented 
here is an alteration from the intended use, but, it is a display of the versatility of the SELEX 
method. 
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Figure 64 Cartoon of the Biorad Mini-prep Cell. The Biorad Mini-prep cell is a tool intended for the 
separation of proteins in bulk according to size using a native agarose gel system. 
Using the Bio-Rad Mini-prep Cell (Figure 64), buffer is flowed across the bottom of an 
acrylamide gel and fractionated. Molecules are sorted by electrophoretic separation 
because their intrinsic overall net charge and the bound and unbound portions are 
partitioned in this manner (Figure 63). The fraction containing bound species of library and 
target are sufficiently separated from the un-bound and the resulting fractions are pooled 
and amplified. This procedure can then be repeated until a suitable library of potential 
aptamers is elucidated. This process has been termed GELEX. 
The GELEX process was undertaken using the Mtase subunit as a model protein. Although 
the potential issue with raising aptamers to a DNA protein have been mentioned above, the 
site is known to be specific to dsDNA whilst the aptamer starting library is ssDNA. Also later 
analysis can identify any sequences that do contain the recognition sequences and they will 
be discarded. Additionally during the partitioning process the DNA occupying the 
recognition site may be out-competed by a higher affinity ligand such as a candidate DNA 
aptamer. Through multiple rounds of GELEX these ligand with a higher affinity for the will be 
preferentially selected for, before becoming the dominant species for that epitope. Finally, 
the equilibirum will shift towards the higher affinity ligands and the lower affinity ligand will 
be washed away in the separation portion of the process B (Figure 63).  
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Figure 65 Recovery of HsdM and HsdS domains of EcoR124I during GELEX. 10% SDS acrylamide gel 
Coomassie stained depicting the recovery of HsdM (58  kDa) and HsdS (64 kDa) subunits of the EcoR124I R-
M system from the BioRad Prep cell. Each fraction was to subjected to PCR amplification then pooled prior 
to base denaturation in preparation for the next round of screening. Lane 1 is SeeBlue pre-stained protein 
ladder, lanes 2-13 are samples of fractions 50-62 of GELEX 
Figure 65 is a SDS PAGE gel depicts the bands of protein found across 12 fractions that result 
from the GELEX process. The fractions were pooled and the protein removed using phenol 
chloroform (Materials and Methods 5.2) extraction before the DNA library was 
concentrated by ethanol precipitation (Materials and Methods 5.1). Following concentration 
the library was amplified using PCR, then subjected to the next round of separation as per 
the GELEX procedure set out above. 
5.3.2 Cloning 
After 3 rounds of GELEX the final DNA library was amplified for the last time using a Taq. 
Polymerase as described in Materials and Methods 5.3 and the recovered sequences are 
presented here: 
 Table 11 DNA sequences recovered from the GELEX process 
Name Aptamer Sequence 
mba1 CCTGCTGATTCGTTGGGTGTTGTGTGGT 
mba2 CCCGTANCGTACAGTCCCAGCTTGGTAT 
mba3 CCCTGAGTCATAGTGTTCACGTGTT  
mba4 CCACAACGAGCCGGGATTGCGGATTGCA 
mba5 CCCTGAGTCATAGTGTTCACGTGTT 
mba6 GGCGAATTGGGCCCCGAGGGGTCGACT 
mba7 CCCGTANCGTACAGTCCCAGCTTGGTAT 
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mba8 GGCGAATTGGGCCCGAGTCGCATGCTCCC 
mba9 CCGGTTGGGATGTGNCNCCCCNNATANN 
 
After alignment the sequences produced from GELEX can be seen to show some consensus 
in positions 1,2,3,4, and 6, which indicates that the conserved region may be involved in 
aptamer binding. There is also a conserved area at bases 18 to 22 with again points towards 
the preservation of a motif, although there could be two populations of sequences with 
cytosine the more dominant over guanine in both of the “motifs”.  
 
Figure 66  Sequence Logo of base occurance of recoverd MTase binding aptamer library. Sequence 
logos depict the relative frequency of each base at each position of the motif. The y axis indicates the 
information content measured in bits, and error bars represent standard deviations at each position due to 
the limited sample size. 
Another interesting note is the comparison with the double stranded DNA Mtase binding 
region GAA(N)6RTCG (Taylor et al. 1994, (Mernagh et al., 1998). In two of the sequences, 
mba6 and mba8 , the binding sequences can be observed but with slight alterations in the 
number of bases between the 5’ and 3’ portions of the recognition sequences. In Mba 6 the 
recognition sequence may be amended to GAAN14RTCG, and in mba8, GAAN10RTCG, the 
striking resemblance to a DNA binding enzymes’ recognised binding site indicates that the 
DNA may be adopting a secondary structure that enables the single stranded DNA aptamer 
to mimic it.  
Table 12 Comparison with mtase binding region GAAN6RTCG (Mernagh et al., 1998) 
Mba1 CCTGCTGATTCGTTGGGTGTTGTGTGGT 
mba2 CCCGTANCGTACAGTCCCAGCTTGGTAT 
mba3 CCCTGAGTCATAGTGTTCACGTGTT  
mba4 CCACAACGAGCCGGGATTGCGGATTGCA 
mba5 CCCTGAGTCATAGTGTTCACGTGTT 
mba6 GGCGAATTGGGCCCCGAGGGGTCGACT 
mba7 CCCGTANCGTACAGTCCCAGCTTGGTAT 
mba8 GGCGAATTGGGCCCGAGTCGCATGCTCCC 
mba9 CCGGTTGGGATGTGNCNCCCCNNATANN 
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Recognition Sequence GAANNNNNNRTCG 
5.3.3 Dot blot of MTase Binding aptamer sequences 
The recovered candidate sequences were assayed for binding to MTase using the dot blot 
procedure. Dot blot of MBA 1,2,3,4,5,6,7, 9, and a no DNA control from top to bottom 
against decreasing concentrations of MTase (10 µM, 5µM, 1 µM, 0.5 µM, 100 nM, 50 nM, 10 
nM, 5 nM, 1 nM, and 0) progressing from left to right, probed using streptavidin:HRP 
conjugate (0.125 ng/mL) and visualised using Fujifilm™ Las3500 Intelligent Dark Box. 
 
Figure 67  Dot blot of MTase Binding aptamer sequences. Dot blot of MBA 1,2,3,4,5,6,7, 9, and a no 
DNA control from top to bottom against decreasing concentrations of MTase (10 µM, 5µM, 1 µM, 0.5 µM, 
100 nM, 50 nM, 10 nM, 5 nM, 1 nM, and 0) progressing from left to right, probed using streptavidin:HRP 
conjugate (0.125 ng/mL) and visualised using Fujifilm™ Las3500 Intelligent Dark Box. 
The binding of the aptamers to MTase was not clarified by this method due to a large 
amount of non-specific binding, analysis using ImageJ (data not shown), a further method 
for MTase aptamer validation was sought.   
5.3.4 Aptamer facilitated Protein sedimentation 
The process of affinity purification is a well documented and widely practiced method of 
purifying proteins from solution by using a partner molecule with reversible binding to the 
desired target.  Aptamer facilitated protein sedimentation is a variation of 
immuoprecipitation using aptamers immobilised on a surface. The aptamers are 
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biotinylated and bound to streptavidin that has been covalently bonded to Dynal® 
paramagnetic beads through proprietary chemistry. After significant washing, the beads are 
incubated with the target protein and unbound protein is removed. The bound portion can 
then be released using a high ionic strength buffer (such as 2 M NaCl) and examined using a 
denaturing SDS PAGE gel.  
Using this technique it is possible to pull the target molecule out of solution by the magnetic 
attraction properties afforded by the beads. Although the beads are designed to stay in 
suspension they will sediment over time (>24hrs), this sedimentation can be exacerbated by 
centrifugation.  
The method of pulling protein from solution can give some insight into the specificity of the 
protein for the target, if the aptamer does bind the target at all.  
 
Figure 68  Aptamer facilitated pull down of Mtase from purified protein. Repeat of figure 4 10 % SDS 
PAGE gel of MBA 5 and MBA 9 facilitated Mtase pull down. Lane 1 See Blue Protein Ladder (Invitrogen), Lane 
2 No DNA control Lane 4 MBA5 unbound fraction, Lane 5 Mba5 eluate, Lane 7 Mba9 Unbound flowthrough, 
Lane 8 MBA 9 Eluate . Such and such conc of aptamer was incubated with X conc of beads for X mins, 
washing etc. 
Figure 68 is the SDS PAGE gel that resulted from the protein sedimentation with lane 5 and 
lane 6 representing the recovered protein whilst lanes 4 and 7 are examples of the unbound 
portion. The two bands observed in lanes 4 and 7 correspond to the co-purification partners 
of, HsdM and HsdS, EcoR124I subunits with the upper band corresponding to HsdM and the 
lower HsdS band. It can be then observed that although the aptamers do bind to a protein, 
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it is not the intended target, but the partner protein to which the aptamers have been 
raised. This can help to explain the resemblance of some of the sequences to the binding 
site desired by the specificity subunit.  
 
 
Figure 69   Aptamer facilitated pull down of MTase from crude lysate. 10 % SDS PAGE gel of MBA 5 
and MBA 9 facilitated Mtase pull down. Lane 1 See Blue Protein Ladder (Invitrogen), Lane 2 MBA5 unbound 
fraction, Lane 3 Mba5 eluate, Lane 4 Mba9 Unbound flowthrough, Lane 5 MBA 9 Eluate, Lane 6 No DNA 
control 
This method also lends itself the crude purification from a complex background. Figure 69 
depicts the recovery of the desired protein from cell lysate. 500 mL of JM109 cells were 
grown overnight and gently lysed by incubation with a high salt buffer. The lysate was 
incubated with 5 µL of 10 mL mL-1 MyOne Dynal paramagnetic beads (Invitrogen UK) that 
had been prepared with biotinylated aptamer and followed the protocol described above. 
Although some other proteins have been purified it is postulated that they could be 
removed through a more stringent washing methodology. 
5.4 HPLC SELEX 
To complete the suite of laboratory based aptamer isolation methods a technique was 
sought that would be suitable for the enrichment of SELEX libraries against small molecule 
targets. Currently, SELEX methods directed to small targets require either the use of 
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capillary electrophoresis (CE-SELEX  (Bowser, 2005)or NECEEM (Berezovski et al., 2006) or 
the immobilisation of the target to an affinity matrix (Green et al., 1996; Jellinek et al., 1994) 
or organic dyes (Ellington and Szostak, 1990,1992). High Performance Liquid 
Chromatography (HPLC) is a common laboratory technique based on the separation of 
molecules in a liquid phase, either by ionic charge, size, or other. The separation is achieved 
by the migration of species through a column of a solid matrix.  
The proposed method relies on the fact that the small molecule target will migrate through 
the matrix at a higher rate than the random DNA library, and that a DNA:target complex will 
migrate at a further separate rate. Once complete separation can be assumed to have been 
achieved the fraction that is known to contain the complex can be isolated and amplified as 
in regular SELEX. Again the enriched library will be incubated with the target, and separated 
a second time, and the process repeated until the library is sufficiently enriched before 
cloning and identification of candidate aptamers.  
Any fraction found to absorb light at 450 nm and elute away from the known elution time 
associated with the unbound NT fraction can be considered to contain NT. This fraction can 
then be amplified as per the SELEX procedure.  
5.4.1 Results 
Figure depicts the four chromatograms drawn from NT SELEX, A shows the migration of NT 
with a peak found at approximately 1.25 minutes from the void volume. With only NT 
present and the detector set to λ450 nm it can be confidently assume that 1.25 minutes is 
where NT will elute. B is a chromatogram of the elution profile of the 1 µM random naked 
DNA library at λ260 nm, this shows a broad profile with a large peak at 6 minutes which can 
be assumed to be the DNA library. The other earlier peaks present are most likely 
incomplete synthesis products, and although they may interfere with binding by providing 
false motifs, they will not be selected for in subsequent rounds of SELEX due to incomplete 
sequences which would most likely mean the absence of priming regions. C is a 
demonstration of the absorbance of NT at λ260 whilst D is the λ450 nm chromatogram 
depicting the elution profile of NT and the random DNA library after incubation together. E 
is λ260 nm representation of D with a large peak that occurs at 1.25 minutes and another 
that occurs at 6 minutes, which could be considered to be the elution of NT and the library 
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respectively. The overlay F, however, highlights a shift of the λ450 nm NT profile upon the 
mixing with the DNA library. This would appear to be the formation of a complex.  
Figure 70 Chromatograms depicting HPLC SELEX of Nitrotyrosine. Chromatograms produced using Dionex 
LC2000 HPLC machine, with a DNApac PA200 column, samples run for a total of 20 minutes at a flow rate of 
1 mL min-1. Section A is a chromatogram of Nitrotyrosine with detection at λ450 nm, Section B is a 
chromatogram of the naked DNA library with detection at λ260 nm, Section C is a chromatogram of 
Nitrotyrosine with detection at λ260 nm, Section D is a chromatogram of the combination of nitrotyrosine 
incubated with the random library with detection at λ450 nm, E is a chromatogram of the combination of 
nitrotyrosine incubated with the random library with detection at λ450 nm, F is an overlay of 
chromatograms A, B, C, D, and, E. 
5.4.2 Cloning 
The isolated sequences were cloned in to pGEM-T-Easy as defined in Materials and Methods 
5.3. 
5.5 Q-Nano DNA electrophoresis 
The concepts introduced in this chapter investigate the isolation of aptamer libraries using 
processes that partition the random library from the bound target:DNA complex through 
alternative separation methods. The qNano (Figure 71) nanopore provides a suitable 
platform for the dynamic separation of molecules by size (Sowerby et al 2007). The tuneable 
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aperture can be adjusted, giving a nanopore that range from 10-100 nm in size. By 
immobilising the target to a surface of a particle that is too large to translocate through the 
aperture, the non-binding species can be removed.  
 
Figure 71 qNano Scanning Ion Occlusion Sensing Platform. Image of the qNano nanopore sensing 
platform 
Through the attachment of biotinylated Human Rhinovirus 14 3C to streptavidin conjugated 
MyOne paramagnetic beads the DNA library is incubated with the target, then separated 
using the electrophoretic force applied across the nanopore. After sufficient time under the 
field the aperture can be closed, and the partitioned components recovered. The bound 
species are then eluted from the target and amplified and the process repeated until the 
library can be considered to be sufficiently enriched prior to identification of the sequences 
by cloning and sequencing. 
5.5.1 Analysis of translocation by qPCR 
The dynal beads have streptavidin immobilised on the surface through proprietary 
chemistry. HRV143C has been produced that carries a biotin moiety (article submitted) 
which will bind to the streptavidin with a high affinity (Weber et al. 1989). Using this 
interaction as an anchor point allows the confident separation of non-biotinylated species 
through methods such as electrophoresis. In this experiment the random sequence DNA 
starting library was introduced to the upper reservoir of the qNano instrument. After a 
series of intervals, small aliquots were taken from the lower reservoir was undertaken. Each 
aliquot was then subjected to PCR to amplify any of the target sequence present. The 
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amount of amplified product, will allow the estimation of speed of translocation, and then 
allow further extrapolation to the amount of time that is needed for the SELEX process.  
5.6 qNano SELEX 
100 µL of the SELEX random library  (Materials and Methods 7) was incubated with 30 µL of 
10 mg/mL MyOne streptavidin coated paramagnetic Dynal beads that had been pre-
incubated with biotinylated HRV14 3C and incubated in electrolyte buffer (0.1 M KCl, 10 mM 
Tris pH 8, 0.01% Triton X-100 (Willmott et al.)). After 10 minutes at room temperature the 
bead:DNA mixture was introduced to the top reservoir of the qNano system. With the 
aperture of the nanopore set to 100 nm and the beads reported to have an average of over 
1 µm in diameter (Invitrogen) the majority of the beads can be said remain in the upper 
reservoir. After 4 hours under 170 mV potential the upper and lower reservoir were 
collected. The lower reservoir was concentrated using QIAquick PCR cleanup columns and 
prepared for cloning. 
5.7 Cloning 
Sequences were cloned, expressed and isolated according to protocol (Materials and 
Methods 5.3) and the following sequences were recovered (Table 13). 
Table 13 DNA sequences recovered from qNano SELEX 
Sequence Name DNA sequence 
qNanoHRV143C1 TGTCTATGCAATAGTCGTTGGAGATAGTT 
qNanoHRV143C2 GCCATGATGAGCATGCTTGTCCTAGACCG 
qNanoHRV143C3 GCACCCACTAGGCGGGGAGCAGTACTCC 
 
Unfortunately this method only yielded three novel DNA sequences, which, when compared 
to each other appear to be completely random. This allows us to surmise that although the 
procedure may have been sufficient to produce novel aptamers the method on this occasion 
was flawed. Pressure on time prevented the complete examination of the technique, but it 
can be seen as pilot study in much need of further investigation.  
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Table 14 ClustalW output of multiple alignment of qNanoPPBA sequences against HRV143CBA sequences 
1               -----------CCCACACACTACTCTGCCGATTTGGT-- 26 22              -------CCCAAT-GAACATGCCACAGTTGGTCGT---- 27 
14              -----------CCCACACACTACTCTGCCGATTTGGT-- 26 48              -------CCCAAT-GAACATGCCACAGTTGGTCGT---- 27 
17              -----------CCCACACACTACTCTGCCGATTTGGT-- 26 7               -------CCCAAT-GAACATGCCACANTTGGTCGT---- 27 
25              -----------CCCACACACTACTCTGCCGATTTGGT-- 26 42              -------CCCAAT-GAACATGCCANANTTGGTCNT---- 27 
38              -----------CCCACACACTACTCTGCCGATTTGGT-- 26 31              -------CCCAAT-GAANATGCCANANTTGGTCNT---- 27 
50              -----------CCCACACACTACTCTGCCGATTTGGT-- 26 32              -------CCNANCAAAAGGTGCNATGCTTTACN------ 26 
56              -----------CCCACACACTACTCTGCCGATTTGGT-- 26 43              -------CCNANCANAANGTGCNATGCTTTACNGN---- 28 
57              -----------CCCACACACTACTCTGCCGATTTGGT-- 26 23              -------CCGAGCAGAAGGTGCGATGCTTTACGGT---- 28 
58              -----------CCCACACACTACTCTGCCGATTTGGT-- 26 19              -------CCCATCGACA-GT-CTGCTTCAGATCGGT--- 27 
68              -----------CCCACACACTACTCTGCCGATTTGGT-- 26 39              -------CCCATCGACA-GT-CTGCTTCAGATCGGT--- 27 
70              -----------CCCACACACTACTCTGCCGATTTGGT-- 26 qNanoHRV143C2      ----GCCATGATGAGCATGC-TTGTCCTAGACCG----- 29 
75              -----------CCCACACACTACTCTGCCGATTTGGT-- 26 53              -------CCAAGCGGGCGCGAGAACAACGTACGGT---- 28 
16              -------CCAAGCGGGATAC-ACACTACTGGGACGC--- 28 66              -------CCAANCGGGCGCNAGAACAACGTACGGT---- 28 
24              -------CCAAGCGGGATAC-ACACTACTGGGACGC--- 28 5               ---------AGGCGGGGGGACTGACAATGTG-------- 22 
63              -------CCAAGCGNNATAC-ACACTACTGANANNC--- 28 11              --CCCGGGCGGACAGCAGGCTGTTCGTTGC--------- 28 
18              ----CCTCGGGACGGTGCTTCACCCTGCTGGT------- 28 12              --CCCGGGCGGACAGCAGGCTGTTCGTTGC--------- 28 
26              ----CCTCGGGACGGTGCTTCACCCTGCTGGT------- 28 27              --CCCGGGCGGACAGCAGGCTGTTCGTTGC--------- 28 
2               --CACCTCGGGACGGTGCTTCACCCTGCTGGT------- 30 49              --CCCGGGCGGACAGCAGGCTGTTCGTTGC--------- 28 
30              -CCCACAGACATTANGACGCTACATGGGGT--------- 29 51              --CCCGGGCGGACAGCAGGCTGTTCGTTGC--------- 28 
41              -CCCACANACATTANGACGCTACATGGGGT--------- 29 74              --CCCGGGCGGACAGCAGGCTGTTCGTTGC--------- 28 
76              -CCCACAGACATTAGGACGCTACATGGGGT--------- 29 15              --CCCGGGCGGACAGCAGGCTGTTCGTTG---------- 27 
73              -CCCACAGACATTAGGACGCTACATGGGGT--------- 29 33              -------CCAACCGGAATCCAGTCGAGGT---------- 22 
72              -CCCACAGACATTAGGACGCTACATGGGGT--------- 29 47              ----CCGGCGGGCGGGAGGCATCTGAGGGAGT------- 28 
69              -CCCACAGACATTAGGACGCTACATGGGGT--------- 29 qNanoHRV143C3      GCACCCACTAGGCGGGGAGCAGTACTCC----------- 28 
59              -CCCACAGACATTAGGACGCTACATGGGGT--------- 29 4               -----------CCACATTGTCCTTCCTTGTGTGT----- 23 
55              -CCCACAGACATTAGGACGCTACATGGGGT--------- 29 8               -----------CCACATTGTCCTTCCTTGTGTGT----- 23 
52              -CCCACAGACATTAGGACGCTACATGGGGT--------- 29 54              ----------CCCATGACCTGCGTTCATCG-TGTTCGGT 28 
46              -CCCACAGACATTAGGACGCTACATGGGGT--------- 29 61              ------------CCGGCTGTGCTTTTACTGGTGTTGGGT 27 
45              -CCCACAGACATTAGGACGCTACATGGGGT--------- 29 44              -------TCGTGCGTAACGTGTGCTTGGTGGT------- 25 
40              -CCCACAGACATTAGGACGCTACATGGGGT--------- 29 65              ----CCATCGT-CGTNAATTGTCTTCNGTGGT------- 27 
36              -CCCACAGACATTAGGACGCTACATGGGGT--------- 29 29              -----CGTTTT-CTTGATGTTTTTGCATTGGT------- 26 
28              -CCCACAGACATTAGGACGCTACATGGGGT--------- 29 9               ----------CATGGCAGGG---TGCANTTGTGGT---- 22 
21              -CCCACAGACATTAGGACGCTACATGGGGT--------- 29 35              -------CTCTATGGCAAGCGT-TGTGTTTGTGGT---- 27 
20              -CCCACAGACATTAGGACGCTACATGGGGT--------- 29 60              -------CCCGGGAATAACCGTACGAGTTCGGGGT---- 28 
10              -CCCACAGACATTAGGACGCTACATGGGGT--------- 29 qNanoHRV143C1      ----TGTCTATGCAATAGTCGTTGGAGATAGTT------ 29 
3               -CCCACAGACATTAGGACGCTACATGGGGT--------- 29 62              ----CCGGGGCACACT-GACGGGACTAACAGCGCGC--- 31 
71              -CCCACAGACATTAGGACGCTGCATGGGGT--------- 29 67              ----CCGGGGCACACT-GACGGGACTAACAGC------- 27 
64              -CCCACATACATTAGGACNCTACATGGGGTGCGC----- 33 34              ----CCTGTGCACACTTAATGTTGCGTTCGGT------- 28 
37              ------CCTCATCAGTAGTCATCATCGT----------- 22  
6               -------CCCAAT-GAACATGCCACAGTTGGTCGT---- 27 Consensus      --CCCACAGCCATCAGGACGCTACACGGTGGGTTTGGTGT 
13              -------CCCAAT-GAACATGCCACAGTTGGTCGT---- 27 
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5.8 Conclusions 
Overall the each of the three aptamer isolation methods presented in this chapter produced 
novel sequences, although the apparent low yields of aptamer sequences from the enriched 
highlight a need for further investigation.  
The aptamer facilitated pull down of MTase from solution to purified protein (Figure 68) 
appears to be a suitable method of assaying overall aptamer binding and the specificity of 
putative aptamer sequences. Although the aptamers preferentially bound the target 
protein’s purification co-partner, the method would highlight the specificity of the aptamer 
and indicate a user error rather than an issue with the method. When the aptamers are 
probed against a complex mixture in the form of the crude cell lysate the two aptamers 
appear to perform badly. Upon further examination however it can be deduced that the 
purification is ~90% of the target MTase and HsdS subunit with the contaminants a 
carryover from the purification process. Further work indicates that the contaminants are 
avoidable with further, more stringent washes, (data not shown) but this has an impact on 
the yield of protein. In conclusion, the method is suitable for the screening and analysis of 
aptamer binding and specificity, but the result is hard to quantify due to the inconsistency of 
using paramagnetic beads. As some of the bead volume is lost through the coarse washing 
involved in removing non specific binding proteins, a discrepancy arises from experiment to 
experiment. This could possibly be overcome with the immobilisation of the aptamers to a 
column with a known and consistent volume.  
The novel process of library enrichment using Dionex 3000LC HPLC machine can be 
considered a success because N novel sequences have been isolated, but the proposed 
aptamers lack a suitable assay to determine aptamer binding. Possibly, this could be 
overcome by conjugation of the sequences to the interior of an aperture of a nanopore(Gu 
L. Q., Shim J.W. 2010), for if the target or the aptamer sequences were bound the 
translocation profile and dwell time of the analyte may be slowed and this signal analysed to 
give an indication of any binding activity. An attempted experiment to define the nature of 
the aptamer to nitrotyrosine binding for the candidate aptamers using an affinity matrix 
with the target molecule perfused throughout an agarose gel has been attempted  (not 
shown here), but the experiment failed  due the overall negative charge of NT which 
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migrated in the along with the DNA. This made it difficult to determine any retardation of 
the aptamers that could be due to binding with NT.  
All three methods of aptamer separation presented here are examples of methods of 
aptamer library enrichment that can be attempted by most adequately equipped molecular 
biology laboratories. The techniques demonstrated here do not require specific and 
expensive equipment and can produce aptamers for a variety of targets.  Nanopore 
selection may further be advanced by a variation upon the method presented here, where 
the target is immobilised to the rim of the nanopore which would provide the potential to 
give real time analysis of the proposed aptamer binding kinetics.  
These methods all represent the potential of aptamers as a complement and alternative to 
antibodies in a variety of applications. 
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6 Aptamers within biosensors: A Novel Sandwich ELISA 
based Molecular Amplifier 
Along with many other parallels with antibodies, the use of aptamers in biosensors as a 
molecular recognition element is highly advocated (Tombelli et al., 2006). Within this 
chapter the aim is to demonstrate modifications on known biosensing systems, and to 
highlight the applications and benefits of aptamers through substitution with antibodies.  
6.1 The Molecular Amplifier 
A potential problem that can occur in the development of a sensitive biosensor is the ability 
to accurately detect signals that can be considered to be below the conventionally received 
detection limits (Cho et al., 2009). In order to truthfully amplify the signal whilst keeping 
false positives and noise to a minimum, a method with high specificity is required. The 
molecular amplifier facilitates this by forming a modified ELISA sandwich (Figure 72) around 
the antigen or target molecule and by utilising the ability of streptavidin to bind up to four 
biotin molecules amplify the signal (DeChancie & Houk, 2007).  
 
Figure 72 Construction of Modified Sandwich ELISA. A schematic diagram of the construction of a 
modified Sandwich ELISA.  
 
The sandwich, is formed by a primary antibody that is immobilised on an activated surface. 
Subsequently, the antigen is introduced to the immobilised antibody which, if specific, will 
then form a complex together. Following the removal of any unbound protein a secondary 
antibody specifically binds to an unoccupied epitope of the target protein. As in some 
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traditional ELISA technology the secondary antibody is conjugated with a streptavidin 
molecule to produce an attachment point for 1-4 biotinylated molecules. The streptavidin 
provide a flexible attachment point to which any molecules with a biotin moiety can be 
easily and reliably attached. In the case of the molecular amplifier system the streptavidin is 
occupied by the protease Human Rhinovirus 14 3C (HRV143C) which then cleave a peptide 
bond that releases a further protein (Figure 73). This further protein can be any protein with 
the correct peptide recognition sequence, for example the motor protein HsdR to further 
downstream applications or eGFP for quantification of the release efficiency.  
 
Figure 73 Human Rhinovirus 14 3C mediated eGFP release. Schematic diagram of eGFP release upon 
specific cleavage of a peptide bond  
6.2 HRV143C mediated release of eGFP  
6.2.1 eGFP spin column preparation 
Microcentrifuge spin columns were constructed from G-25 spin columns (GE Healthcare®, 
Amersham, U.K) by application of 300 µL of Glutathione Sepharose™ 4 Fast Flow (GE 
Healthcare®, Amersham, U.K) then spun in a micro centrifuge at 1000 x g for 1 minute. The 
column was washed by re-suspension in 300 µL dH2O, followed by a spin in a micro 
centrifuge at 1000 x g for 1 minute and repeated three times. The column was then 
equilibrated by re-suspension in 300 µL of HRV143C cleavage buffer (50 mM Tris-HCl, 150 
mM NaCl, 1 mM EDTA, 1 mM dithiothreitol (DTT), pH 7.5) then spun at 1000 x g for 1 minute 
and repeated three times. 100 µL of 10 µM eGFP-GST (~54 kDa) was applied to the column 
and allowed to bind to the media incubate at room temperature for 10 minutes. Any 
134 
 
unbound protein was removed by a 1 minute spin at 1000 x g then equilibrated with three 
300 µL HRV143C cleavage buffer washes.  
6.2.2 eGFP Release and quantification 
The eGFP-GST fusion protein contains a HRV143C cleavage site for release of the eGFP 
portion.  The HRV143C released from the ELISA sandwich by Factor Xa was applied to a pre-
prepared eGFP glutathione sepharose column then incubated at 4 oC for 4 hours. After 
incubation eGFP released from by HRV143C digestion was quantified by fluorescence using 
a BMG LABTECH OPTIMA POLARstar™ plate reader using 490 nm excitation wavelength and 
510 nm emission detection. 
6.2.3 eGFP Calibration Curve Construction 
In order to determine the potential limit of detection for eGFP a calibration curve was 
constructed measuring the amount of fluorescence detected at 510 nm at pre-determined 
concentrations (Figure 74). Extrapolations from Figure 74 indicate that detection becomes 
limited at concentrations below 1 µM when compared to the higher (79 µM to 5 µM) 
concentrations; a second curve was assembled at the lower concentrations (Figure 75). 
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Figure 74 Calibration Curve of eGFP concentrations to determine limit of detection. Concentration 
dependent eGFP response calibration curve Decreasing concentrations of eGFP dissolved in HRV143C 
cleavage buffer were analysed using a BMG LABTECH OPTIMA POLARstar™ Filters used: emission 490 nm, 
excitation 510 nm and arbitrary fluorescence response units used. 
Detection of eGFP by fluorescence can give concentration estimates down to approximately 
5 µM, from Figure 74 however a signal is detectable to 1 µM. For a more detailed grasp on 
the lower concentrations a second curve was constructed that allows displays the lower 
fluorescent response in greater detail. From this graph (Figure 75), it is possible to deduce 
with some confidence that the lower level of detection is approximately 500 nM, any 
response below 500 nM eGFP cannot be confidently discerned from background noise.  
The overall fluorescence emission spectra can be drawn to produce a roughly sigmoidal 
curve of observed response units (Figure 77). This curve allows the accurate prediction of 
eGFP present in a solution following extrapolation from a curve.  
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Figure 76 A titration of fluorescence emission of eGFP protein. Fluorescent output from a dilution 
series of the purified eGFP protein was determined as described (Materials and Methods) and plotted 
against a logarithmic plot of protein concentration.  However, as can be seen the relationship between 
fluorescence and protein concentration is not linear and even appears somewhat sigmoidal. 
6.2.4 HRV143C mediated release  
After establishment of eGFP concentration dependant fluorescence and the standard curve 
that can be drawn from the result, a second set of data is needed to determine the 
efficiency of GST-eGFP cleavage by HRV143C. Earlier experimentation showed that an 
excess of HRV143C will cleave it’s substrate within 4 hours, therefore an on-column 
cleavage using HRV143C and bound eGFP-GST as the substrate over 4 hours was 
undertaken. By simulating the release conditions of the second part of the modified ELISA 
sandwich it may be possible to predict eGFP release from the GST fusion and extrapolate 
the concentration of HRV143C from this. From the results (Figure 77) it can be seen that the 
limit for detection of concentration is ~1 µM HRV143C in 100 µL of HRV143C cleavage buffer 
applied to the column. The fluorescent response units have been converted to a percentage 
of the top concentration (in this case 10 µM HRV143C to minimise error and allow 
comparison between repeat experiments and limit the effect of degradation of the eGFP.  
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Figure 77 HRV143C controlled eGFP release Calibration Curve expressed as a percentage. eGFP 
released from column by HRV143C cleavage expressed as a percentage of the highest concentration. 
Detection of eGFP released from column by HRV143C in HRV143C cleavage buffer analysed using a BMG 
LABTECH OPTIMA POLARstar™. Filters used: emission 490 nm, excitation 510 nm and arbitrary fluorescence 
response units used. 
As the concentrations of HRV143C are based on a logarithmic scale a simple transformation 
of the x axis provides a scatter graph that gives a linear progression of fluorescence 
response (Figure 78.). This indicates that the fluorescent response is concentration 
dependent and directly related to the concentration of HRV143C applied to the column. 
Again, the results indicate that the sensing of low concentrations of HRV143C is difficult 
below 5 µM with a detection limit of ~1-2 µM for a reliable extrapolation of HRV143C 
concentration. 
Further investigation into the efficiency of 1-10 µM HRV143C cleavage (Figure 78) 
corroborate the earlier concentration mediated release of eGFP from the column (Figure 77) 
and fit around the trend line drawn from the mean percentage decrease, this provides a 
useful tool for estimating the amount of eGFP, and subsequently, HRV143C concentration 
within the 100 µL eluent of a column.   
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Figure 78 eGFP Release Calibration Curve. A graph summarising repeats of eGFP released from 
column by HRV143C cleavage expressed as a percentage of the highest concentration with extra points for 
mid µM range. Detection of eGFP released from column by HRV143C in HRV143C cleavage buffer analysed 
using a BMG LABTECH OPTIMA POLARstar™. Filters used: emission 490 nm, excitation 510 nm and arbitrary 
fluorescence response units used. 
6.2.5 Sandwich ELISA construction 
The ELISA sandwich is assembled by the addition of known decreasing concentrations of a 
nitrotyrosine containing protein standard to the surface pre-immobilised primary antibody, 
followed by the biotinylated secondary antibody (Hycult Biotech®, Uden, The Netherlands). 
each step interspersed with one hour long incubations at room temperature. To each well 
100 µL of 2 µM streptavidin (Thermo Fisher Scientific®, Loughborough, U.K.) and incubated 
for 1 hour at ~23 oC then washed with 1x Phosphate Buffered Saline (PBS). After washing, 
100 µL of 12 µM biotinylated Human Rhinovirus 14 3C [GE Healthcare®, Amersham, U.K]) 
and incubated for 1 hour at ~23 oC. Following washing, the complete sandwich was 
incubated with Factor Xa (GE Healthcare®, Amersham, U.K ) in Factor Xa cleavage buffer (20 
mM Tris-HCl pH 8.0,100 mM NaCl, 2 mM CaCl2) for 16 hours at ~23 
oC.  
 
6.2.6 Molecular Amplifier ELISA sandwich 
Following the creation of calibration curves and the completion of the eGFP on column 
release data the full ELISA sandwich was constructed (Figure 72 and Figure 73). The full 
experiment relies on each sub-section of the sandwich binding and releasing properly and 
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uses the assumption that in 4 hours one molecule of HRV143C will cleave and release one 
eGFP molecule from the eGFP-GST fusion. The amplifying effect of the streptavidin is caused 
by the availability of the three vacant biotin binding sites of the surface bound streptavidin 
being taken up by an excess of biotinylated HRV143C. Assuming complete release of the 
HRV143C from the surface bound ELISA sandwich, there should be an increase in signal from 
the original protein standard concentrations of approximately 2-3 fold. Using this method it 
should be possible to detect concentrations lower than the limit of detection of the eGFP 
release curve (Figure 77) from ~1 µM to theoretically 500 nM to 250 nM.  
 
 
 
Figure 79 Molecular Amplifier final results. Molecular Amplifier final results. Accumulated, blank 
adjusted, mean fluorescent response results of eGFP release from GST fusion via 4h HRV143C cleavage, 
following 16h release of HRV143C from ELISA sandwich by Factor Xa. Error bars show standard error.   
From the final results graph (Figure 79) it is possible to draw the conclusion that only the 
1.5 µM protein standard concentration can confidently be detected by this method. 
Although the results are blank adjusted the red line indicated the upper threshold of the 
standard deviation and therefore the only reliable and confident conclusion is that anything 
that lays below that line cannot be accepted. Although there may be an amplification event 
it is not possible to divorce this from natural eGFP-GST decay causing the either the eGFP 
fusion to auto-cleave or dissociation from the Glutathione sepharose column.  
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Figure 80 Fluorescent detection of eGFP release from a column by bHR3Cp protein. The GST-(pp)-
eGFP fusion protein was immobilized on a glutathione column and activity of the bHR3Cp protease was 
determined by release of eGFP, measured as fluorescent output, through cleavage at the bHR3Cp (pp) 
cleavage site.  The bHR3Cp protease demonstrates activity on this column based assay down to micromolar 
concentrations.  
10-5 10-6 10-7 
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6.3 Enzyme Linked OligoNucleotide Assay (ELONA) 
The use of antibodies as molecular recognition elements is well documented (Bang et al., 
2005, Centi et al., 2008, Deisingh, 2006, Mairal et al., 2008), it stands to reason therefore 
that if aptamers are to be considered true replacements or alternatives to antibodies the 
substitution of one for the other should be achievable. The Enzyme Linked ImmunoSorbant 
Assay provides a useful, quick and cheap way of assaying proteins in solution. Through the 
use of primary and secondary antibodies, a protein, or other molecule, can be captured and 
probed. The three common methods of probing for the secondary antibody are 
fluorescence, chemiluminesence, and colourmetric. For each of the methods the signal is 
produced by a chemical group that has been conjugated to the secondary antibody. It has 
already been stated that, due to the methods of synthesis of nucleic acids, the attachment 
of these (and other) groups is readily attainable in high quantity and cost-effectively.  
The Enzyme Linked OligoNucleotide Assay (ELONA) is a method where the ELISA model has 
been altered to incorporate the use of primary and secondary aptamers rather than the 
traditional antibodies (Figure 81).  
 
Figure 81 Schematic diagram of ELONA. Diagram of the adjucsted ELONA sandwich. Biotinylated 
Aptamer 1 is bound to a streptavidin coated paramagnetic bead, aptamer 1 binds the target molecule. 
Aptamer 2 selectively binds to the same target but at an alternative epitope. Aptamer 2 is conjugated with a 
streptavidin Horseradish Peroxidase molecule which can be detected using chemiluminescence. 
The ELONA were constructed as follows: 5 μL 5 ug/mL streptavidin coated paramagnetic 
beads (MyOne beads, Invitrogen) were washed 3 times with 1 mL 1 x PBS. The beads were 
then incubated with 1 mL 1 μM of the designated biotinylated primary aptamer for 2 hours 
at 4oC. The unoccupied biotin binding sites were then blocked by a blocking solution of 
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150 μL 1 ug/μL Biotin in 1 x PBS. The beads were then washed with 1 mL1 x PBS a further 3 
times.  The aptamer activated beads were then incubated with 1 μM MTase for 2 hours at 
4oC and then washed with 1 x PBS as before. The beads were then incubated with 1 mL1 μM 
of the assigned secondary aptamer for 2 hours before a washing step with  1 mL 1 x TBST 3 
times. Finally, the beads were incubated with 1:5000 dilution HRP streptavidin conjugate 
(Invitrogen) in 1 X TBST 2 hours. The beads were then washed with 1 x TBS 3 times. Before 
development of the ELONA as described for the dot blot method in (Materials and Methods 
5.1) imaging on Fujifilm Intelligent Dark Box reader. 
 
 
Figure 82 Diagram of the aptamer layout for MBA ELONA. Table to display the locations of each 
primary (A-I) and each secondary (1-9) aptamer to construct a suitable ELONA sandwich. 
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Figure 83  Chemiluminescent image of ELONA of MTase binding aptamers. Chemiluminescent image 
of 9 x 9 grid of MTase ELONA using candidate aptamers as set out in Figure 82. 5 μL 5 ug/mL MyOne beads 
were incubated with 1 μM of the designated biotinylated primary aptamer for 2 hours at 4oC, incubated 
with 1 μM MTase for 2 hours at 4oC,  then 1 μM of the assigned secondary aptamer for 2 hours. The beads 
were incubated HRP streptavidin conjugate. ELONAs were developed and imaged using the Fujifilm 
Intelligent Dark Box reader. 
The ELONA was undertaken with streptavidin coated paramagnetic beads as the 
immobilisation surface due to the inherent adaptability and ease of use. A grid was then 
constructed that contained combinations of two of each of the candidate aptamers that 
that have been selected against MTase (Figure 82). The relative intensities of each point on 
the grid was analysed using ImageJ software and the intensities plotted. The aim of the grid 
was to determine which of the pairs of aptamers could be used in conjunction with each 
other to create the best possible combination for a ELONA sandwich.  
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Figure 84 Figure 85 ELONA constructed from HsdR binding aptamers. Chemiluminescent image of 9 x 9 grid 
of HsdR ELONA using candidate aptamers as set out in Figure 82. 5 μL 5 ug/mL MyOne beads were incubated 
with 1 μM of the designated biotinylated primary aptamer for 2 hours at 4oC, incubated with 1 μM MTase 
for 2 hours at 4oC,  then 1 μM of the assigned secondary aptamer for 2 hours. The beads were incubated 
HRP streptavidin conjugate. ELONAs were developed and imaged using the Fujifilm Intelligent Dark Box 
reader 
Figure 83 and Figure 84 display that aptamers can be used in conjunction with each other in 
an ELONA sandwich. Although the intensity does vary between duplicate cells this can be 
attributed to uneven dispensing of magnetic beads, also athe controls highlight that the 
microplate used for this experiment contributed to non-specific signal of the HRP substrate. 
Time constraints prevented the completion of this area of the study, but it is a noteworthy 
addition to the biosensor concept.  
6.4 Conclusions 
In this chapter it has been demonstrated that the controlled release of a marker or further 
probe such as eGFP can be achieved using the modified ELISA system as a scaffold.  This 
method will provide a suitable pre-cursor to the downstream applications of the biosensor, 
for example, if the eGFP is modified to the proposed alternative HsdR, (the molecular 
motor) the signal can be amplified sufficiently for a signal to be observed. The HsdR carries 
the same affinity attachment group, GST-transferase, and an identical proteolytic cleavage 
site, which would allow the substitution of the motor for eGFP. HsdR would then form a 
complex with HsdM in the configuration H1M2, and in the presence of ATP would recognise, 
bind to, and, translocate (Janscák et al., 1998) the immobilised DNA substrate to produce a 
signal that is observable using the magnetic tweezers as described in the literature (Sisakova 
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et al., 2008). The potential for this as a biosensor is that it is a direct link between the 
biological and silicone worlds, as the proposed biosensor would produce a signal that carries 
very little background.  This, coupled with the amplification method described here also 
allows the detection of analytes that is potentially far below current methodologies.   
After multiple attempts using the modified ELONA method, it became clear that the 
streptavidin-Horse Radish Peroxidase conjugate which was acting as the probe for biotin 
was non-specifically binding the polystyrene assay plate. A limitation to the method became 
apparent in that the use of the paramagnetic beads provided a chance for the 
immobilisation surface to reduce. Further washes to reduce the non-specific binding also 
reduced the final signal indicating that additional washes also remove a significant 
proportion of the beads. Time constraints prevented the full exploration of the approach, 
however, initial runs of the procedure provide an insight into the benefits of this method.  
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7 Discussion 
In this study it has been demonstrated that the isolation of aptamers through the SELEX 
process can be achieved using equipment and methodologies available to many molecular 
biology laboratories. It has also been shown that the analysis of aptamers can be achieved in 
a reliable repeatable and high throughput manner. 
Though the analysis of the thrombin binding aptamer utilised techniques that may not be 
widely available, such as SPR , further work such as that performed on the HsdR binding 
aptamers have shown that this technique is not necessarily universally applicable as has 
been claimed. Affinity SELEX and GELEX have demonstrated the application of existing 
technologies to a novel problem, and as a consequence both methodologies have 
demonstrated the ability to enrich random aptamer libraries. 
HPLC selection of Nitrotyrosine has demonstrated the enrichment of an aptamer library 
through progressive rounds of selection and whilst the study lacks a suitable assay to 
evaluate the efficacy of the enrichment process there was enough data to suggest 
successful enrichment in the form of novel sequences. 
The dot blot method has proven to be the most applicable and versatile technology for the 
analysis of differing proteins, although this also limits the user to targets which bind to 
nitrotyrosine, or another similar membrane. The technique can probe many sequences in 
multiplex, and the high throughput manner of the method can even be used to give insight 
into binding affinities and kinetics.  
Though the final experiment is missing from the series, where the aptamers are substituted 
for antibodies, evidence throughout is presented that enforces the notion that the 
substitution can be successful. Within the molecular amplifier, the protease cascade could 
release the molecular motor HsdR which would act as a nano-actuator translocating DNA in 
the presence of ATP and causing a positive signal on the optical tweezers for example. 
A potential hurdle for the substitution of aptamers into the ELISA sandwich is the 
immobilisation of the aptamers onto a surface. Whether this is done through a biotin 
streptavidin linkage (which would be preferable), or through another attachment chemistry 
such as a terminal thiol linker to the functionalised surface could present some problems. 
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The surface may prevent the aptamers binding through steric interference or due to the 
target protein having some inherent charge that prevents the interaction from forming. This 
can be avoided through the application of polymeric linkers that move the aptamers away 
from the surface, which would serve well to avoid the problem of steric hindrance but the 
linker, may be detrimental to the binding of the aptamer to the target. The isolation of 
multiple sequences for each of the targets highlights the benefit of refinement of an 
aptamer library rather than a single binding motif. If a candidate aptamer is prevented from 
binding due to the conditions in which it was raised differing from the end point application, 
SELEX can be undertaken with the desired buffer conditions present throughout the 
selection process. This will result in an aptamer library that has been tailor made for the 
application for which it was intended. 
An advantage of the HsdR aptamers is that the aptamers may bind to multiple epitopes of 
the protein. If an aptamer is found to inhibit one of the functionalities of the protein, 
another can be selected from the list that fulfils the criteria. This obstacle could potentially 
derail the substitution of aptamers for antibodies in the generic biosensor. The obstacle 
could be surmounted through the successful application of the ELONA assay, which allows 
the user to evaluate and avoid possible occupation of binding sites for other cofactors such 
as ATP. This application signifies one of the great advantages aptamers have over 
antibodies. The modular aspect of the list of potential aptamers allows the interchanging of 
a series of aptamers in the search for a suitable candidate that fits the specifications for the 
task. This, when coupled with the ability to produce large amounts of the oligonucleotide 
synthetically and bypassing the labourious task of producing antibodies in vivo, strengthens 
the case for aptameric molecular recognition elements. Aptamers also present another 
advantage over antibodies in the form of reproducibility. Due to the nature of the 
production of aptamers and the formation of distinct structural motifs, it can be assumed 
that aptamers of a known sequence will form a discreet number of structures of transition 
through them in a predictable way. As antibodies are the result of a long process drawn 
from animal immune responses that can take weeks to occur, the batch to batch efficacy of 
the antibody products hampers their use in vitro as each consignment needs to be assayed 
for affinity with known standards whenever binding needs to be examined.  
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Future work would involve the refinement of aptamer libraries to further proteins of 
interest, with a greater emphasis on the inhibitive and catalytic effects as part of the 
selection process. The use of aptazymes as a tailored molecular toolbox is restricted by the 
existence of a sensitive enough assay to enable to enrichment to select sequences that 
promote the desired effect. If a highly sensitive assay for the reaction already exists the 
random library can be subdivided to a size where such an effect would be observable. 
Another future direction would be the structural analysis of the complex formed during 
aptamer:antigen interactions. Through the use of Nuclear Magnetic Resonance, and protein 
crystallography data on the nature of the motif which the aptamers are folding to could give 
some insight into predesigned libraries that have some motifs surrounded by random 
regions, directing the library towards sequences that are similar to those that are known to 
bind. This may reduce specificity but, this may allow the user to enhance the power of in 
vitro evolution by providing a selection pressure towards an acknowledged goal. 
In conclusion this work displays that aptamers are a useful tool that can work in conjunction 
and in place of antibodies as molecular recognition elements within biosensors, and that 
aptamers can be produced efficiently and reliably for many applications in most molecular 
biology laboratories.  
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9 Appendices 
9.1 Appendix 1 
 
Examples of targets used for aptamer selections 
Examples of 
targets used for 
aptamer 
selections 
 
Target for 
aptamer 
selection 
KD 
 
References 
 
 
Inorganic 
components 
 
Zn2+ 
 
 
 
 
RNA 
 
 
 
 
1.2 mmol/L  
 
 
 
 
 
Ciesiolka et al. (1995) 
 
Ni2+ RNA 0.8–29 mmol/L Hofmann et al. (1997) 
 
Small organic 
molecules 
 
   
Ethanolamine DNA 6–19 nmol/L Mann et al. (2005) 
 
Theophylline 
 
RNA 
 
100 nmol/L 
 
Jenison et al. (1994) 
 
Malachite green 
 
RNA 
 
1 mmol/L 
 
Grate and Wilson 
(2001) 
 
Organic dyes RNA 
DNA 
100–600 mmol/L 
33–46 mmol/L 
Ellington and Szostak 
(1990) 
Ellington and Szostak 
(1992) 
 
Sulforhodamine B DNA 190 nmol/L Wilson and Szostak 
(1998) 
 
Hematoporphyrin DNA 1.6 mmol/L Okazawa et al. (2000) 
 
Ricin toxin DNA 58–105 nmol/L Tang et al. (2006) 
 
Cholic acid DNA 5–67.5 mmol/L Kato et al. (2000) 
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4,4’-
Methylenedianiline 
RNA 0.45–15 mmol/L Brockstedt et al. 
(2004) 
 
Dopamine RNA 2.8 mmol/L Mannironi et al. (1997) 
 
Cocaine DNA n.s.
a
 Stojanovic et al. (2000) 
 
 
Nucleotides and 
derivatives 
 
Adenine 
 
 
 
 
 
RNA 
 
 
 
 
10 mmol/L 
 
 
 
 
Meli et al. (2002) 
 
ATP (adenosine) RNA 0.7–50 mmol/L Sassanfar and Szostak 
(1993) 
 
Adenosine/ATP DNA 6 mmol/L Huizenga and Szostak 
(1995) 
 
ATP RNA 4.8–11 mmol/L Sazani et al. (2004) 
 
Xanthine RNA 3.3 mmol/L Kiga et al. (1998) 
 
cAMP RNA 10 mmol/L Koizumi and Breaker 
(2000) 
 
 
Cofactors 
 
Coenzyme A 
 
 
 
RNA 
 
 
 
n.s.
a
 
 
 
 
Saran et al. (2003) 
 
Cyanocobalamin RNA 88 nmol/L Lorsch and Szostak 
(1994) 
 
Riboflavin RNA 1–5 mmol/L Lauhon and Szostak 
(1995) 
 
FMN RNA 0.5 mmol/L Burgstaller and 
Famulok (1994) 
 
FAD RNA 137–273 mmol/L Burgstaller and 
Famulok (1994) 
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NAD RNA 
 
 
RNA 
n.s.
a
  
 
 
2.5 mmol/L 
 
Burgstaller and 
Famulok (1994)  
 
Lauhon and Szostak 
(1995) 
 
 
S-adenosyl methionine RNA n.s.
a
 Burke and Gold (1997) 
 
S-adenosyl 
homocysteine 
RNA 0.1 mmol/L Gebhardt et al. (2000) 
 
Biotin RNA 5 mmol/L Wilson et al. (1998) 
and Wilson and 
Szostak (1995) 
 
 
Nucleic acids 
 
TAR RNA element of 
HIV-1 
 
 
 
 
DNA  
 
RNA 
 
DNA 
 
 
 
 
50 nmol/L 
 
20–50 nmol/L 
 
50 nmol/L 
 
 
 
 
 
Boiziau et al. (1999)  
 
Duconge and Toulme 
(1999) 
Sekkal et al. (2002) 
 
 
Yeast phenylalanine 
tRNA 
RNA 12–26 nmol/L Scarabino et al. (1999) 
 
E.coli 5S RNA RNA 
 
RNA 
6–12 mmol/L 
 
3 mmol/L 
Ko et al. (1999) 
 
Ko et al. (2001) 
 
 
Amino acids 
 
L-Arginine 
 
 
 
RNA  
 
DNA 
 
 
 
330 nmol/L 
 
2.5 mmol/L 
 
 
 
Geiger et al. (1996) 
 
Harada and Frankel 
(1995) 
L-Citrulline RNA 62–68 mmol/L  
 
Famulok (1994) 
L-Valine RNA 12 mmol/L  
 
Majerfeld and Yarus 
(1994) 
L-Isoleucine RNA  
 
RNA 
1–7 mmol/L  
 
200–500 mmol/L  
 
Lozupone et al. (2003)  
 
Majerfeld and Yarus 
(1998) 
D-Tryptophan RNA 18 mmol/L  Famulok and Szostak 
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 (1992) 
L-tyrosinamide DNA 45 mmol/L  
 
Vianini et al. (2001) 
L-histidine RNA 8–54 mmol/L Majerfeld et al. (2005) 
 
 
Carbohydrates 
 
Cellobiose 
 
 
 
DNA 
 
 
 
600–nmol/L  
 
 
 
 
Yang et al. (1998) 
Sialyl Lewis X RNA  
 
0.085–10 nmol/L  Jeong et al. (2001) 
Chitin  
 
DNA  n.s.
a
 Fukusaki et al. (2000) 
Sialyllactose  
 
DNA  4.9 mmol/L  Masud et al. (2004) 
Sephadex DNA  
 
n.s.
a
 Srisawat et al. (2001) 
 
Antibiotics 
 
Kanamycin A   
 
 
 
 
RNA 
 
 
 
300 nmol/L 
 
 
 
Lato et al. (1995) 
Kanamycin B  
 
RNA 180 nmol/L Kwon et al. (2001) 
Streptomycin  
 
RNA n.s.
a
 Wallace and Schroeder 
(1998) 
Neomycin  
 
RNA 100 nmol/L Wallis et al. (1995) 
Tobramycin  
 
RNA 2–3 nmol/L Wang and Rando 
(1995) 
Lividomycin  
 
RNA 300 nmol/L Lato et al. (1995) and 
Lato and Ellington 
(1996) 
Moenomycin A  
 
RNA 300–400 nmol/L Schu¨rer et al. (2001) 
Tetracycline  
 
RNA 1 mmol/L Berens et al. (2001) 
Chloramphenicol  
 
RNA 25–65 mmol/L Burke et al. (1997) 
 
Peptides and 
proteins 
 
T4 DNA polymerase  
 
 
 
 
 
 
RNA 
 
 
 
 
 
5–30 nmol/L 
 
 
 
 
 
Tuerk and Gold (1990) 
α-Thrombin DNA  
 
RNA 
200 nmol/L 
 
<1–4 nmol/L 
Bock et al. (1992) 
White et al. (2001) 
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Bovine thrombin RNA 164–240 nmol/L Liu et al. (2003) 
 
Neurotensin receptor 
NTS-1 (rat) 
RNA 0.37 nmol/L Daniels et al. (2002) 
Immunglobulin E DNA 
RNA  
DNA 
 
23–39 nmol/L  
30–35 nmol/L  
10 nmol/L  
 
Mendonsa and Bowser 
(2004) 
Wiegand et al. (1996) 
Wiegand et al. (1996) 
Interferon-g  
 
RNA  2.7 nmol/L Kubik et al. (1997) 
MCP-1 (mouse) RNA 180–370 pmol/L  
 
Rhodes et al. (2001) 
PDGF  
 
DNA  0.1 nmol/L  Green et al. (1996) 
VEGF  
 
 
RNA 
 
RNA 
0.1–2 nmol/L 
 
0.05–0.13 nmol/L 
Jellinek et al. (1994)  
 
Ruckman et al. (1998) 
 
HIV-1 integrase  
 
 
RNA 
 
10–800 nmol/L 
 
Allen et al. (1995) 
HIV-1 RT RNA 
 
DNA  
 
DNA 
5 nmol/L  
 
1 nmol/ 
 
180–500 pmol/L  
 
Tuerk et al. (1992) 
 L Schneider et al. 
(1995)  
 
Mosing et al. (2005) 
HIV-1 nucleocapsid 
protein  
RNA  0.84–1.4 nmol/L  Kim et al. (2002) 
TTF1 DNA 3.3–67 nmol/L  
 
Murphy et al. (2003) 
HGF  
 
DNA  19–25 nmol/L  Saito and Tomida 
(2005) 
Streptavidin  
 
RNA  
 
RNA  
 
DNA  
 
7 nmol/L  
 
70–200 nmol/L  
 
57–85 nmol/L 
Tahiri-Alaoui et al. 
(2002)  
Srisawat and Engelke 
(2001)  
Stoltenburg et al. 
(2005) 
L-Selectin  
 
DNA 1.8–5.5 nmol/L Hicke et al. (1996) 
Taq DNA polymerase  
 
DNA 0.04–9 nmol/L  Dang and Jayasena 
(1996) 
Prion protein (PrPc) RNA 0.1–1.7 nmol/L Proske et al. (2002) 
 
PrPSc fibrils RNA 23.4 nmol/L Rhie et al. (2003) 
 
rPrPc RNA n.s.
a
 Weiss et al. (1997) 
 
rPrPc DNA n.s.
a
 Takemura et al. (2006) 
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C5 protein RNA 2–5 nmol/L Biesecker et al. (1999) 
 
Hepatitis C virus 
RdRp  
 
DNA  1.3/23.5 nmol/L Jones et al. (2006) 
Hepatitis C virus NS3  
 
RNA  n.s.
a
 Kumar et al. (1997) 
Hepatitis C virus NS3 
helicase  
 
DNA  140 nmol/L Zhan et al. (2005) 
ppERK2/ERK2  
 
RNA  4.7/50 nmol/L  Seiwert et al. (2000) 
Protein kinase C delta  
 
DNA  122 nmol/L  Mallikaratchy et al. 
(2006) 
RNase H1  
 
DNA  10–80 nmol/ L Pileur et al. (2003) 
Colicin E3  
 
RNA  2–14 nmol/L  Hirao et al. (2004) 
Oncostatin M  
 
RNA  7 nmol/L  Rhodes et al. (2000) 
Tumour marker 
MUC1  
 
DNA  0.1–34 nmol/L  Ferreira et al. (2006) 
GnRH  
 
 
L-RNA  
 
L-DNA  
190 nmol/L 
 
45 nmol/L 
Leva et al. (2002) 
 
Vasopressin  
 
 
L-DNA  
 
1.2 mmol/L  
 
Williams et al. (1997) 
Amyloid peptide 
bA4(1-40)  
 
RNA  29–48 nmol/L  Ylera et al. (2002) 
Microcystin  DNA  1 mmol/L Nakamura et al. (2001) 
 
 
Complex 
structures 
 
Anthrax spores  
 
 
 
 
 
DNA  
 
 
 
 
n.s.
a
 
 
 
 
 
Bruno and Kiel (1999) 
Ribosomes/ribosomal 
protein S1  
 
RNA  4-5 nmol/L  Ringquist et al. (1995) 
Rous sarcoma virus 
(RSV)  
RNA  n.s.
a
 Pan et al. (1995) 
Differentiated PC12 
cells  
 
DNA  n.s.
a
 Wang et al. (2003) 
Transformed YPEN-1 
endothelial 
DNA  n.s.
a
 Blank et al. (2001) 
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cells/pigpen  
 
U251 glioblastoma 
cells/tenascin-C  
 
DNA 
 
RNA  
 
150 nmol/L 
 
5 nmol/L  
Daniels et al. (2003)  
 
Hicke et al. (2001) 
Live African 
trypanosomes) 
 
RNA  60 nmol/L Homann and Go¨ringer 
(1999) 
Jurkat T cell 
leukaemia  
 
RNA  n.s.
a
 Lee and Lee (2006) 
Receptors of host-cell 
matrix 
molecules on 
Trypanosoma cruzi 
 
RNA  
 
40–400 nmol/L Ulrich et al., (2002) 
Leukemia cells 
CCRF- 
 
CEM DNA  0.8–229 nmol/L Shangguan et al. 
(2006) 
 
 
a n.s., not specified. (Stoltenburg et al., 2007) 
9.2 Appendix 2 
Designation  
 
Description References 
Negative SELEX - Minimizes the co-selection of 
unwanted nucleic acid ligands 
(e.g. for immobilization matrix) 
- Pre-selection with molecules, 
which should not be 
recognized, removing of 
unwanted oligonucleotide 
structures from the pool 
 
Blank et al. (2001), Haller and 
Sarnow (1997), 
Vater et al. (2003) and Geiger 
et al. (1996) 
 
Counter-SELEX or 
subtractive SELEX 
 
- Generates aptamers which are 
able to discriminate 
between closely related 
structures 
- Introducing of a selection step 
Jenison et al. (1994), Geiger et 
al. (1996) 
Haller and Sarnow (1997), Lee 
and Lee (2006), 
Shangguan et al. (2006), Wang 
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to the related target 
for elimination of aptamers 
from the oligonucleotide 
pool, which are not able to 
distinguish 
between the related structures 
 
et al. (2003) 
and White et al. (2003) 
 
Blended SELEX -  - To give additional properties 
to aptamers 
beyond the binding capability 
- Enlarging of nucleic acid 
molecules by special 
non-nucleic acid components 
 
Smith et al. (1995) and 
Radrizzani et al. (1999) 
 
Expressions cassette 
SELEX or SELEX-SAGE 
 
- Special forms of Blended 
SELEX (with transcription 
factors)  
- Optimizes aptamer activity for 
gene therapy applications 
Martell et al. (2002) and Roulet 
et al. (2002) 
Chimeric SELEX Using of two or more different 
libraries for production 
of chimerical aptamers with 
more than one wanted 
feature or function 
- Each of the parent libraries 
will be selected first to a 
distinct feature, then fusion of 
the selected aptamers 
 
Burke and Willis (1998) 
 
Multi-stage-SELEX - Special form of Chimeric 
SELEX 
- After fusion of preselected 
aptamer components, 
reselection to the entirety of 
Wu and Curran (1999) 
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the targets 
 
Deconvolution-SELEX - To generate aptamers for 
complex  
- Discrimination between 
relevant aptamers 
(binding to distinct target 
structures within the 
complex mixture) and 
irrelevant oligonucleotides 
targets Blank et al. (2001) and 
Morris et al. (1998) 
Covalent SELEX or 
cross-linking SELEX 
 
- Aptamers containing reactive 
groups which are 
capable of covalent linking to a 
target protein 
 
Jensen et al. (1995) and 
Kopylov and 
Spiridonova (2000) 
 
Photo-SELEX - Aptamers bearing photo-
reactive groups 
- Bind and photo cross-link to a 
target and/or 
photo activate a target 
molecule 
 
Brody et al. (1999), Golden et 
al. (2000), 
Jensen et al. (1995) and 
Johnson and 
Gershon (1999) 
 
SPIEGELMER
®
- 
Technology 
 
- Selection with ordinary D-
nucleic acids for the 
mirrored (enantiomer) target 
- Synthesis of the resulting 
aptamers as L-isomers which 
bind now to the originally un-
mirrored target 
 
Eulberg and Klussmann (2003), 
Klussmann et al. 
(1996) and Faulhammer et al. 
(2004) 
 
Tailored-SELEX - Integrated method to identify 
aptamers with only 10 fixed 
nucleotides through ligation 
and removal of primer binding 
Vater et al. (2003) 
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sites within the SELEX process 
- Useful for selection of short 
aptamers and  Spiegelmers 
Signalling aptamers or 
molecular beacons 
 
- Aptamers which report target 
binding by switching their 
structures and show a signal 
(e.g. fluorescent) 
 
Jhaveri et al. (2000) and 
Rajendran and 
Ellington (2003) 
 
Genomic SELEX 
or cDNA-SELEX 
 
- Construction of a SELEX library 
of an organism’s genome 
(e.g. cDNA fragments) 
- Target proteins or metabolites 
from the same organism are 
used to identify meaningful 
interactions 
- Allows the identification of 
protein targets directly 
from mRNA pools 
 
Dobbelstein and Shenk (1995), 
Singer et al. 
(1997), Gold et al. (1997a,b), 
Zolotukhin et al. 
(2001), Chen et al. (2003), 
Shimada et al. 
(2005) and Wen and Gray 
(2004) 
 
Toggle-SELEX - Switching (‘‘toggling’’) 
between targets during 
alternating 
rounds of selection 
 
White et al. (2001) 
andBianchini et al. (2001) 
 
Indirect selection - Selection target (e.g. metal 
ions) is not the actual binding 
partner of the aptamer, but 
binding is target-dependent 
(occurs only in 
presence of the target) 
 
Kawakami et al. (2000) 
 
In vivo selection - One possibility to select RNA-
processing signals 
- Uses transient transfection in 
Coulter et al. (1997) 
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an iterative procedure in 
cultured vertebrate cells 
 
Tissue SELEX - Method for generating 
aptamers capable of binding to 
complex 
tissue targets such as 
collections of cells in diseased 
tissues 
 
Daniels et al. (2003) and Morris 
et al. (1998) 
 
TECS-SELEX - Cell-surface displayed 
recombinant or natural protein 
is directly used as the selection 
target 
 
Ohuchi et al. (2006) and 
Shangguan et al. (2006) 
 
FluMag-SELEX - DNA oligonucleotides with a 
fluorescein modification 
- Target immobilization on 
magnetic beads 
 
Stoltenburg et al. (2005) 
 
CE-SELEX - Use of capillary 
electrophoresis (CE) For 
separation 
Mendonsa and Bowser (2004), 
Mosing et al. 
(2005), Tang et al. (2006) and 
Drabovich 
et al. (2006) 
 
Non-SELEX - A process that involves 
repetitive steps of partitioning 
with no amplification between 
them 
- Non-equilibrium capillary 
electrophoresis of equilibrium 
mixtures (NECEEM) used for 
partitioning 
Berezovski et al. (2006) 
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EMSA-SELEX - Use of electrophoretic 
mobility shift assay (EMSA) 
for partitioning in every round 
 
Tsai and Reed (1998) 
 
Use of 
nanoManipulatoratomic 
Force Microscope 
(nM-AFM) 
 
- Only one round of selection 
necessary 
- Picking up and visualizing of 
singled aptamer target 
complexes by nM-AFM 
- Affinity measurement of 
single aptamer-target 
complexes possible by dynamic 
force spectroscopy 
- Amplification by single-
molecule-PCR 
 
Guthold et al. (2002) 
 
On-chip selection  
- Selection (in combination with 
a method for point 
mutations) and analyzing of 
DNA aptamers on chips 
 
Asai et al. (2004) 
 
Yeast genetic selection - In vivo optimization of in vitro-
preselected aptamers  
- Library with degenerated 
aptamers 
- Use of a yeast three(one)-
hybrid system 
 
Cassiday and Maher (2003) 
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